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IMMUNOGLOBULINS AND IMMUNOGLOBULIN FC RECEPTORS IN
NONHUMAN PRIMATES COMMONLY USED IN BIOMEDICAL RESEARCH
by
KENNETH ALTON ROGERS
Under the Direction of Roberta Attanasio
ABSTRACT

Antibodies neutralize and eliminate pathogens, malignancies, and toxins by acting
either alone or in association with Fc receptors which, once engaged, activate the
elimination mechanisms of phagocytic cells. Based on structural differences, antibodies
are divided into functionally distinct classes (IgM, IgD, IgG, IgE and IgA). Structurefunction relationships within these classes are not well characterized. In addition, animal
models for the assessment of potential therapeutic strategies for the modulation of the
interaction between antibodies and Fc receptors are not established. Nonhuman primates
are widely used to model human diseases and, represent excellent in vivo systems for this
assessment. Therefore, we have studied nonhuman primate IgD as well as IgG and IgA
specific Fc receptors in rhesus macaques, cynomolgus macaques, baboons and sooty
mangabeys. IgD genes had not been identified in nonhuman primates nor the IgD
receptors characterized in any species. We characterized IgD genes of the four monkey
species, as well as chimpanzees and dogs. In contrast to other antibody classes, the IgD
hinge regions are highly conserved between human and nonhuman primates, thus
indicating a role in Fc receptor binding. In humans, Fc receptors CD16a (natural killer

cells) and CD16b (neutrophils) bind IgG1 and IgG3, and CD89 (myeloid cells) binds
IgA. To assess ligand binding and glycosylation properties of nonhuman primate CD16a,
CD16b, and CD89, we sequenced, cloned, and generated recombinant molecules in a
mammalian expression system. Our results verify the presence of CD16a, but not CD16b
in nonhuman primates. CD16a is expressed on monocytes and a subpopulation of
lymphocytes. In sooty mangabeys, CD16 is also expressed on neutrophils. Recombinant
sooty mangabey/baboon CD16a binds to human IgG1 and IgG2, but not IgG3 and IgG4.
Monkey CD89 has the same peripheral blood leukocyte expression profiles as humans,
and binds human and recombinant macaque IgA. Blocking of N-glycans inhibited
expression of CD89, but only marginally CD16a expression. Although extensive
similarities of antibody/Fc receptor interactions exist between human and nonhuman
primates, several differences must be considered when evaluating therapeutic strategies.
However, these differences can be exploited to further characterize the structure-function
relationships existing within antibody molecules and respective receptors.
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CHAPTER 1
Introduction and Study Objectives

Organisms as diverse as bacteria and humans have evolved defense mechanisms
against pathogens. In simple organisms, defenses are generally limited to the level of
single cells. For example, bacteria produce endonucleases to cleave DNA of invading
bacteriophages as they enter the cell (King and Murray, 1994). With the increasing
complexity of the organism, the task of defense becomes more intricate. Complex
multicellular organisms must not only mount a defense at the level of the single cell, but
must coordinate a defense of the organism as a whole, while preventing any detrimental
responses. The immunity of more complex organisms is distinguished by the
development of a proper immune system consisting of specialized cells and tissues
dedicated to controlling pathogens, toxins and malignancies. In the lower organisms these
defenses are limited to innate immunity, which is established prior to the encounter with
a pathogen and does not require education of the immune system to function (Akira et al.,
2006).
Innate immunity has been highly conserved throughout evolution, and entails
specialized cells and molecules that recognize and target foreign structural components
common to different classes of pathogens. For example, toll-like receptors are molecules
expressed by cells to detect pathogen components, such as bacterial cell wall molecules
and DNA, and are found in species from insects to vertebrates (Akira et al., 2006).
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Specialized cells of the innate immune system include several types of phagocytic cells:
neutrophils, eosinophils, monocytes, macrophages, and dendritic cells (Kuby, 1997).
These cells engulf and inactivate pathogens and substances that need to be cleared from
the body. Toll-like receptors and other receptors on the surface of phagocytes may bind
directly to substances to initiate phagocytosis, or the substances may first be coated with
serum proteins called opsonins that are recognized by phagocytes and assist in
phagocytosis (Henricks et al., 1986). Opsonins include complement proteins of the innate
immune system and antibodies, also called immunoglobulins, of the adaptive immune
system (Rus et al., 2005; Henricks et al., 1986). Other cells of the innate immune system,
including basophils, mast cells and natural killer cells, are not phagocytic and use other
mechanisms to kill pathogens (Kuby, 1997). For example, natural killer cells recognize
infected and malignant cells, and can kill these cells by signaling the cells to undergo
apoptosis (O’Connor et al., 2006).
Although innate immunity is critical for survival, over time pathogens have
evolved mechanisms to evade and overcome innate immunity (Finlay and McFadden,
2006). It was under this selective pressure that an adaptive immune system evolved in
vertebrates. The adaptive immune system first emerged in early fish and consists of
lymphocytes and their products, which likely evolved from the more ancient innate
immune system (Cooper and Alder, 2006). As its name suggests, adaptive immunity is
not preexistent to an encounter with a specific pathogen as is innate immunity. Instead,
adaptive immunity develops with specificity for a pathogen when the body encounters
that particular pathogen for the first time. Adaptive immunity is further distinguished
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from innate immunity because of a unique property: memory (Nayak et al., 2005). That
is, upon subsequent infection with the same pathogen, the adaptive immune system
remembers the pathogen and mounts a faster and stronger response to eliminate the
pathogen from the body. However, the adaptive immune system does not operate alone,
but works in coordination with the innate immune system. The role of antibodies as
opsonins directing phagocytosis has already been mentioned. Conversely, innate immune
cells play roles in activating the adaptive immune system (Clark and Kupper, 2005).
The cells of adaptive immunity are B and T lymphocytes. Lymphocytes make up
20-40% of the human leukocyte population and also include natural killer cells (Kuby,
1997). B lymphocytes, or B cells, mature in the bone marrow. T lymphocytes, or T cells,
mature in the thymus. B cells are responsible for the production of antibodies, which are
the major effector molecules of humoral immunity. On the basis of their function in the
immune response, T cells are divided into two categories: T helper (TH) lymphocytes and
cytotoxic T lymphocytes (CTLs) (Fabbri et al., 2003). TH cells orchestrate the activity
of other cells of the immune system by releasing messenger molecules known as
cytokines and are subdivided into T helper type 1 (TH1) and T helper type 2 (TH2) cells
on the basis of the cytokines they produce. TH1 cytokines preferentially direct immune
responses against pathogens that invade cells and against tumors, whereas TH2 cytokines
preferentially direct immune responses against extracellular pathogens (Mosmann and
Sad, 1996). CTLs eliminate target cells, such as tumor cells or cells infected by viruses,
by producing molecules that form pores on their surface. CTLs then use the pores on the
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target to insert additional molecules that specifically induce cell death (Andersen et al.,
2006).
The keystones to adaptive immunity are receptors that recognize parts of the
pathogens referred to as antigens. These receptors are of two different types that are
known as B cell receptors (BCR) and T cell receptors (TCR) for the respective
lymphocytes on which they are found. BCRs are composed of membrane bound
immunoglobulin molecules and ancillary signaling proteins (Ollila and Vihinen, 2005). In
contrast to receptors of innate immunity, BCR and TCR expression involves
reorganization of the genes encoding them (Ollila and Vihinen, 2005; von Boehmer,
2006). This reorganization occurs in the lymphocyte progenitor cells, found in the bone
marrow for B cells and in the thymus for T cells, and involves stochastic shuffling of
gene segments and insertion of nucleotides to create receptors with unique antigen
specificity that are exclusive to each differentiated lymphocyte and its daughter cells
(Ollila and Vihinen, 2005; von Boehmer, 2006). Each clone produced in this manner
undergoes negative selection whereby clones with antigen receptors that recognize selfproteins are induced to undergo apoptosis or to enter a state of inactivation known as
anergy (Kappler et al., 1987; Ferry et al., 2006). Unfortunately, this process is imperfect
and can lead to autoimmune disorders in which the body attacks itself (Copper and Alder,
2006). Hence, autoimmunity is a byproduct of a dysfunctional adaptive immune system.
TCRs only recognize processed antigen presented by major histocompatibility molecules
(MHC) expressed on the surface of cells, in contrast to BCRs that recognize unprocessed
antigen directly (Kuby, 1997). Therefore, T cells also undergo positive selection. The
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process of positive selection allows only development of T cells bearing TCRs that
recognize MHC molecules (Kersh, 2004). All other T cells undergo apoptosis.
Newly formed B cells and T cells are naïve and must first be activated prior to
performing the immune effector functions that ultimately eliminate pathogens (Kuby,
1997). B cell activation generally requires two signals. The first signal is provided when
antigen is recognized by the BCR. The second signal comes from the cognate interaction
with a T cell. The antigen bound to the BCR is internalized, processed, and presented as a
peptide on MHC class II molecules to a T helper cell (McHeyzer-Williams and
McHeyzer-Williams, 2005). T helper cells that recognize the antigen through their TCR
become activated and provide costimulatory signals and cytokines that complete the
activation process of B cells (McHeyzer-Williams and McHeyzer-Williams, 2005). Some
antigens provide a strong enough signal to activate B cells in the absence of T cells.
These antigens are known at T cell independent antigens, an example of which is
vesicular stomatitis virus that has multiple identical antigen binding sites, or epitopes
(Freer et al., 1994). By having these epitopes located in close proximity to each other,
several BCRs are brought together by binding a single virion at once. This cross-linking
of the BCR then leads to an intracellular signaling cascade that activates the B cell. Once
activated, B cells proliferate and differentiate into effector memory cells and antibody
secreting plasma cells (Shapiro-Shelef and Calame, 2005; McHeyzer-Williams and
McHeyzer-Williams, 2005). As mentioned, antigen presented in the context of MHC
class II molecules can activate T helper cells. For this reason, B cells along with
macrophages and dendritic cells that also bear MHC class II molecules are known as

6

professional antigen presenting cells (APC). CTL like T helper cells must be presented
with antigen in the context of MHC molecules, but CTL recognize antigen presented by
MHC class I molecules, which present endogenous antigens and are expressed on
virtually all cell types (the only exception is represented by red blood cells) (Kuby,
1997). CTLs activated through recognition of MHC class I presented antigen kill the
presenting cell. Adaptive immune responses are classified as humoral or cellular based on
whether the response to clear antigen involves antibodies, or cellular mechanisms, such
as those used by CTL.
Antibodies play vital roles in immune defenses. Without medical intervention,
individuals born with antibody deficiencies succumb to infections and die early in life
(Bonilla and Geha, 2006). Even before the adaptive immune system has developed and
produced antibodies of its own, fetuses and infants receive protection from maternal
antibodies transferred across the placenta (Simister, 2003). At mucosal surfaces,
antibodies are important for blocking the initial entry of bacteria and viruses into the
body (Woof and Kerr, 2006). If such a barrier is bypassed, then antibodies are employed
in systemic defense. In addition to their role in killing pathogens and neutralizing viruses
and toxins, antibodies coordinate the immune response by acting as adaptor molecules
that bring antigens together with cells and proteins of the innate immune system (Burton,
2002). These interactions are made possible by the unique structure of antibodies.
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Immunoglobulin (antibody) structure
Immunoglobulins are composed of four peptides, two identical light chains and
two identical heavy chains (Figure 1.1). Each heavy chain is covalently linked to the
other by one or more disulfide bonds, and a single light chain is linked to each heavy
chain by an additional disulfide bond (Kuby, 1997). At the quaternary level the
immunoglobulin is Y-shaped (Ramsland and Farrugia, 2002). Each immunoglobulin
chain is divided into a series of immunoglobulin domains that all share a common tertiary
immunoglobulin fold held together by an intra-domain disulfide bond. Immunoglobulin
domains are further subdivided into variable immunoglobulin domains and constant
immunoglobulin domains. A single variable immunoglobulin domain is located at the
amino-terminal end of each immunoglobulin chain, followed by one constant domain in
the light chains (CL) and three to four constant domains in the heavy chains (CH).
Together, one variable domain from a light chain and one from a heavy chain form the
antigen-binding portion of the antibody (Kuby, 1997). Since immunoglobulins have two
pairs of heavy and light chains, each molecule has two antigen binding sites at the ends of
the arms of the Y-shaped molecule, making it divalent. Variable domains vary
extensively in their amino acid content as a result of the previously mentioned
reorganization of the gene segments that encode them (Fugmann et al., 2000). It is this
diversity of the variable domains that allows antibodies of each B cell and its clones to
have unique antigen binding properties. By contrast, constant domains are highly
conserved and form the structure of the immunoglobulin that allows it to interact with
other components of the immune system to elicit immune effector functions that destroy
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Antigen
Binding
Site
VH
Hinge
VL

CH1
Fab

CL
CH2
Fc
CH3

Figure 1.1. Structure of an immunoglobulin molecule. Immunoglobulin light chains
consisting of VL and CL domaind are shown in blue. Immunoglobulin heavy chains are
shown in orange and red and consist of VH, CH1, CH2, and CH3 (some have a CH4).
The four polypeptide chains are linked together by disulfide bonds (Kuby, 1997). VL:
light chain variable domain; VH: heavy chain variable domain; CL: light chain constant
domain; CH heavy chain constain domain.
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and eliminate immunoglobulin-tagged antigens (Kuby, 1997).
The original elucidation of the structure of immunoglobulin molecules was aided
in the 1950’s and 1960’s by experiments carried out by Rodney Porter. In these
experiments, immunoglobulins of the IgG class were proteolytically fragmented (Porter,
1967). Since the resulting fragments of the immunoglobulin are functionally different, it
is still convenient to refer to the portions of an immunoglobulin by the names of these
fragments. Digestion with pepsin cleaves immunoglobulins at the heavy chains between
the first and second constant domains in a region known as the hinge. This releases two
fragments, the F(ab’)2 , which is capable of binding antigen and the Fc, so named because
the fragment is easily crystallized. Alternatively, papain cleaves also at the hinge, but at a
position N-terminal to all the disulfide bonds that hold the heavy chains together.
Therefore papain digestion releases a similar Fc fragment and two antigen binding Fab
fragments. Primarily, it is through the Fc portion that other immune system components
bind immunoglobulins to initiate immune effector functions. For this reason,
immunoglobulin receptors that bind this portion the immunoglobulin are called Fc
receptors (FcR) (Ravetch and Kinet, 1991).
The constant domains of each immunoglobulin peptide are encoded by constant
region genes located downstream of the variable region genes, which recombine together
to encode the variable domain of the same immunoglobulin chain. In humans, constant
region genes are located at three loci. Immunoglobulin light chain constant regions are
encoded by either the κ light-chain locus on chromosome 2 or by the λ light-chain locus
on chromosome 22 (Lefranc and Lefranc, 2001). Accordingly, the resulting light chains
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are referred to as κ and λ light. The heavy chain constant region locus on chromosome 14
has nine functional heavy chain constant region genes and three pseudogenes. The nine
heavy chain regions that are encoded by the functional genes are grouped into five types:
µ, γ, α, δ, and ε, which in turn define the five isotypes or classes of immunoglobulins:
IgM, IgG, IgA, IgD and IgE respectively (Lefranc and Lefranc, 2001). IgG antibodies can
be further subdivided into four subclasses (IgG1, IgG2, IgG3 and IgG4), whereas IgA
antibodies are found as two subclasses (IgA1 and IgA2). The heavy chains of the
antibody subclasses are designated γ1, γ2, γ3, γ4 (for IgG1, 2, 3 and 4) and α1, α2 (for
IgA1 and IgA2). The constant region heavy chain genes are named according to the
standardized ImmunoGeneTics nomenclature as IGH, followed by the appropriate letter
and number to designate the specific subclass, i.e. IGHG3 for the γ3 gene, and IGHA1 for
the α1 gene (Lefranc and Lefranc, 2001). Immunoglobulins of a common class have
highly conserved peptide sequences, share common features and have similar functional
properties. The immunoglobulin classes IgA, IgD and IgG have heavy chains containing
three immunoglobulin constant domains with a hinge that separates the CH2 and CH3
domains. IgM and IgE by contrast have four CH domains and no hinge. Most of the
differences between immunoglobulin subclasses are located in the hinge region.
The hinge region contributes to segmental flexibility (Nezlin, 1990) and in IgA
and IgG also to intermolecular covalent assembly (Coloma et al. 1997). Variability of the
length and amino acid content of the hinge region from each subclass results in a
different degree of flexibility and to the overall shape of the immunoglobulin (Løset et
al., 2005; Sun et al., 2005). The hinge of IgG consists of three segments, the upper,
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middle and lower hinge. The middle hinge is a rigid region that contains a variable
number of cysteines, which form the inter-chain disulfide bonds by connecting two
parallel polyproline double helices. It is connected to the Fc region by the lower hinge
and to the Fab portion by the upper hinge. The lower hinge is involved in binding the low
affinity Fc gamma receptors (Radaev and Sun, 2001). In humans, the IGHG1, IGHG2
and IGHG4 genes include only one separate hinge exon, whereas the IGHG3 hinge is
usually encoded by four exons and less frequently by two, three, or five distinct exons
(Dard et al., 1997; Lefranc and Lefranc, 2001). Since the IgG3 hinge region is encoded
by more than one exon, IgG3 molecules are characterized by hinge regions exhibiting
several repetitions and are therefore longer than the hinge regions of the other IgG
subclasses. Consequently, IgG3 molecules are the most flexible of all human IgG
subclasses (Roux et al., 1997). IgA1 molecules include an elongated hinge region rich in
proline residues. The IgA2 hinge region differs from the IgA1 hinge region by a 13residue stretch of amino acids, presumably the result of an evolutionary response to
bacterial IgA1 specific proteases (Kerr, 1990). The human IgD hinge region includes 64
amino acid residues and is, therefore, longer than the hinge region of the other antibody
classes (with the exception of IgG3). Hinge regions are characterized by evolutionary
instability, as they are the most diverse at the interspecies and intraspecies level
(Flanagan, 1984; Scinicariello and Attanasio, 2001; Attanasio et al., 2002; Sumiyama et
al., 2002; Scinicariello et al., 2004). Differences in the hinge of each molecule have been
demonstrated to alter immunoglobulin affinity for antigen and immune complex
formation (Roux et al., 1997; Løset et al., 2004). In some HIV in vitro studies IgG3 with
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its long hinge has been demonstrated to be more efficient than other IgG subclasses at
neutralizing viruses in the absence of affinity differences (Cavacini, 1995; Scharf et al.,
2001). Hence the hinge region greatly contributes to antigen binding and antigen
elimination.
Immunoglobulins are expressed as BCR or as secreted proteins based on the type
of carboxyl-terminal tail they express. Immunoglobulins forming BCRs are anchored to
the plasma membrane by a hydrophobic tail that makes up the transmembrane domain
and a short cytoplasmic tail. The transmembrane domains of all antigen receptors,
including TCRs, have residues that make up a conserved antigen receptor transmembrane
motif (CART). This motif is believed to be necessary for proper association with the
signaling molecules of the antigen receptor complex (Campbell et al., 1995). For BCR,
these signaling molecules are the invariant transmembrane proteins Ig-α and Ig-β, which
contain the necessary cytoplasmic elements for signaling and antigen presentation
(Cambier et al., 1994). For all human immunoglobulin heavy chains, the immunoglobulin
transmembrane tail is encoded by two exons (M1 and M2) found 3’ to the last CH exon
of the gene, whereas secreted antibodies have a short hydrophilic tail that varies greatly
between the different immunoglobulin isotypes. For all isotypes except IgD, the secretory
tail is encoded at the 3’ end of the final CH exon. The IgD secretory tail has been found
to be encoded by a separate exon (CH-S) located between the CH3 exon and the exons
M1 and M2 of the Igδ gene (IGHD) in all species in which it has been characterized.
Polyadenylation of polyA motifs found 3’ of the tail to be used and subsequent
alternative splicing regulate production of the cytoplasmic tail.
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Immunoglobulin subclasses and functions
Antibodies alone in some cases are sufficient to inactivate a pathogen to prevent
infection or render toxins innocuous. These antibodies are called neutralizing antibodies.
The mechanisms responsible for neutralization are not fully understood (Burton, 2002).
Neutralizing antibodies may defend against viruses by occupying all possible virion sites
of interaction with host cells, thus blocking infection. Evidence indicates that other
antibody properties are usually required to prevent or stop infections. Fab fragments from
neutralizing antibodies generally lose the ability to prevent disease (Burton, 2002).
Indeed, many bacteria actively produce proteases that separate antigen binding Fab
fragment from the Fc fragment of the antibody (Kilian et al., 1996). It has been suggested
that some gut bacteria may be able to use IgA Fab fragments created by their proteases to
cloak antigen epitopes from other intact antibodies to escape targeting by the immune
system. Other bacterial proteins like staphylococcal superantigen-like protein 7 bind the
Fc region of IgA antibodies, thereby blocking interactions with complement and Fc
receptors (Langley et al., 2005).
Each immunoglobulin subclass has different properties and consequently
performs different functional roles in the immune system (Figure 1.2 and Table 1.1)
(Spiegelberg, 1989). Particularly, immunoglobulin functional differences include eliciting
different immune effector mechanisms (complement-dependent cytotoxicity, antibody-
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Figure 1.2. Structure of the five mammalian classes of immunoglobulins. Diagram is an
adaptation from Kuby (1997).
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Table 1.1. Functional properties of the human immunoglobulin subclasses (Kuby, 1997).
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+

+
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-

-

-
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dependent cellular cytotoxicity, and opsonization), physiological localization, ability to
multimerize, ability to cross the placenta, and secretion at mucosal surfaces (Burton and
Woof, 1992; Jefferis et al., 1998). Each subclass within an immunoglobulin class appears
similar to the other (only a 5-10% gene difference for the IgG subclasses). However,
there are important differences between them. Production of a specific subclass is
controlled by genetic rearrangement at the heavy chain gene locus, a process called
isotype switching (Stavnezer, 1996). This process results in a heavy chain consisting of
the same variable domain (and therefore with identical antigen specificity). The
environmental milieu of a B cell dictates which subclass of antibody is produced and is a
reflection of the assault with which the immune system is challenged. For example, a
viral infection stimulates T helper type I cytokines that will result in isotype switching to
produce antibody classes best able to fight intracellular infections.
IgM and IgD with the same antigen specificity are coexpressed on the surface of
naïve B cells and act as the initial BCR to bind antigen. No other combination of two
immunoglobulins can be expressed. Uniquely, Igµ and Igδ genes are transcribed in a
single RNA molecule which is then polyadenylated 3’ of either the Igµ exons or the Igδ
exons and then spliced (Preud’homme et al., 2000). Of the two, IgD is the least
understood. Results from a few recent studies show that IgD and IgM may modulate B
cell activation differently. Secreted IgD makes up only about 0.5% of serum
immunoglobulins and very little research has been performed to determine its role
(Brandzaeg et al., 1991). Both membrane and secreted IgD can bind to receptors
expressed on T cells, hence modulating immune responses (Amin et al., 1991; Rudd et
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al., 1995). IgM constitutes 5-10% of the total serum immunoglobulin. Low affinity IgM
is the first immunoglobulin secreted in a primary immune response and is thought to
represent the major isotype of natural antibodies. Natural antibodies are secreted in the
absence of prior exposure to antigen, and often have broad antigen specificity. Natural
antibodies may play an important role by priming the immune response through an initial
capture of pathogens for processing by APC (Ochsenbein et al., 1999). Multimeric IgM is
efficient at activating the classical complement pathway. IgD does not form multimers
and does not activate the classical complement pathway.
Both IgA and IgM multimerize and are transported across epithelial cells to
mucosal surfaces (Brandzaeg et al., 1999). IgM molecules form pentamers and IgA
predomintly forms dimers, although IgA polymers can exist also in trimeric and
tetrameric forms. Multimerization is facilitated by the attachment of a polypeptide chain
called the J chain. The J chain in turn can associate with the poly-immunoglobulin
receptor (pIgR) expressed on the basolateral surface of epithelial cells. The pIgR then
endocytoses and transports the immunoglobulin to the apical surface. The pIgR is then
cleaved to release the immunoglobulin, leaving a portion of the pIgR (referred to as the
secretory component) still attached to the molecule. IgA is the most abundant
immunoglobulin class, accounting for 10-15% of serum immunoglobulin and for almost
all of secreted immunoglobulin (76-90% in the gut mucosae, 69-86% in nasal, lacrimal
and parotid glands) (Brandtzaeg et al., 1999). In the mucosae, IgA acts via immune
exclusion by coating pathogens and preventing them from binding to the mucosal linings.
IgA also helps with clustering of pathogens and their subsequent expulsion from the

18

mucosae (van Egmond et al., 2001). IgA is considered an anti-inflammatory
immunoglobulin. Through binding Fc receptors (FcαRI or CD89), IgA can down regulate
the effector functions of leukocytes from the myeloid lineage, such as inflammatory
cytokine release induced by IgG immune complexes. Somewhat paradoxically, IgA
immune complexes can interact with the same receptor to induce leukocyte effector
functions (Pasquier et al., 2005).
IgG makes up 80% of serum immunoglobulins with the relative abundance of the
human subclasses being IgG1>IgG2>IgG3>IgG4 (Kuby, 1997). IgG are usually high
affinity antibodies and are produced late in a primary immune response. IgG modes of
action differ between subclasses. IgG3 followed by IgG1 then IgG2 can activate
complement, whereas IgG4 cannot. IgG1, IgG3 and IgG4 are transported across the
placenta to protect the fetus. IgG1 and IgG3 are most efficient at binding Fc receptors
(Gessner et al., 1998).
IgE has a very low serum concentration and is mostly bound to mast cells and
eosinophils through the high affinity IgE Fc receptor. Antigen cross-linking of Fc
receptor bound IgE on these cells results in the release of type I hypersensitivity reactions
mediators. Type I hypersensitivity reactions range from common allergies to anaphylaxis.
In addition, IgE plays an important role in defense against parasites (Kuby, 1997).
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Immunoglobulin Fc receptors
The humoral immune system consists mostly of antibodies and is connected to the
cellular immune system though immunoglobulin Fc receptors (FcRs). FcRs exist for all
antibody isotypes and are present on all leukocytes (Ravetch and Kinet, 1991). However,
different Fc receptors are present for the different types of leukocytes and each is specific for
one or a few immunoglobulin subclasses. Antigen/immunoglobulin complexes act to crosslink FcR and subsequently set off intracellular signaling cascades. FcRs contain either
immunoreceptor tyrosine activation motifs (ITAMs) or immunoreceptor tyrosine inhibition
motifs (ITIMs), which function to activate or inactivate cells, respectively. The first step of
the signaling cascades is the phosphorylation at tyrosines of one of these motifs (Cox and
Greenberg, 2001). Most leukocytes have both ITAM and ITIM-containing receptors and the
balance of these competing signals determines the activation status of the cell. Although FcR
activation is similar in different classes of leukocytes, the induced effector functions are
dictated by which type of leukocyte is activated. FcR-induced effector functions that directly
target antigens include phagocytosis, antibody-dependent cell-mediated cytotoxity (ADCC),
and respiratory burst (Ravetch and Kinet, 1991). Additionally, FcR-controlled events include
release of cytokines and inflammatory mediators, and antigen presentation. The IgA Fc
receptor I, CD89, can regulate IgA half-life by protecting endocytosed IgA for transport back
out of the cell or by transporting it to the lysosome compartment for degradation (Launay et
al., 1999). IgG Fc receptors may modulate antibody production by IgG-mediated feedback
suppression or by enhancement of antibody responses (Heyman, 2003).
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FcRs are diverse in their structure, but share common features and nomenclature.
FcRs were first described in the 1970’s, and the IgE high affinity immunoglobulin receptor
(FcεRI) was the first characterized at the molecular level. FcεRI is made up of four
polypeptide chains: α, β, and a γ dimer formed by an inter-chain disulfide bond (Conner and
Saini, 2005). The FcεRI α chain is the IgE ligand binding chain. The β and γ chains are
responsible for intracellular signaling and each consists of a transmembrane portion and a
cytoplasmic tail containing ITAMs. Subsequent to the description of FcεRI, other FcR
(FcγRI, FcγRIII and FcαRI) were found to consist also of unique ligand binding α chains and
the same γ chain dimer (FcRγ2) (Ravetch and Kinet, 1991). The α chains associate with
FcRγ2 through conserved charged residues in the transmembrane domain of each chain.
Alternatively, in human natural killer cells FcRγ2 can be substituted with a TCR ζ signaling
chain dimer or a heterodimer of a TCR ζ and FcRγ (Lanier et al., 1989). For the IgG
receptors FcγRI and FcγRIIIa, the signaling chains have been shown to be required for
efficient transport from the endoplasmic reticulum to the plasma membrane, whereas the IgA
receptor FcαRI may be transported to the plasma membrane without association with FcRγ2
(van Egmond et al., 2001). In contrast to other receptors, the IgG Fc receptors FcγRIIa and
FcγRIIb consists of single α chain only with an extended cytoplasmic tail that contains either
an ITAM or ITIM, respectively (Ravetch and Bolland, 2001). Human neutrophils may also
express FcγRIIIb. This receptor is almost identical to FcγIIIa, but is truncated and connected
to the plasma membrane by a GPI-link. This receptor lacks any signaling motif and functions
by modulating the function of other neutrophil FcRs with which it becomes cross-linked
(Ravetch and Bolland, 1998). FcR α chains are members of the immunoglobulin superfamily,
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because they all have two or more immunoglobulin-like domains forming their extracellular
portion. The IgG Fc receptors bind IgG with their membrane proximal immunoglobulin-like
domain at an 1:1 ratio (Radaev and Sun, 2001). By contrast, FcαRI binds IgA at its first
immunoglobulin-like domain in a 2:1 ratio (Herr et al., 2003). FcRs have different affinities
for immunoglobulins. The high affinity FcεRI allows it to bind to monomeric IgE, thus
resulting in a low concentration of free IgE in serum (Conner and Saini, 2005). Fc receptors
with low affinities usually bind antibodies as part of immune complexes.
Fc receptors are important not only for initiating immune responses to pathogen. IgG
receptors are polymorphic within the human population and it is now well established that
certain polymorphisms are risk factors for susceptibility to some infectious diseases and
autoimmune disorders (van der Pol and van de Winkel, 1998). Polymorphisms of FcγRIII
are associated with severity of Guillain-Barré syndrome (Sorge et al., 2005). Soluble FcαRI
released from cells has been proposed in a model for the mechanism of IgA nephropathy, the
most common form of primary glomerulonephritis and renal failure (Launay et al., 1999;
Monteiro et al., 2002; Monteiro, 2005). Although this model is still hotly debated, there is a
tacit consensus that one or more Fc receptors are likely to be involved in IgA nephropathy
(van der Boog, 2003; van der Boog et al., 2004). Fc receptor interactions are also critical to
the design and use of therapeutic antibodies. Monoclonal antibodies are effectively used to
prevent and/or control a variety of disorders, including cancer, autoimmune diseases and
infectious diseases (Schulze-Koops and Lipsky, 2000; Zeitlin et al., 2000; Park and Smolen,
2001). At least eleven therapeutic antibodies are currently approved for human therapy and
the need for novel engineered antibodies continues to expand (Presta, 2002; Cohen-Solal,
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2004). Currently, over 300 different clinical trails involving monoclonal antibodies are listed
on the National Institute of Health website (http://www.clinicaltrial.gov). A clear
understanding of the mode of action of monoclonal antibodies should take into account Fc
receptor interactions. Antibodies designed to ameliorate autoimmune diseases often have as
their goal to stimulate inhibitory receptors like FcγRIIb, while at the same time avoiding
stimulation of activating receptors. For antibodies being used for cancer treatment just the
opposite is true. Therefore, antibodies with modified Fc regions are being engineered. Such
modifications can be designed only if a detailed characterization of Fc receptor/antibody
interaction is available (Newman et al., 2001; Bisikirsha et al., 2005). To further complicate
matters, engineered bispecific antibodies that have one variable region with specificity for a
tumor antigen and the other with specificity for an Fc receptor are considered to have great
potential as cancer therapeutics. Even once a monoclonal antibody is developed and shows
efficacy in clinical trails, the reasons for the success are often unknown and required further
research (Bisikirsha et al., 2005).
Antibodies and their Fc receptors are studied widely in different species to understand
their structure and function. It is hoped that information from these studies will help to devise
means to better bolster positive or attenuate harmful immune responses in humans and in
economically important species. These studies also have yielded important insights into the
evolution of the immune system, which has given us a better understanding of host-pathogen
interactions. The antibodies and Fc receptors most extensively studied have been those of
humans and species important as models of human diseases and immunity. In particular,
mice are well studied and have given us great insight into how the immune system operates.
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However, mice differ from humans in their humoral immune system. For example, mice have
only one subclass of IgA and their IgD is quite structurally distinct from the human IgD
(Mushinski et al., 1980; Shimizu et al., 1982). Fc receptors show major differences between
mice and humans. Mice have no homologues of several human Fc receptors: IgA Fc receptor
I (CD89), IgG Fc receptor IIa (CD32a), and IgG Fc receptor IIIb (CD16b) (Ravetch and
Kinet, 1991). Additionally, the mouse IgG Fc receptor CD16a does not appear to be a true
orthologue of human CD16a (Hughes, 1996). Indeed, comparative studies with other species
show that the biology of antibodies and their receptors is quite diverse throughout
vertebrates. Therefore, to perform research with the goal of understanding human humoral
immune responses, it is often necessary to use species phylogenetically closely related to
humans. Hence, nonhuman primates are often the animal models of choice. This choice is
based on the assumption that antibodies and Fc receptors are highly conserved between
humans and nonhuman primates. Existing data generally support this assumption, but
antibodies and Fc receptors have not been fully characterized in any species including
nonhuman primates.

Animal models
The use of animal models in biomedical research has provided and will continue
to provide the basis for numerous advances in medicine. Despite ever mounting
bioethical pressures to minimize the numbers of animals used in research and despite the
increasing availability of in vitro experimental systems, animal models are indispensable
to understand human physiology and human diseases. Only in vivo models can reproduce
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the complexity of the interactions connecting the human organ systems. These systems
cannot be fully understood through reductive studies of their individual components.
According to the United States Department of Agriculture, an estimated 1.13
million animals were used in research in 2002. Rodents make up the majority of these
animals, whereas nonhuman primates account for about one percent (~50,000) of animals
used in research. The absolute number of nonhuman primates currently in use has been
steady for over 20 years. Recent developments in biomedical research have increased
demand for these species, despite considerable efforts made to minimize their use
whenever possible. Nonhuman primates remain an appropriate model for research in
hematology, immunology and virology (Hérodin et al., 2005; Patterson and Carrion
2004). Furthermore, the demand for nonhuman primates is expected to increase because
of needs related to the development of therapeutics and vaccines against potential
bioterrorism threats (Patterson and Carrion, 2004). Indeed, the US Food and Drug
Administration’s new guideline for the assessment of reagents against select agents
would require testing in at least two animal models, one of which should be a nonhuman
primate (Patterson and Carrion, 2004). The evaluation of therapeutic strategies now
includes the understanding of their mechanism of action as well as the careful analysis of
potential side effects, thus requiring the presence of minimal differences resulting from
species divergence.
Nonhuman primates used in biomedical research are represented by many species.
Therefore, we will briefly discuss the evolution of primates and their phylogenetic
relationships.
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Primate evolution
Although mammals are as ancient as the dinosaurs, the fossil record suggests that
mammal diversity was limited until the end of the Cretaceous period, when the die off of
the dinosaur allowed for the rapid adaptive radiation of mammals to fill the opening
niches. Placental mammals emerged about 140 million years ago (MYA) and radiated
during the Cenozoic period. Most of the major groups were established during the
Paleocene epoch about 65 MYA. The fossil record indicates that distinct primate forms
emerged at this time starting with the prosimians. Only recently some consensus has been
reached by taxonomists on the overall relationship of placental mammals. Currently,
placental mammals are divided into Afrotheria, Xenarthra, Laurasiatheria, and
Euarchontoglires, the group in which primates and rodents are placed (Springer et al.,
2004). This new phylogeny clearly removes chiroptera from its previous grouping with
primates making flying lemur and members of scandentia the closest relatives of
primates. It is also now accepted that rodents are more closely related to primates than to
carnivores and ungulates (Springer et al., 2004). Primate evolution is believed to have
started in the old world where the ancestors of modern prosimians, Old World monkeys
(Catarrhines) and New World monkeys (Platyrrhines), coexisted perhaps up to the late
Eocene epoch.
The history of anthropoids (Old World monkeys, New World Monkey and
hominoids) is based on the exchange of species between Eurasia and Africa, and it’s still
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an area of controversy. The latest fossil evidence suggests that the earliest African
anthropoids emigrated from Asia before the late Paleocene, just before 37 MYA. At the
same time, other species were being swapped between these continents (Jaeger and
Marivaux, 2005; Seiffert et al., 2005; Beard 1995). Recently, molecular studies have
placed the split off of the New World monkey around 35 MYA. At that time, the
ancestors of these monkeys may have crossed the Atlantic to South America where their
descendants are found today (Schrago and Russo, 2003). The ancestors of modern Old
World monkeys and hominoids, which include humans and the apes, probably stayed in
Africa until they split around 25 MYA ago. Further splits occurred about 18 MYA when
the lesser apes (Gibbons and Siamangs) split from the great apes, and around 14 MYA
when the papionins split from the colobines (Stewart and Disotell, 1998). Investigators
generally agree on the relationship of the greater apes: humans are most closely related
to chimpanzees, with whom they share a common ancestor about some 5 MYA (Schrago
and Russo, 2003; Stewart and Disotell, 1998). By contrast, the relationships between Old
World monkey species (papionins, which include baboons, mangabeys, and macaques)
are far from resolved. As a general rule, however, the African species of baboons,
mangabeys, and mandrill are grouped together apart from the mostly Asian macaques
(Stewart and Disotell, 1998). There is only one non-Asian macaque species, Macaca
sylvanus. This species raises doubts on the monophyletic origin of the genus Macaca
(Groves, 2000). Figure 1.3 depicts the phylogentic tree of Old World monkeys and
hominoids along with a chronology of evolutionary events.
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Figure 1.3. Phylogeny of catarrhine primates. Adapted from evolution and phylogeny
proposed by Stewart and Distell (1998). Estimated times of splits for the major groups
are shown. The intercontinental dispersal events between Africa and Eurasia are indicated
by the arrows with the stem of the tree starting in Africa.
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Nonhuman primates in research
Evolutionarily humans are most closely related to the great apes (chimpanzees,
gorillas, organutans and gibbons), and therefore our physiology is most similar that of
these species (Rogers and VandeBerg, 1998).Only a few studies are carried out in great
apes since, they are endangered. In addition, the costs associated with research in these
animals are prohibitively expensive (Shearer, 1999). Therefore, most nonhuman primate
research is performed using the papionini group of Old world monkeys. A review of
publications in which nonhuman primates were recently used shows that the most widely
used species are, in descending order, Macaca mulatta (rhesus macaque), Macaca
fascularis (cynomolgus macaque) and Papio spp. (baboons). Chlorocebus aethiops
(African green monkey), is the most commonly used species when counting in vitro
studies using cells lines, i.e. Vero cells, which are derived from this species (Carlsson et
al., 2004). On a smaller scale, some species of New World monkeys and prosimians are
also used in research. The primary areas of research that use nonhuman primates are
microbiology including HIV/AIDS (26%), neuroscience (19%), biochemistry (12%) and
pharmacology/physiology (11%) (Carlsson et al., 2004).

Macaques
The macaques are included in the living cercopithecine. Macaques used in
research include rhesus macaques (M. mulata), crab eating or cynomolgus macaques (M.
fascicularis) and pig-tailed macaques (M. nemestrina).
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Rhesus monkeys have been the primary primate used in medical research up
until recently, but their use is now likely to decrease. Once abundant for use and
inexpensive, a decline in their numbers resulted in an embargo in their trade from India
in 1978 and subsequently a shift to imports from China which has been accompanied by
a rising cost. The vital role of rhesus macaques in HIV pathogenesis and in AIDS
vaccine development research has placed this species at the forefront of immunological
studies in primates (Earl et al., 2002; Horton et al., 2002; Barber et al., 2004; Evans et
al., 2003; Lifson et al., 2003; Monceaux et al., 2003; Willey et al., 2003; Lena et al.,
2002). In addition, these monkeys have been and continue to be employed for
immunological characterization and vaccine design for viral, bacterial, and protozoan
infections associated with Ebola virus (Geisbert et al., 2002), West Nile/dengue virus
(Pletnev et al., 2003), hepatitis E (Purcell et al., 2003), Mycobacterium tuberculosis,
Borrelia burgdorferi (Lyme’s disease), Helicobacter pylori (Del Giudice, 2001;
Langermans et al., 2001; Pachner et al., 2001; Lai et al., 2003), Leishmania major
(Freidbag et al., 2003) and Plasmodium species (Angov et al., 2003).
As rhesus macaques become less available and more costly, researchers have
focused on other macaques as animal models including pigtail macaques and
cynomolgus macaques. Pigtail macaques are now being extensively used as animal
models for AIDS-related studies (Qian et al., 1994; Dale et al., 2002; Herz et al., 2002;
Yu Kimata et al., 2002; Ambrose, 2003; Shen et al., 2003). They are being developed
as animal models for mucosally transmitted HIV-1 infection using R5-tropic SHIV
(simian/human immunodeficiency virus) and characterizing neutralization-resistant

30

virus variant of SHIV (Stephens et al., 1997; Narayan et al., 1999; Chen et al., 2000).
Other research studies using pigtail monkeys include studying the pathogenesis of viral
gastroenteritis (Subekti et al., 2002) and identifying immunological markers of aging
(Bowden et al., 1994). Cynomolgus macaques are being used similarly to other
macaques species for pathogenesis and vaccine studies a sampling of which include
yellow fever-dengue (Guirakhoo et al., 2004), hepatitis E virus (Li et al., 2004), HIV
(Reimann et al., 2005), SARS (Qin et al., 2006), scrub typhus (Chattapadhyay et al.,
2005) and Yersina pestis (bubonic plague) (Honko et al., 2006). Additionally, macaques
have frequently been used to test evaluate therapeutic antibodies and have been used in
transplantation studies, two area of research that are not mutually exclusive (Cendales et
al., 2005; Cozzi et al., 2005; Gaudreault et al., 2005; Martin et al., 2005; Hering et al.,
2006; Kim et al., 2006).

Baboons and sooty mangabeys
Two types of African papionini monkeys used in research are baboons (Papio
species) and sooty mangabeys. Baboons are used as models for numerous biomedical
interests including transplantation (Elster et al., 2001; Hoerbelt and Madsen, 2004),
therapeutic antibodies (Wu et al., 2002; Deckmyn et al., 2005), vaccine development,
and cardiovascular disease (Kushwaha and McGill, 1998; Holm, 2001), which in recent
years has been recognized to involve immune responses. The use of baboons benefits
several areas of research because many of these animals from the primate centers in the
US are pedigreed (VandeBerg and Williams-Blangero, 1997). Baboons are now
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commonly used as animal models for the development of several vaccines, including
HIV infection/AIDS (Locher et al., 2001; Wang et al., 2002; Locher et al., 2003)
influenza virus (Bot et al., 2001), hepatitis B virus (Watts et al., 1999), Hemophilus
influenza (Shearer et al., 1997), Mycobacterium tuberculosis (Pehler et al., 2000),
Neisseria mengiditis (Granoff et al., 1997), group B Streptococcus (Paoletti et al.,
2000), and Schistosoma mansoni (Farah and Nyindo, 1996). Sooty mangabeys
(Cercocebus torquatus) are natural hosts of SIV, but rarely develop AIDS-like
pathogenesis as do macaques infected with SIV (Ling et al., 2004). Therefore sooty
mangabeys represent useful animal models for evaluation of AIDS pathogenesis and
potential vaccines (Villinger, 1996; Kaur et al., 2000; Ansari et al., 2003; Bostick et al.,
2003; Silvestri et al., 2003; Veazey et al., 2003, Silvestri, 2005). Mangabeys represent a
useful model to study leprosy (Wolf et al., 1985; Gormus et al., 1995).

Study objectives

The immune system is an essential defense without which we would quickly
succumb to pathogens and malignancy. Just as the challenges to this defense are many,
diverse and complex, so is the makeup of the immune system. Although in vitro studies
are pivotal to advance our understanding of immune responses, in vivo studies are
indispensable to complete this understanding. Since the first use of vaccines, medical
science has constantly strived to develop new ways to manipulate the immune system to
bolster or attenuate it where needed for better health. These developments come through
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experimentation, which for ethical considerations and availability of proper controls
cannot be done in humans. Therefore, animal models are often used in immunological
research. Nonhuman primates are excellent animal models because they are most similar
to humans when compared to other species commonly used in biomedical research. In
order to optimize the value of research performed in nonhuman primates, it is necessary
to understand their physiology. Antibodies and hence their Fc receptors are crucial to the
adaptive humoral immune system. These molecules are being actively researched and
used as tools to modulate the immune responses in humans, yet their structure and
functions are not fully characterized, especially for the nonhuman primate species in
which testing of immunotherapeutic strategies is carried out.
Our laboratory seeks to understand how the immune system is shaped by and
responds to challenges from pathogens and immunosenescence. We have characterized
humoral immune responses generated against antigen challenge or as a result of aging in
healthy nonhuman primates. In addition, we have characterized the immunoglobulin
variable and constant region gene repertoire as well as antibody gene polymorphisms in
these species, focusing on IgA and IgG molecules. The present study was designed to
expand the characterization of nonhuman primate humoral responses.

Specifically, our objective was to answer the following questions:
1) What is the extent of similarity between human antibody genes and nonhuman primate
antibody genes, in particular the IgD heavy chain gene? Are IgD molecules conserved in
these species and might they have conserved features that suggest shared function? What
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insights can this information bring to understanding structure/function relationships in
other antibody isotypes?
2) Do humans and nonhuman primates share the same immunoglobulin Fc receptors and
are Fc receptors expressed on the same cell types in humans as in nonhuman primates?
3) How do human and nonhuman primate antibodies interact with nonhuman primate Fc
receptors?
Answers to these questions will enhance and guide work performed with nonhuman
primates, improving our understanding of the strengths and weaknesses of scientific
results obtained using these species. Ultimately, this work will provide a foundation for
research that focuses on the development of therapies to prevent and treat infectious
diseases and cancers, prevent transplant rejection, and control autoimmune diseases.
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CHAPTER 2
Identification and Characterization of Macaque CD89 (IgA Fc Receptor)
The content of this chapter was published as: Rogers et al., Immunology 2004;
113:178-86.
Keywords: CD89, IgA receptor, Macaques, Splice variants, Nonhuman primate
models

Summary
The interaction of the IgA molecule with its specific cellular receptor is
necessary to trigger a variety of effector functions able to clear IgA-opsonized
antigens. The human IgA-specific Fc receptor, FcαRI or CD89, is expressed on cells
of the myeloid lineage. Recently, CD89 homologues have been identified in rats and
cattle. Because nonhuman primates represent well established models for a variety of
human diseases and for the testing of immunotherapeutic strategies, we cloned and
sequenced cDNAs corresponding to the CD89 gene from rhesus (Macaca mulatta)
and cynomolgus (Macaca fascicularis) macaques. Macaque sequences of full-length
CD89 consist of five exons of length identical to the corresponding human CD89
exons. The rhesus and cynomolgus macaque derived amino acid sequences are highly
homologous to each other (99.3% identity) and exhibit 86.5% and 86.1% identity to
the human counterpart, respectively. Transfection of HeLa cells with plasmids
containing the cloned macaque cDNAs resulted in the expression of surface
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molecules recognized by an anti-human CD89 antibody. Five splice variants were
identified in rhesus macaques. Three of the five variants are similar to described human
CD89 splice variants, whereas two variants have not been described in humans. Three
splice variants were identified in cynomolgus macaques. Of the three variants, one is
present also in humans and rhesus macaques, whereas the other two are shared with
rhesus macaques but not humans. Similarly to the human CD89, macaque CD89 is
expressed on myeloid cells from peripheral blood. The characterization of macaque
CD89 represents an essential step in establishing a nonhuman primate model for the
testing of immunotherapeutic approaches based on the manipulation of the IgA/CD89
interaction.

Introduction
Fc receptors (FcRs) are expressed on a variety of immune effector cells and, by
binding the constant region of antibody molecules, provide an essential link between the
humoral and cellular arms of the immune system (Ravetch and Kinet, 1991). FcαRI
(CD89), the Fc receptor specific for IgA molecules, is a transmembrane glycoprotein that
belongs to the immunoglobulin gene superfamily (Maliszewski et al., 1990). It is
expressed on monocytes, eosinophils, neutrophils and macrophages (Monteiro and van de
Winkel, 2003) and its signaling capacity is dependent on the association with the FcR γchain subunit (Pfefferkorn and Yeaman, 1994). The human CD89 gene is located within
the leukocyte receptor cluster on chromosome 19 (Kremer et al., 1992), appears to exist
as a single copy (Maliszewski et al., 1990), spans 12 kb and includes five exons (de Wit
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et al., 1995). Exons S1 and S2 encode the leader peptide, EC1 and EC2 each specify an
extracellular immunoglobulin-like domain of 103 amino acids, and TM/C codes for the
transmembrane domain (19 amino acids) and cytoplasmic tail (41 amino acids) of the
receptor.
The CD89/IgA interaction mediates immune effector responses, including
antibody-dependent cell-mediated cytotoxicity, phagocytosis and respiratory burst, as
well as release of cytokines and inflammatory mediators (Monteiro and van de Winkel,
2003). Therefore, this interaction is necessary to maintain the integrity of the immune
responses in both systemic and mucosal compartments. Indeed, IgA is the most
abundantly produced antibody isotype and represents a first line of defense at mucosal
surfaces. The IgA system differs in the animal species most extensively studied. In
humans, there are two IgA subclasses, designated IgA1 and IgA2. Both subclasses bind
FcαRI with a low affinity of approximately Ka = 106 M-1 (Wines et al., 1999). Only one
IgA subclass is present in mice (Shimizu et al., 1982), whereas rabbits possess 13 IgA
subclasses (Burnett et al., 1989). In rhesus macaques, IgA molecules are characterized by
an extremely high level of intraspecies heterogeneity (Scinicariello and Attanasio, 2001;
Scinicariello et al., 2004). This IgA heterogeneity appears in several nonhuman primate
species (Sumiyama et al., 2002). Interestingly, no FcαRI homologue has been identified
in mice. Recently, FcαRI homologues have been identified in rats (Maruoka et al., 2004),
and cows (Morton et al., 2004). Here, we describe the rhesus and cynomolgus macaque
CD89.
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Materials and methods
Amplification, Cloning and Sequencing of Macaque CD89
Heparinized blood samples were collected from one healthy rhesus macaque
(Macaca mulatta) and one healthy cynomolgus macaque (Macaca fascicularis). Total
RNA was extracted from whole blood using the QIAamp RNA Blood Mini Kit (Qiagen
Inc., Valencia, CA), and reverse transcribed into cDNA using oligo d(T)17 primers,
followed by primer extension with the AMV reverse transcriptase (Roche Diagnostic
Corp., Indianapolis, IN). PCR amplification of the cDNA was performed with Expand
High Fidelity polymerase (Roche Diagnostic Corp.). The nucleotide sequences of the
PCR primers used to amplify the complete CD89 transcripts have been previously
reported by Pleass and co-workers (Pleass et al., 1996). Forward (RP1) and reverse (RP2)
primers specific for the human CD89 located at the start codon of the S1 exon and the
stop codon of the TM/C exon, respectively, were employed. The PCR conditions used
were those described by Pleass and coworkers (Pleass et al., 1996) except that forty
cycles of PCR were performed.
An alternate form of CD89, known also as FcαRIb (which lacks exon TM/C but
contains nucleotide sequences present in the intron located between exon EC2 and exon
TM/C of variant 1) has been described (van Dijk et al., 1996). There are two FcαRIb
isoforms, known as CD89 transcript variants 9 and 10 (van Dijk et al., 1996). In order to
amplify this alternate form, we designed the FCARB2 primer (5’TCTAGCGAGGAAGTGAAAGCGG-3’) located at the 1024-1003 nt of the CD89
transcript variant 9 (GenBank NM_133279) that, used with the RP1 primer, allows
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amplification of the complete FcαRIb transcripts. After reverse transcription of total
RNA, the cDNA was amplified with the FCARB2 and RP1 primers using the same
conditions described for the RP1 and RP2 primers (Pleass et al., 1996). Fifty microliters
of a PCR reaction was run on a 2% agarose gel. The bands of interest were excised from
the gel, purified using the QIAquick Gel Extraction Kit (Qiagen Inc.) and ligated into the
pCR2.1 vector (Invitrogen Corp., Carlsbad, CA). After transformation into the
appropriate Escherichia coli, colonies from each sample were expanded. Plasmid DNA
was screened on a 1% agarose gel after EcoRI digestion, to confirm the presence of the
correct fragment size. All DNA sequences were determined using the ABI Prism Dye
Termination Cycle Sequencing kit (PerkinElmer, Inc., Wellesley, MA) on an ABI model
3100 automated sequencer (PerkinElmer, Inc.). The forward and reverse M13 primers
were used for sequencing. Completed sequences were edited and aligned using the
MacVector sequence analysis package (Accelrys Inc., Burlington, MA).

Expression of Macaque CD89 cDNAs in HeLa Cells
Full length rhesus and cynomolgus CD89 cDNAs ligated into the pCR2.1 vector
were subjected to digestion with XhoI and EcoRI. The resulting fragments were ligated
into the XhoI and EcoRI digested expression vector pcDNA3.1 (+) (Invitrogen Corp.) and
amplified in E. coli. Twenty µg of expression vector was then added to HeLa cells
suspended in 250µl of Dulbecco’s modified Eagle medium (DMEM) at 14×106 cells/ml.
After ten min of incubation on ice, cells were electroporated by one or two pulses using
the power supply set to 300V, 25mA, and 25W and the Electroporator II (Invitrogen
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Corp.) set to 1000µF and ∞Ω, according to the manufacturer’s recommendations. Cells
were then incubated at room temperature for ten minutes and grown in 10ml of DMEM
with 10% fetal calf serum in 5% CO2 at 37°C. For rhesus macaque CD89, stably
transfected cells were established by selection with Geneticin (400µg/ml) added 72 hours
post transfection. After several passages non-transfected and transfected HeLa cells were
harvested from cell culture following three PBS washes from wells with 90% confluent
growth. 1×106 cells were stained at 4°C with either 20µl of phycoerythrin-conjugated
mouse anti-human CD89 (clone A59) or SimultestTM Control γ1/γ2a (both from Becton,
Dickinson and Co., San Diego, CA) for 15 min, followed by 3 washes with PBS. A59
binds to the extracellular domain 2 (EC2) of CD89 (Morton et al., 1999). Cells were then
fixed with 1% paraformaldehyde and analyzed using a FACSCalibur flow cytometer
(Becton, Dickinson and Co.). Repeated flow analysis of cells transfected for rhesus CD89
confirmed that cells stably expressed rhesus CD89. Expression of cynomolgus macaque
CD89 in HeLa cells was determined as described above, with the exception that only
transient transfectants were generated and examined by flow cytometry analysis.

Determination of CD89 Expression on Blood Leukocytes
Blood from 4 rhesus and 7 cynomolgus macaques was collected in EDTA
Vacutainer® tubes (Becton, Dickinson and Co.) by venipuncture under anesthesia.
Leukocyte expression of CD89 was analyzed by two-color flow cytometry analysis using
phycoerythrin (PE)-conjugated anti-human CD89 and fluorescein isothiocyanate (FITC)conjugated monoclonal antibodies for CD14, CD20, and CD3 and cy-chrome conjugated
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anti-CD16 (Becton, Dickinson and Co.). Monoclonal antibody clones for CD14, CD20,
CD3 and CD16 were M5E2, L27, SP34, and 3G8 respectively. SimultestTM Control
γ1/γ2a was used to detect non-specific binding of mouse IgG to cells. Staining of whole
blood was done using a standard procedure. Briefly, 100µl of blood was incubated with
20µl of each antibody in the dark at room temperature. Erythrocytes were lysed with 2ml
of BD PharM Lyse (Becton, Dickinson and Co.), washed 3 times with PBS and fixed
with 1% paraformaldehyde. 5000 events were counted by flow cytometry.

Results
We cloned and sequenced macaque cDNA obtained through reverse transcription
of total RNA followed by amplification performed using primers complementary to
sequences located in the S1 and TM/C exons. The introduction of errors into the
sequence was minimized by using a high fidelity polymerase with proofreading ability.
To validate the amplification strategy, we amplified, cloned and sequenced the full length
human CD89 as well as two human alternatively spliced variants. All human sequences
matched those available in GenBank (accession numbers NM_002000, NM_133271 and
NM_133279) (data not shown). We then used the same strategy to amplify, clone and
sequence rhesus and cynomolgus macaque CD89. Each sequence was confirmed by
cloning and sequencing the products of another independent PCR performed using the
same total RNA. A complete transcript including all five exons along with several
additional transcripts representing alternatively spliced forms of the CD89 mRNA were
identified. Figure 2.1 shows the deduced amino acid sequences of the complete cDNA
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from rhesus and cynomolgus macaques along with the corresponding human sequences.
All five macaque exons were of length identical to the corresponding human CD89
exons. The rhesus macaque and the cynomolgus macaque CD89 amino acid sequences
exhibit 86.5% and 86.1% identity to the human counterpart, respectively. The rhesus
macaque CD89 amino acid sequence shows 99.3% identity to the corresponding
cynomolgus macaque sequence. Therefore, the CD89 sequences from these two
nonhuman primate species are highly homologous to each other, differing for only two
amino acids (a methionine/isoleucine substitution at position 40 and a
phenylalanine/leucine substitution at position 85). We did not identify amino acid
differences in the S1 and S2 exons between human and macaque sequences. The majority
of human/macaque substitutions are clustered in the EC1 exon.
To ascertain whether or not expression of the isolated full-length CD89 cDNA
resulted in the production of a cell surface product, we generated HeLa cell transfectants
using plasmids containing either rhesus or cynomolgus macaque full-length CD89
cDNA. Transfected cells were stained with a PE conjugated anti-human CD89 and a
mouse isotype control and analyzed by flow cytometry. Transfected cells exhibited
increased fluorescence intensity when stained for CD89 as compared to staining with a
control mouse antibody (Figure 2.2). Staining with anti-human CD89 PE did not result in
detectable fluorescence of untransfected HeLa cells indicating that CD89 was not
expressed in these cells prior to introduction of the expression vectors. The lower
fluorescence intensity levels observed in cynomolgus macaques as compared to rhesus
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TDPEFVIDHMDANKAGRYQCQYRIGHYRFRYSDTLELVVTGLYGKPFLSADRGLVLMPGENISLTCSSAHIPFDRFSLAK
TTPEFVIDHMDANKAGRYRCRYRIGFSRFRYSDTLELVVTGLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAK
TTPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVTGLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAK
│
▼
TM/C
EGELSLPQHQSGEHPANFSLGPVDLNVSGIYRCYGWYNRSPYLWSFPSNALELVVTDSIHQDYTTQNLIRMAVAGLVLVA
EGELSLPQHQSGEHPANFSLGPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVTDSINRDYTTQNLIRMAMAGLVLVA
EGELSLPQHQSGEHPANFSLGPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVTDSINRDYTTQNLIRMAMAGLVLVA
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HuCD89.1
LLAILVENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK 287
MamuCD89.1 LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287
MafaCD89.1 LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287

Figure 2.1. Alignment of CD89 derived amino acid sequences obtained by cloning and sequencing rhesus macaque (GenBank
accession number AY386684) and cynomolgus macaque (GenBank accession number AY386690) cDNA from whole blood
and comparison with the published human sequence (GenBank NM_002000). Amino acid differences are underlined. The first
amino acid of the preprotein is numbered as residue 1. The mature peptide starts at residue 22. Arrows indicate distinct
domains. The first two amino acids for EC1 are encoded at the end of the S2 exon. The signal peptide is encoded by both S1
and S2 sequences. Potential N-glycosylation sites, cysteines involved in disulfide bonds and arginine 209 critical for
association with the FcRγ chain are bolded. Hu: Homo sapiens; Mamu: Macaca mulatta; Mafa: Macaca fascicularis.
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A

B

Figure 2.2. Expression of recombinant macaque CD89 on HeLa cells. Cells were
transfected with a plasmid containing full-length (A) rhesus macaque CD89 cDNA or (B)
cynomolgus macaque CD89 cDNA and stained with anti-human CD89: red line (rhesus
MFI = 120.70, SD= 343.04; cynomolgus 30.35, SD=345.04) or with isotype control
mouse IgG: tan line (rhesus MFI = 8.65, SD=7.40; cynomolgus MFI=9.27, SD=34.47).
Untransfected HeLa cells stained with anti-human CD89: green line (MFI = 5.26, SD=
28.69). MFI= Mean fluorescence intensity, SD= standard deviation. Stable transfectants
were used for detection of rhesus macaque CD89 and transient transfectants were used
for detection of cynomolgus macaque CD89. 5,000 events were counted per sample.
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macaques are likely to reflect the transient transfection of Hela cells with the cynomolgus
macaque cDNA (as mentioned above, stable transfectants were used to detect cell surface
expression of rhesus macaque CD89).
Several distinct mRNA isoforms of the human CD89 have been identified. These
isoforms are generated through deletion of exons or parts of exons via alternative RNA
splicing, resulting in the expression of closely related but functionally different receptor
variants (Morton et al., 1996; Patry et al., 1996; Pleass et al., 1996; Reterink et al., 1996).
Therefore, alternative splicing may represent the mechanism underlying the
diversification of CD89 functions (Pleass et al., 1996). Ten human variants are listed in
the GenBank data base. In addition to the complete CD89 transcript, we have identified
several alternatively spliced transcripts in macaques. Specifically, five splice variants
were present in the rhesus macaque blood sample analyzed and three splice variants in
the cynomolgus macaque sample. Figure 2.3 depicts the derived amino acid sequences of
the rhesus macaque variants. Three of the five variants (MamuCD89.3, MamuCD89. 7
and MamuCD89.9) are similar to described human CD89 isoforms (Monteiro and van de
Winkel, 2003), whereas two variants (MamuCD89.∆EC1 and MamuCD89.
∆EC1∆TM/C) have not been described in humans. The derived amino acid sequences of
the splice variants from cynomolgus macaques are shown in Figure 2.4. Of the three
isoforms, one (MafaCD89.9) is present also in humans and rhesus macaques, whereas the
other two (MafaCD89.∆EC1 and MafaCD89.∆EC1∆TM/C) are shared with rhesus
macaques but not humans. Figure 2.5 shows the schematic representation of the complete
CD89 transcript and corresponding splice variants identified in both macaque species.
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Figure 2.3. Alignment of the five rhesus macaque CD89 splice variants (GenBank accession number AY386684-AY386689)
with full-length CD89 from the same species. Arrows indicate distinct domains. Mamu: Macaca mulatta.
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Figure 2.4. Alignment of the three cynomolgus macaque CD89 splice variants (GenBank accession number AY386690AY386693) with full-length CD89 from the same species. Arrows indicate distinct domains. Mafa: Macaca fascicularis.
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MamuCD89.1

MamuCD89.3 (∆EC2)

MamuCD89. ∆EC1

MamuCD89.7 (∆S2∆EC1)

MamuCD89.9 (∆EC1∆TM/C)
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Figure 2.5. Schematic representation of the complete CD89 transcript and corresponding
splice variants identified in rhesus and cynomolgus macaques. Mamu: Macaca mulatta;
Mafa: Macaca fascicularis.
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The two variants identified in macaques and not described in humans are characterized
by a deletion of the EC1 exon or by a deletion of the EC1 and TM/C exons. The latter
variant maintains the tail sequences, as found in a human isoform with deletion of the
TM/C exon. This human isoform is designated FcαRIb and results from an alternate
splicing that, by skipping the 3’ splice site located at the end of the exon EC2, introduces
a tail of 23 new amino acids before reaching the stop codon (van Dijk et al., 1996).
Human CD89 is expressed only in selected cells of the myeloid lineage and not in
lymphocytes. To determine whether or not macaque CD89 is similarly expressed, whole
blood from four rhesus and seven cynomolgus macaques was stained with the anti-human
CD89 PE as well as various FITC-conjugated antibodies against markers of leukocyte
populations and then analyzed by flow cytometry. Both macaque species expressed CD89
on granulocytes and monocytes, but not on lymphocyte populations. Cells positive for
markers of B cells, T cells and natural killer cells (CD20, CD3 and CD16 respectively)
were all CD89 negative in both species (Figure 2.6). In humans, CD16 is present on
neutrophils as well as on natural killer cells (Fleit et al., 1982). However, our results
indicate that either macaque granulocytes do not express CD16 or granulocyte CD16 is
present in a form not recognized by the antibody clone used in our study. Rhesus
macaque leukocytes stained for CD14 can be plotted along with their side scatter
properties to distinguish the lymphocyte, eosinophil, neutrophil, and monocyte
populations (Lafont et al., 2000). Taking advantage of this, we stained whole blood for
CD89 and CD14, and gated cell populations using a sidescatter versus CD14 dot plot
(Figure 2.7). Without gating, CD14/CD89 staining identified three clusters of cells: a
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Figure 2.6. CD89 is not expressed on lymphocytes of rhesus and cynomolgus macaques.
Two-color dot-plots of whole blood leukocytes from a representative rhesus (A-D) and
cynomolgus macaque (E-H). (A and E) forward scatter (FSC) versus side scatter (SSC). CD89
versus CD20 (B and F), CD3 (C and G), and CD16 (D and H).
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Figure 2.7. CD89 is expressed on monocytes and on granulocytes of rhesus and
cynomolgus macaques.Two-color dot-plots of whole-blood leukocytes from a
representative rhesus (A-D) and cynomolgus macaque (E-H). (A and E) CD14 versus
side scatter. CD14 versus CD89 (B and F) total leukocytes, (C and G) granulocytes, (D
and H) monocytes. Gates used for granulocyte (R1) and monocyte (R2) populations of
rhesus (A) and cynomolgus macaque (E) are shown.
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double negative population in the bottom left hand corner corresponding to lymphocytes,
a population with intermediate fluorescence on both axes, and a cluster of cells positive
for CD89 with a broad range of expression for CD14. Gating of the granulocyte
population revealed that the latter two populations contained granulocytes. The cluster of
cells with intermediate fluorescence likely corresponds to a portion of eosinophils, as
eosinophils are known to exhibit greater autofluorescence than other cell populations
(Lafont et al., 2000). A percentage of the eosinophil population was always found in the
CD89 high fluorescence cluster of cells, with the remaining CD89 positive cells
representing neutrophils and monocytes.

Discussion
Macaques are widely used in biomedical research as models for pathogenesis
studies, vaccine development and testing of immunotherapeutic approaches, including
experimental strategies to prevent transplant rejection (Attanasio et al., 2000; Guirakhoo
et al., 2000; Solnick et al., 2000; Hahn et al., 2001; Asiedu et al., 2003; Custer et al.,
2003; Lu et al., 2003; Vugmeyster et al., 2003; Xu et al., 2003). It is well recognized that
macaques infected with simian immunodeficiency viruses (SIV) or simian-human
immunodeficiency viruses (SHIV) are the best animal model currently available to study
AIDS pathogenesis and vaccine development (Hirsch and Lifson, 2000). Given the
importance of CD89 in the immune response, we identified and characterized CD89
cDNA in two different macaque species. Results from our experiments show that HeLa
cells transfected with plasmids containing rhesus macaque or cynomolgus macaque
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CD89 cDNA express the CD89 molecule on their cell surface, and this molecule is
recognized by an anti-human CD89 antibody. In addition, our results indicate that,
similarly to the human counterpart, macaque CD89 is expressed on blood leukocytes of
the myeloid lineage.
The rhesus and cynomolgus macaque CD89 amino acid sequences exhibit 86.5%
and 86.1% identity with the human counterpart, respectively, and are highly homologous
to each other (99.3% identity). The human CD89 cDNA encodes a protein containing six
potential N-glycosylation sites, four of which are located in the extracellular domains
(Maliszewski et al., 1990). The presence of ordered carbohydrates at these four sites
(N44, N58, N120, and N156) has been recently demonstrated in the crystal structure of
the human CD89 (Herr et al., 2003). The other two sites are located at positions 165 and
177. Differentially glycosylated CD89 species are expressed on monocyte/macrophages
and granulocytes (Monteiro et al., 1992). As shown in Figure 2.1, the six glycosylation
sites are also present in the CD89 sequences from both macaque species. However, an
additional potential glycosylation site is present in the EC1 domain of the macaque CD89
(asparagine at position 4). In the human CD89 molecule, cysteines involved in disulfide
bonds are located at positions 28 and 79 of the EC1 domain and at position 125 and 172
of the EC2 domain. As expected, these four cysteines are conserved in the CD89
sequences from both macaque species. Additionally, arginine 209, critical for CD89
association with the signaling molecule FcR γ chain (Morton et al., 1995), is conserved in
macaques.
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Human CD89 interacts with human IgA molecules through residues located on
the EC1 domain. These residues, which include Y35, Y81 and R82 (along with R52 and
to a lesser extent H85 and Y86), appear to form a single face at the N-terminus of the
molecule and have been identified by scanning mutagenesis (Wines et al., 1999; Wines et
al., 2001). While Y35 and Y81 are conserved in both macaque species, the arginine at
position 52 and the tyrosine at position 86 are substituted by a glutamic acid and a serine,
respectively, in both macaque species. In addition, the histidine located at position 85 of
the human sequence is replaced by a phenylalanine in rhesus macaques and by a leucine
in cynomolgus macaques. Recently, additional human CD89 residues involved in IgA
binding (along with those previously described) have been identified by analyzing the
crystal structure of the molecule (Herr et al., 2003). Of these amino acids, L54, F56, W57
and G84 are conserved in the human and macaque CD89 molecules, whereas the arginine
at position 53 and the lysine at position 55 of the human molecule are substituted by a
lysine and by a glycine, respectively, in both macaque species. To date, the only CD89
homologue model for IgA binding is the recently described bovine CD89 (bCD89),
which was found to bind human and bovine IgA similarly (Morton et al., 2004). Binding
of macaque IgA to macaque CD89 has not yet been shown. Interestingly, two of the
human CD89 residues identified in the crystal structure as contributing to IgA binding
(R53 and K55) are lysine and glycine, respectively, in both bovine and macaque CD89.
This and the observation that bCD89 is more dissimilar than macaque CD89 to human
CD89 indicates that, although some of the amino acids involved in the human IgA/CD89
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interaction are not conserved in macaques, macaque CD89 is likely to bind IgA from the
same species.
Lack of identification in the macaque samples of additional splice variants similar
to human transcripts may be due to different factors. Macaques may express only a
limited number of the isoforms described in humans or, most likely, the identified
macaque isoforms are a reflection of the samples used for RNA purification and therefore
of transcripts that are present in cells found in peripheral blood. Human CD89 splice
variants are indeed cell-type specific. The CD89.2 isoform is found only in alveolar
macrophages (Patry et al., 1996). Similarly, expression of the CD89.3 variant (∆EC2) is
cell-type specific (Togo et al., 2003). The presence of variants found only in macaques
may indicate that such variants are specific to these species or that the corresponding
human isoforms have not been identified yet. In addition, it has been demonstrated that
the ratio of variants to wild type CD89 is regulated by inflammatory cytokines and can be
differentially modulated by diseases (Monteiro et al., 2002; Togo et al., 2003). Indeed,
we have observed differences in the relative intensity of bands for cDNA of the various
splice variants from an individual varied compared with other individuals (data not
shown). Therefore, CD89 isoform expression may be dependent on the particular
individual analyzed and on the concomitant presence of inflammatory conditions or other
disorders. Clearly, additional studies are necessary to fully characterize the entire set of
macaque CD89 splice variants.
The IgA Fc receptor has been characterized only in a few species. The rat CD89
gene homologue shares 53% amino acid identity with the human CD89 (Maruoka et al.,
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2004). Only full-length CD89 and a single splice variant (characterized by a deletion of
the S2 exon) have been identified in rat spleen (Maruoka et al., 2004). The cattle CD89
homologue shares 56.2% amino acid identity with the human CD89. However, no splice
variants have been reported in this species (Morton et al., 2004). The identification of
several variants in macaques indicates that CD89 transcript processing may vary
considerably between species.
There is currently increased interest in the manipulation of the IgA/CD89
interaction for immunotherapeutic purposes (Dechant and Valerius, 2001; Corthesy,
2002; Presta, 2002). CD89 represents an effective target molecule for immunotherapy
mediated by bispecific antibodies (Valerius et al., 1997). Results from a more recent
study show that a chimeric surfactant protein D/anti-CD89 protein may effectively target
pathogens to neutrophils (Tacken et al., 2004). Like humans, macaques express CD89 on
granulocytes and monocytes. Because of the potential use of macaques as models for the
development of IgA-based therapies, the characterization of CD89 and corresponding
isoforms in these species represents an essential step to define a valuable system for the
testing of therapeutic antibodies.
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CHAPTER 3
Immunoglobulin A Fc receptor I (CD89) Homologues in Nonhuman Primates:
Identification and Characterization of Baboon and Sooty Mangabey CD89 and
Characterization of Rhesus Macaque CD89 Interactions with Human and Rhesus
Macaque IgA
Keywords: IgA, CD89, IgA receptor, Nonhuman primate models

Summary
Immune complexes containing IgA interact with the IgA Fc receptor I (CD89) to
initiate the pathogen elimination processes carried out by cells of the myeloid lineage.
Results from in vitro studies using IgA bispecific antibodies directed to either tumor or
pathogen antigens and to CD89 show the great potential of therapeutic antibodies capable
of harnessing immune responses. In addition, IgA/CD89 immune complexes appear to
contribute to IgA nephropathy, the leading cause of first stage renal failure. Therefore,
the characterization of IgA/CD89 interactions is essential to understand both
physiological and pathological mechanisms mediated by these interactions. Currently,
there is no established in vivo model for studying IgA/CD89 interactions. We have
previously characterized the CD89 blood leukocyte expression profile in macaques and
identified macaque CD89 genes. Here, we have extended our studies by characterizing
CD89 gene transcripts and protein expression patterns in two additional nonhuman
primate species important in biomedical research, baboons and sooty mangabeys.
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Furthermore, we have employed recombinant rhesus macaque IgA and recombinant
CD89 molecules to evaluate macaque IgA/CD89 binding properties. Our results show
that leukocytes from baboons and sooty mangabeys produce several alternatively spliced
CD89 gene transcripts. In these species, CD89 is detected only on monocytes and on
granulocytes. Multiple CD89 alleles that fit a Mendelian mode of inheritance are present
in baboons. Macaque CD89 binds to macaque IgA as well as to human IgA1 and IgA2.
This binding is nearly abolished by blocking N-glycosylation. We have expressed two
macaque CD89 isoforms produced from alternatively spliced transcripts in HeLa cells.
One of these isoforms appears to be secreted and is capable of interacting with IgA
complexes. This interactions reduces initial binding of IgA to CD89 expressed on HeLa
cells and may act in vivo to block cross-linking of CD89 by IgA, thus resulting in
inhibition of cellular activation. Together, these results greatly contribute to the
development of animal models for studying the function of serum IgA, the mechanisms
involved in the pathogenesis of IgA nephropathy, and the therapeutic potential of
antibodies that interact with CD89 molecules.
Introduction
The human immunoglobulin A (IgA) Fc receptor I (CD89) is expressed on
neutrophils, monocytes, and other select myeloid lineage cells. Cross-linking of CD89
with IgA-opsonized pathogens initiates a variety of cellular immune responses, including
phagocytosis, that assists in killing and removing these pathogens. In the absence of
antigen binding IgA can act through CD89 to suppress activation of coexpressed IgG Fc
receptors, thus helping to explain the anti inflammatory properties of this
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immunoglobulin isotype (Pasquier et al., 2005). CD89 is not present in mice (Maruoka et
al., 2004). CD89 homologues have been identified in few species (cow, horse, rat,
macaques and chimpanzee) (Maruoka et al., 2004; Rogers et al., 2004; Morton, 2005;
Morton et al., 2005). However, these homologues are still poorly characterized. Even
human CD89 is incompletely characterized.
As discussed in chapter 2, we have recently identified rhesus and cynomolgus
macaque CD89 (Rogers et al., 2004). The whole blood leukocyte expression profile of
these receptors matches that of humans. Macaques produce several alternatively spliced
transcripts of CD89, including unique transcripts and transcripts similar to those
generated by human cells. Macaque and human CD89 are highly conserved. However,
they differ for few amino acid substitutions at positions that in humans are necessary for
interactions with IgA. To further our understanding of CD89 structure and function, we
have identified and characterized CD89 full length transcripts and several splice variants
from baboons and sooty mangabeys. In addition, we show that recombinant rhesus
macaque CD89 generated in HeLa cells is able to specifically bind human IgA1 and IgA2
as well as recombinant rhesus macaque IgA. Efficient expression of rhesus macaque
CD89 in HeLa cells is dependent on N-glycosylation.
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Materials and methods
Animals
Blood samples were collected from a total of five healthy sooty mangabeys
(Cercocebus torquatus) and twenty healthy baboons (Papio hamadryas anubis). The
sooty mangabey samples were from animals housed at the Yerkes National Primate
Research Center, Emory University, Atlanta, GA. Baboon samples were from animals
housed at the Southwest National Primate Research Center San Antonio, TX. The
animals used for sequencing of the CD89 gene were different from those used for flow
cytometric analysis of blood leukocyte expression of CD89.

Amplification, cloning and sequencing of baboon and sooty mangabey CD89
Heparinized blood samples were collected from one sooty mangabey (Cercocebus
torquatus) and sixteen baboons (Papio hamadryas anubis). Total RNA was extracted
from whole blood using the QIAamp RNA Blood Mini Kit (Qiagen Inc., Valencia, CA),
and reverse transcribed into cDNA using oligo d(T)17 primers, followed by primer
extension with the AMV reverse transcriptase (Roche Molecular Biochemicals,
Indianapolis, IN). Reverse transcription PCR amplification, cloning and sequencing were
performed following a previously described protocol to identify CD89 in primates
(Rogers et al., 2004). PCR forward (RP1) and reverse (RP2) primers used to amplify the
full-length CD89 transcripts have been previously described (Pleass et al., 1996).
Forward (RP1) and reverse (RP2) primers specific for human CD89 are located at the
start codon of the S1 exon and the stop codon of the TM/C exon, respectively. An

61

alternate form of CD89, known as FcαRIb or CD89.9 (which lacks exon TM/C but
contains nucleotide sequences present in the intron located between exon EC2 and exon
TM/C) has been described for humans and macaques (van Dijk et al., 1996; Rogers et al.,
2004). Baboon and sooty mangabey splice variants of this type were amplified here as
described previously with the reverse primer FCARB2 and forward primer RP1, which
yield full-length FcαRIb transcripts (Rogers et al., 2004). Each sequence was confirmed
by cloning and sequencing the products of another independent PCR performed using the
same total RNA.

Analysis of DNA sequences
Overlapping regions were identified and sequences were edited using the
MacVector software program (Accelrys Inc., San Diego, CA). Sequences were aligned
with each other and other known CD89 genes using the CLUSTAL function of the
MEGALIGN part of the LASERGENE software package (DNASTAR Inc., Madison,
WI). The GenBank accession numbers for the CD89 sequences previously published are
human NM_0020000, chimpanzee BK005386, rhesus macaque AY386684, cynomolgus
macaque AY386690, rat AB109767, cow AY247821, pig CR45038 and horse
AY587560. The pig gene has not previously been identified. We have predicted its
sequence from a pig contig sequence on the basis of sequence homology with other CD89
genes.

62

Determination of CD89 expression on blood leukocytes
Blood from 4 baboon and 4 sooty mangabeys was collected in EDTA
Vacutainer® tubes (Becton, Dickinson and Co., San Jose, CA) by venipuncture under
anesthesia. Mangabey leukocyte expression of CD89 was analyzed by two-color flow
cytometry using phycoerythrin (PE)-conjugated anti-human CD89 (clone A59) and
fluorescein isothiocyanate (FITC)-conjugated anti-human CD16 (clone 3G8) (Becton,
Dickinson and Co.). Baboon leukocyte expression of CD89 was analyzed by staining
with PE anti-human CD16 alone. SimultestTM Control γ1/γ1 was used to detect nonspecific binding of mouse IgG to cells (Becton, Dickinson and Co.). Staining of whole
blood was done using a standard procedure. Briefly, 100µl of blood was incubated with
20µl of each antibody in the dark at room temperature for 15 min. Erythrocytes were
lysed with 2ml of BD PharM Lyse (Becton, Dickinson and Co.), washed 3 times with
PBS and fixed with 1% paraformaldehyde. 10000 cells were counted by flow cytometry.
Samples were read using a FACSCalibur flow cytometer and data analyzed using BD
CellQuestTM Pro version 5.2 software (Becton, Dickinson and Co.).

Generation of HeLa cell clones expressing recombinant rhesus macaque CD89
Previously we generated recombinant rhesus macaque CD89 in HeLa cells using
a vector constructed with pcDNA3.1 (Invitrogen Corp., Carlsbad, CA) (Rogers et al.,
2004). However, even after extensive selection with G418, expression of CD89 using this
vector in HeLa cells was only temporary. To improve the stability of the expression
vectors in transfected cells, part of the pcDNA3.1 constructs (containing cDNA of rhesus
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macaque CD89, a cytomegalovirus promoter, a bovine growth hormone polyadenylation
signal, and a f1 origin) were amplified and inserted into the vector pLSXN (Clontech
Laboratories, Inc., Mountain View, CA), which contains long terminal repeats for
integration into chromosomes. pLSXN contains a neomycin resistance gene, which
allows for transfectant selection. Insertion of a pcDNA-CD89 fragment into pLXSN was
carried out by amplifying with primers PcHp (5’CTGCTGTTAACCGTTAGGGTTAGGCGTTTTGCG-3) and PcSa (5’ACTTTGTCGACGCTCAGCGGCCGGCCATCGATCCACAGAATTAATTCGCGTT‘3). The resulting fragment was then digested with Hpa I and Sal I, whereas pLXSN was
digested with Hpa I and Xho I. The two fragments were then ligated together to form
pLXSN-CD89. The Sal I digested fragment can be ligated to the Xho I digested vector
because both enzymes produce the same sticky ends. Similarly, vectors were generated
for rhesus macaque CD89 splice variants CD89.9 ∆TM/C and CD89 ∆EC1 from
expression vectors created with pcDNA 3.1 according to the method used to generate the
original CD89 expression vector with pcDNA3.1 (Rogers et al., 2004).
Large quantities of vector for transfection were prepared using EndoFree®
Plasmid Maxi kits (Qiagen, Inc.). Twenty µg of expression vector was added to HeLa
cells suspended in 250µl of Dulbecco’s modified Eagle medium (DMEM) at 14×106
cells/ml. After 10 min of incubation on ice, cells were electroporated by one pulse using
the power supply set to 300V, 25mA, and 25W and the Electroporator II (Invitrogen
Corp.) set to 1000µF and ∞Ω, according to the manufacturer’s recommendations. Cells
were then incubated at room temperature for 10 min and grown in 10ml DMEM

64

(containing 10% FCS) in 5% CO2 at 37°C. Antibiotic G418 (400µg/ml) was added to
cells 72 hours post transfection to obtain stable transfectants.
Selection and expansion was performed to isolate HeLa cell clones stably
expressing CD89 at high levels. To isolate single clones, cells were diluted serially into
96 well microtiter plates and grown in 100µl of DMEM (containing 10% FCS and
consisting of 50% fresh media and 50% conditioned media collected from flasks of
untransfected HeLa cells and filtered with a 0.2µm filter) with 400µg/ml G418. Plates
were examined by microscopy to identify wells with a single cell. Clones were
subsequently expanded in wells of increasing size until cell numbers were sufficient to
screen for CD89 expression. Reverse transcription PCR was performed to identify clones
with CD89 transcripts. CD89 expression was then verified by staining cells with antihuman CD89 PE (clone A59) or a mouse isotype control, followed by flow cytometric
analysis. HeLa cells were prepared for flow cytometry as follows. Adherent cells were
removed from flasks with 0.25% trypsin/EDTA and counted. Viability was determined
by trypan blue exclusion. Cells were then aliquoted (0.5 ×106 cells/tube), washed with
PBS, stained with 5µl of the appropriate antibody for 30 min at 4º C, washed three times
with PBS to remove unbound antibody, and resuspended in 1% paraformaldehyde.
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Generation of recombinant rhesus macaque IgA
The generation of recombinant rhesus macaque IgA has been previously
described (Jayashankar, 2004) (Figure 3.1). This IgA molecule consists of a mouse
variable region with specificity for the hapten 5-iodo-4-hydroxy-3-nitrophenacetyl (NIP)
and a Chinese rhesus macaque IgA heavy chain constant region. Expression of
recombinant rhesus macaque IgA was performed by transfection of J558L mouse
myeloma cells (a gift from Dr. S. L. Morrison, UCLA) with a vector encoding the cDNA
from the Chinese rhesus macaque IGHA gene (GenBank accession number AY29614;
Scinicariello et al., 2004). The vector also contains the mouse immunoglobulin variable
heavy region with affinity for the hapten NIP. The complete set of antibody genes
includes the variable region of the mouse Igλ light chain produced in J558L cells
(Jayashankar, 2004). J558L cells do not produce a mouse immunoglobulin as a result of a
spontaneous loss of the immunoglobulin heavy chain from the parental cells line J558 (Oi
et al., 1983). Vector construction was performed in our laboratory by Lakshmi
Jayashankar from the parental human genomic IgG3 expression vector pLNOH2
(provided by Drs. Lars Nordehaug and Inger Sandlie, University of Oslo and Antibody
Design AS, Nesoddtangen, Norway). pLNOH2 was derived from pcDNA3 (Invitrogen
Corp.). To create the final expression vector the human IGHG3 gene was removed from
pLNOH2 by digestion with HindIII and BamHI followed by ligation with a rhesus
macaque IGHA cDNA cassette, previously digested with HindIII and BamHI.
Production of recombinant rhesus macaque IgA from J558L cells was
verified by ELISA as follows. Microtiter plates were coated with antigen consisting of
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Figure 3.1. General outline of vector construction and expression of nonhuman primate
recombinant antibodies. Antibody domains are rhesus: red and mouse: purple and orange.
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bovine serum albumin conjugated to five molecules of NIP (NIP (5) BSA) (Biosearch
Technologies, Inc., Novato, CA) in coating buffer at 15µg/ml overnight at 4ºC. The
plates were blocked with 5% FCS at 37ºC for 30 min and washed 3 times in PBS with
0.05% Tween 20. One hundred µl of supernatants from the transfected and untransfected
cells were added and incubated overnight at 4ºC. After washing, 50 µl of 1:2000 HRPlabeled goat anti-rhesus IgA antibody (KPL, Inc., Gaithersburg, MD) and goat antimouse Igλ (Invitrogen Corp.) was added. After incubation for 1 hour at 37ºC, plates were
washed and ABTS/H2O2 was added. After addition of the stop solution, absorbance was
measured at 405 nm with a Benchmark microplate plate reader (Bio-Rad Laboratories,
Inc., Hercules, CA). Samples with the greatest OD values for rhesus macaque IgA were
used to examine binding to rhesus macaque CD89.

Immunoglobulin binding assay
Binding of immunoglobulin molecules to CD89 was assessed by flow cytometry
using antibodies that were heat aggregated (HA) at 63ºC for 1hr. Human myeloma
proteins IgA1, IgA2, IgG and IgM (Binding Site Ltd., Birmingham, UK) with
immunoglobulin κ light chains were added to 0.5×106 cells at 20µg/ml in PBS and
incubated for 1 hr at 4ºC. For experiments using media from cells transfected with rhesus
macaque CD89.9 (CD89 ∆TM/C) and media from untransfected cells, human HA IgA2
or IgM was incubated with cells suspended in media instead of PBS. PBS washed cells
were then stained with either FITC-conjugated mouse anti-human Igκ (Invitrogen Corp.),
FITC-conjugated mouse anti-human Igα (KPL, Inc.) or FITC-conjugated mouse isotype
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control (Becton, Dickinson and Co.) for 30 min at 4ºC. For some experiments,
noncompetitive mouse anti-human CD89 PE (clone A59) was added. Cells were washed
and analyzed by flow cytometry as described above. For N-glycosylation blocking
experiments, tunicamycin was added to half of the cell cultures at 1µg/ml 30 hr prior to
harvesting cells. Tunicamycin blocks the addition of N-glycans to proteins by inhibiting
the transfer of N-acetylglucosamine-1-phosphate to dolicholmonophosphate.
Experiments to determine binding of recombinant rhesus macaque IgA were
performed as variations on the above protocol. Two ml of supernatant from J558L cells
secreting recombinant IgA or supernatant from control J558L cells was mixed with NIP
(5) BSA (15µg/ml final concentration) and incubated for 2 hours at 37°C. Cells
expressing rhesus macaque CD89 and control HeLa cells were prepared as described
above followed by suspension in 50µl of either supernatant and incubated for 40 min at
4°C. This step was repeated twice more with 20 min incubations following spinning of
cells and removal of supernatant each time. Two hundred µl of supernatants without NIP
(5) BSA was then added to cells and incubated for 30 min. Finally, cells were washed
with PBS, stained with 20µl goat anti-mouse Igλ FITC and 5µl anti-human CD89 for 20
min at 4°C, washed 3 times with PBS, and fixed with 1% paraformaldehyde.
Experiments to determine whether or not NIP (5) BSA was necessary for rhesus macaque
IgA/CD89 binding were then performed. Three hundred µl of supernatants were added to
cells with NIP (5) BSA at concentrations of 15, 7.5, 3.75, 1.88 or 0 µg/ml and incubated
at 4°C for 1 hour, then washed, stained and prepared as done above.
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Results
Cloning and sequencing of baboon and sooty mangabey full-length CD89 and CD89
splice variants
We cloned and sequenced baboon and sooty mangabey cDNA obtained through
reverse transcription of total RNA followed by amplification performed using primers
complementary to sequences located in the S1 and TM/C exons. Full-length transcripts
including all five exons were identified along with several additional transcripts
representing alternatively spliced forms of the CD89 mRNA. Figure 3.2 shows the
deduced amino acid sequences of the full-length cDNA from baboons (represented by the
sequence most frequently observed in baboons) and sooty mangabeys (one of two variant
sequences) along with the corresponding sequences from humans and other primates. All
five baboon and sooty mangabey exons were of length identical to the corresponding
human CD89 exons. The baboon and the sooty mangabey CD89 amino acid sequences
exhibit 86.4% and 87.1% identity to the human counterpart, respectively. Complete
comparison of percent identity and percent divergence for CD89 of all characterized
species is given in Table 3.1. Amino acid differences in the S1 and S2 exons between any
of the primates were not identified. There is a higher frequency of CD89 substitutions
clustered in the EC1 exon as compared to the overall molecule and EC2 across all phyla
for which CD89 has been identified (Tables 3.1-3.3). Figure 3.3shows a phylogenetic
analysis of CD89 from all available species.
Baboon and sooty mangabey CD89 transcripts were variable due to both
alternative RNA splicing and sequence substitutions. Several distinct mRNA splice
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Figure 3.2. (Next page) Amino acid sequences of baboon and sooty mangabey CD89
aligned with those of other primates. Baboon and sooty mangabey sequences were
deduced from experimentally derived sequences of cDNA from whole blood and
compared with published sequences from human (GenBank accession number
NM_002000), chimpanzee (GenBank BK005386), rhesus macaque (GenBank
AY386684) and cynomolgus macaque (GenBank AY386690). The chimpanzee sequence
is based on a third party annotation derived from the genome project sequence and has
not been confirmed experimentally. Amino acid differences are underlined. The first
amino acid of the preprotein is numbered as residue 1. The mature peptide starts at
residue 22. Arrows indicate distinct domains. The first two amino acids for EC1 are
encoded at the end of the S2 exon. The signal peptide is encoded by both S1 and S2
sequences. Potential N-glycosylation sites, cysteines involved in disulfide bonds and
arginine 209 critical for association with the FcRγ chain are bolded. Amino acids that
form interface with IgA Fc region are in grey (Herr et al., 2003). Hu: human; Chimp:
chimpanzee; Paca: baboon; Soma: sooty mangabey; Mamu: rhesus macaque; Mafa:
cynomolgus macaque.
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┌Mature Peptide
│
▼ │
S1
▼
S2
▼
EC1
HuCD89.1
MDPKQTTLLCLVLCLGQRIQAQEGDFPMPFISAKSSPVIPLDGSVKIQCQAIREAYLTQL
ChimpCD89.1 MDPKQTTLLCLVLCLGQRIQAQEGDSPMPFISAKSSPVIPLDGSVKIQCQAIREAYLTQL
PacaCD89.1a MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
SomaCD89.1 MDPKQTTLLCLVLCLGQRIQAQEGDFPTPFISTRSSPVVPWGGSARIQCQAIPDAYLIWL
MamuCD89.1 MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLIWL
MafaCD89.1 MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLIWL

60
60
60
60
60
60

HuCD89.1
ChimpCD89.1
PacaCD89.1a
SomaCD89.1
MamuCD89.1
MafaCD89.1

MIIKNSTYREIGRRLKFWNETDPEFVIDHMDANKAGRYQCQYRIGHYRFRYSDTLELVVT
MIIKNSTYREIGRKLKFWNETDPEFIIDHMDANKAGRYQCQYRIGHYRFRYSDTLELVVT
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGCYQCRYRIGFSRFRYSDTLELVVT
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGRYRCRYRIGFSRFRYSDTLELVVT
IMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT

120
120
120
120
120
120

│
▼
EC2
HuCD89.1
GLYGKPFLSADRGLVLMPGENISLTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
ChimpCD89.1 GLYGKPFLSADRGLVLMPGENISLTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89.1a GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
SomaCD89.1 GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQYQSGEHPANFSL
MamuCD89.1 GLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
MafaCD89.1 GLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL

180
180
180
180
180
180

│
▼
TM/C
HuCD89.1
GPVDLNVSGIYRCYGWYNRSPYLWSFPSNALELVVTDSIHQDYTTQNLIRMAVAGLVLVA
ChimpCD89.1 GPVDLNVSGIYRCYGWYNRSPHLWSFPSNALELVVTDSIHQDYTIQNLIRMAMAGLVLVA
PacaCD89.1a GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
SomaCD89.1 GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVTDSINRDYTTQNLIRMAVAGLVLVA
MamuCD89.1 GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVTDSINRDYTTQNLIRMAMAGLVLVA
MafaCD89.1 GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVTDSINRDYTTQNLIRMAMAGLVLVA

240
240
240
240
240
240

HuCD89.1
ChimpCD89.1
PacaCD89.1a
SomaCD89.1
MamuCD89.1
MafaCD89.1

Figure 3.2.

LLAILVENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK
LLAILVENWHSHTALNKEASADVAEPRWSQQMCQPGLTFA------LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK

287
280
287
287
287
287
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Table 3.1. Percent identities and divergences of CD89 amino acid sequences. Sequences
represent all identified CD89 molecules. GenBank accession numbers of previously
identified genes are in the text. Paca: baboon; Soma: sooty mangabey; Mamu: rhesus
macaque; Mafa: cynomolgus macaque.

Percent divergence

1

1
2
3
4
5
6
7
8
9
10

2
** 97.5
2.5
***
13.8 16.3
14.2 16.8
15
16.8
15.5 17.2
64.1 63.3
66.4 67.3
60.7 61.5
69.8 67.4
1
2

3
86.4
85.4
***
4.7
4
3.2
65.8
70.9
62.4
71.1
3

Percent
4
5
87.1 86.4
85
85
94.4 95.1
***
97.2
2.8
***
3.6
1.4
67.5 67.5
72.2 70.5
64.9 64.9
69
69
4
5

Identity
6
7
86.1 55.7
84.6 55.7
95.8 54.6
96.5 53.9
98.6 53.9
***
53.5
68.3
***
71.4 39.9
64.1 40.4
69.8 60.2
6
7

8
54
53.6
51.7
51.6
52.3
51.9
69
***
35.1
69
8

9
55.7
54.9
54.9
53.8
53.8
54.2
67.4
70.8
***
60.2
9

10
49.6
50.4
48.6
49.6
49.6
49.3
55
50.7
55.3
***
10

1
2
3
4
5
6
7
8
9
10

Human
Chimpanzee
Paca
Soma
Mamu
Mafa
Horse
Cow
Pig
Rat
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Table 3.2. Percent identities and divergences for deduced amino acid sequences of CD89
extracellular domain 1, the IgA binding domain. GenBank accession numbers of
previously identified genes are in the text. Paca: baboon; Soma: sooty mangabey; Mamu:
rhesus macaque; Mafa: cynomolgus macaque.

Percent Divergence

CD89 EC1

1
2
3
4
5
6
7
8
9
10

1
***
3.2
34.8
34.8
34.8
38.1
84.2
73.1
78.5
98.7
1

2
96.9
***
36.4
36.4
36.4
39.8
75.7
70.5
75.7
95.3
2

3
72.2
71.1
***
11.1
6.5
5.3
93.5
81.3
75.7
95.3
3

Percent Identity
4
5
6
7
72.2 72.2 70.1 46.3
71.1 71.1 69.1 49.5
89.7 93.8 94.8 42.1
***
95.9 92.8 43.2
4.2 ***
96.9 43.2
7.6
3.2 ***
42.1
90.3 90.3 93.5 ***
84.2 78.5 81.3 30.8
81.3 78.5 75.7 34.1
88.8
92 95.3 59.7
4
5
6
7

8
49.5
50.5
46.3
45.3
47.4
46.3
74.7
***
34.1
66.7
8

9
47.4
48.4
48.4
46.3
47.4
48.4
72.6
72.6
***
57.4
9

10
42.6
43.6
41.5
44.7
42.6
41.5
59.6
55.3
59.6
***
10

1
2
3
4
5
6
7
8
9
10

Human
Chimpanzee
Paca
Soma
Mamu
Mafa
Horse
Cow
Pig
Rat
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Table 3.3. Percent identities and divergences for deduced amino acid sequences of CD89
extracellular domain 2. GenBank accession numbers of previously identified genes are in
the text. Paca: baboon; Soma: sooty mangabey; Mamu: rhesus macaque; Mafa:
cynomolgus macaque.

Percent Divergence

CD89 EC2

1
2
3
4
5
6
7
8
9
10

1
***
1
5.4
5.4
5.4
5.4
53.6
53.6
45.8
45.8
1

2
99
***
6.5
6.5
6.5
6.5
55.7
55.7
47.7
47.7
2

3
94.8
93.8
***
2.1
2.1
2.1
55.7
57.8
53.6
49.6
3

Percent Identity
4
5
6
7
94.8 94.8 94.8 61.5
93.8 93.8 93.8 60.4
97.9 97.9 97.9 60.4
***
97.9 97.9 58.3
2.1 ***
100 59.4
2.1
0 ***
59.4
60 57.8 57.8 ***
57.8 55.7 55.7 45.8
53.6 53.6 53.6 43.9
49.6 47.7 47.7 53.6
4
5
6
7

8
61.5
60.4
59.4
59.4
60.4
60.4
65.6
***
30.4
53.6
8

9
65.6
64.6
61.5
61.5
61.5
61.5
66.7
75
***
49.6
9

10
65.6
64.6
63.5
63.5
64.6
64.6
61.5
61.5
63.5
***
10

1
2
3
4
5
6
7
8
9
10

Human
Chimpanzee
Paca
Soma
Mamu
Mafa
Horse
Cow
Pig
Rat
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Rat CD89

Horse CD89

9978
Cow CD89
7300
Pig CD89

Baboon CD89

10000

Sooty Mangabey CD89

5980
Cynomolgus macaque CD89
7117
10000
Rhesus Macaque CD89

Chimpanzee CD89
10000
Human CD89
0.1

Figure 3.3. Neighbor joining (NJ) phylogenetic tree constructed from the amino acid
sequences of all identified CD89 molecules in various species. Bootstrapping of the NJ
tree was performed with 10,000 replicates. Baboon and sooty mangabey sequences are
derived from this study, GenBank accession numbers for the remaining species are given
in the Materials and Methods section. The bar indicates the number of substitution per
site.

76

variants CD89 have been identified in humans and macaques, but few splice variants
have been identified in other species (Morton et al., 1996; Patry et al., 1996; Pleass et al.,
1996; Reterink et al., 1996; Maruoka, 2004; Morton et al., 2004; Rogers et al., 2004;
Morton et al., 2005). As was the case in other primates, we identified several splice
variants in baboons and in mangabeys. We identified eight splice variants for four
different baboons and three splice variants from a single sooty mangabey in addition to
the full length transcript. Figures 3.4 and 3.5 depict schematically the splice variants
identified for the baboons and the sooty mangabey, respectively. For baboons, five of the
eight splice variants (PacaCD89.3, PacaCD89.4, PacaCD89. 7, PacaCD89.9 and
PacaCD89∆EC1∆EC2) are similar to described human CD89 isoforms (Monteiro and
van de Winkel, 2003; Pleass et al., 1997), whereas three of the variants (PacaCD89
∆EC1, PacaCD89 ∆EC1∆TM/C and PacaCD89 ∆S2∆EC1∆TM/C) have not been
described in humans. Two sooty mangabey splice variants are similar to reported human
splice variants (SomaCD89.3 and SomaCD89.9). The third sooty mangabey variant has
not been described in humans (SomaCD89 ∆S2∆EC1∆TM/C).
We have previously noted a high degree of polymorphism of the CD89 ligand, IgA, for
nonhuman primates and have considered the possibility that gene conversion may
account for some of this variation. To determine whether or not this IgA diversity might
correspond to polymorphisms in CD89, we examined CD89 from several baboons.
Genetic variations resulting in amino acid substitutions were identified in three of the
baboons examined and in the sooty mangabey. Two nucleotide sequences that differed
only by a single silent substitution were obtained from the fourth baboon. The deduced
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PacaCD89.1

PacaCD89 ∆EC1

PacaCD89 ∆S2

PacaCD89 ∆EC1∆EC2

PacaCD89 ∆S2∆EC1

PacaCD89.3 (∆EC2)
PacaCD89.9 (∆TM/C)

PacaCD89 ∆S2∆TM/C

PacaCD89 ∆S2∆EC1
∆TM/C
Figure 3.4. Schematic representation of the full-length CD89 transcript and
corresponding splice variants identified in baboons. Paca: Papio hamadryas anubis.
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SomaCD89.1

SomaCD89.3
(∆EC2)
SomaCD89.9
(∆TM/C)
SomaCD89.∆S2
∆EC1
Figure 3.5. Schematic representation of the full-length CD89 transcript and
corresponding splice variants identified in sooty mangabey. Soma: Sooty mangabey.
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amino acid sequences of the different sequence variants of the CD89 transcripts and
splice variants of each of the four baboons and of the sooty mangabey are shown in
Figures 3.6-3.10. CD89 gene sequence variations were studied further in baboons using
two pedigreed families consisting of a sire, a dam and four offspring. All of the different
deduced amino acid sequences for baboon CD89 representing sixteen animals examined
are presented in Figure 3.11. The offsprings’ CD89 genes were inherited with the
expected patterns of normal Mendelian genetics (Figure 3.12).

Expression of CD89 on baboon and sooty mangabey blood leukocytes
In humans and macaques, CD89 is expressed only on select cells of the myeloid
lineage and not on lymphocytes. To determine whether or not baboon and sooty
mangabey CD89 is similarly expressed, whole blood from four animals of each species
was stained with the anti-human CD89 PE and anti-human CD16 FITC (sooty
mangabeys only) and analyzed by flow cytometry. Lymphocytes, monocytes, and
granulocytes (neutrophils and eosinophils) were identified using forward and side scatter
properties and each population gated. For all four baboons examined, no well delineated
population of monocytes could be identified. These samples must be shipped overnight,
and our results possibly reflect a selective loss of this population as the blood ages. By
contrast, mangabey blood which was only two to four hours old when processed had well
defined monocyte populations. Mangabeys expressed CD89 on 72.61±12.25% (mean ±
standard deviation) of their total leukocytes with no appreciable expression on
lymphocytes (0.64±0.17%) and expression on a majority of monocytes and granulocytes
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┌Mature Peptide
│
▼ │
S1
▼
S2
▼
EC1
PacaCD89.1a
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL 60
PacaCD89.1c
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89 ∆EC1
MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89 ∆S2
MDPKQTTLLCL------------GNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89 ∆EC1∆EC2
MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89.9 (∆TM/C)
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89 ∆S2∆EC1∆TM/C MDPKQTTLLCL------------------------------------------------PacaCD89 ∆EC1∆TM/C
MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89.1a
PacaCD89.1c
PacaCD89 ∆EC1
PacaCD89 ∆S2
PacaCD89 ∆EC1∆EC2
PacaCD89.9 (∆TM/C)
PacaCD89 ∆S2∆EC1∆TM/C
PacaCD89 ∆EC1∆TM/C

MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT 120
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
-----------------------------------------------------------MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
-----------------------------------------------------------MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT
----------------------------------------------------------------------------------------------------------------------│
▼
EC2
PacaCD89.1a
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL 180
PacaCD89.1c
GLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆EC1
GLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆S2
GLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆EC1∆EC2
-----------------------------------------------------------PacaCD89.9 (∆TM/C)
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆S2∆EC1∆TM/C GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆EC1∆TM/C
GLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
│
▼
TM/C
PacaCD89.1a
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA 240
PacaCD89.1c
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆EC1
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆S2
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆EC1∆EC2
------------------------------------DSINQDYTTQNLIRMAVAGLVLVA
PacaCD89.9 (∆TM/C)
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------PacaCD89 ∆S2∆EC1∆TM/C GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------PacaCD89 ∆EC1∆TM/C
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------│
▼
Tail
PacaCD89.1a
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287
PacaCD89.1c
LLAILVENWHSHKALNKEASADVVEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆EC1
LLAILVENWHSHKALNKEASADVVEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆S2
LLAILVENWHSHKALNKEASADVVEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆EC1∆EC2
LLAILVENWHSHKALNKEASADVVEPSWSHQMCQPGWTFARTPSVCK
PacaCD89.9 (∆TM/C)
-----------------------------------------------GRYLAVQPCVQVG
PacaCD89 ∆S2∆EC1∆TM/C -----------------------------------------------GRYLAVQPCVQVG
PacaCD89 ∆EC1∆TM/C
-----------------------------------------------GRYLAVQPCVQVG
PacaCD89.9 (∆TM/C)
CPGPCHWAGI
PacaCD89 ∆S2∆EC1∆TM/C CPGPCHWAGI
PacaCD89 ∆EC1∆TM/C
CPGPCHWAGI

Figure 3.6. Alignment of baboon CD89 splice variants and polymorphisms from animal
#35. Amino acid differences between sequences are bolded and italicized. Paca: Papio
hamadryas anubis.
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┌Mature Peptide
│
▼ │
S1
▼
S2
▼
EC1
PacaCD89.1a
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL 60
PacaCD89.1e
MDPKQTTLLCLVLCLGQKIQAQEGNFSTPFISTRSSPVVPWGGSARIQCQAIPDAYLTWL
PacaCD89.9 (∆TM/C)a MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89.9 (∆TM/C)b MDPKQTTLLCLVLCLGQKIQAQEGNFSTPFISTRSSPVVPWGGSARIQCQAIPDAYLTWL
PacaCD89.1a
PacaCD89.1e
PacaCD89.9 (∆TM/C)a
PacaCD89.9 (∆TM/C)b
PacaCD89.1a
PacaCD89.1e
PacaCD89.9 (∆TM/C)a
PacaCD89.9 (∆TM/C)b
PacaCD89.1a
PacaCD89.1e
PacaCD89.9 (∆TM/C)a
PacaCD89.9 (∆TM/C)b
PacaCD89.1a
PacaCD89.1e
PacaCD89.9 (∆TM/C)a
PacaCD89.9 (∆TM/C)b

MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT 120
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGRYQCRYRIGLSSFRYSGTLELVVT
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGRYQCRYRIGLSSFRYSGTLELVVT
│
▼
EC2
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL 180
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
│
▼
TM/C
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA 240
GPVDLNASGSYRCYGWYNRSPYLWSFPSNALELVVTDSINQDYTTQNLIRMAVAGLVLVA
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------GPVDLNASGSYRCYGWYNRSPYLWSFPSNALELVVT-----------------------│
▼
Tail
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQSGWTFARTPSVCK
-----------------------------------------------GRYLAVQPCVRVG
-----------------------------------------------GRYLPVQPCVRVG

PacaCD89.9 (∆TM/C)a CPGPCHWAGI
PacaCD89.9 (∆TM/C)b CPGPCHWAGI

Figure 3.7. Alignment of baboon CD89 splice variants and polymorphisms from animal
#36. Amino acid differences between sequences are bolded and italicized. Paca: Papio
hamadryas anubis.

82

┌Mature Peptide
│
▼ │
S1
▼
S2
▼
EC1
PacaCD89.1a
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL 60
PacaCD89.1b
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89 ∆S2∆EC1
MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89.3 (∆EC2) MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89 ∆EC1∆EC2 MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89 ∆EC1∆TM/C MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89.9 (∆TM/C) MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89.1a
PacaCD89.1b
PacaCD89 ∆S2∆EC1
PacaCD89.3 (∆EC2)
PacaCD89 ∆EC1∆EC2
PacaCD89 ∆EC1∆TM/C
PacaCD89.9 (∆TM/C)

MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT 120
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
-----------------------------------------------------------MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
----------------------------------------------------------------------------------------------------------------------MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT

│
▼
EC2
PacaCD89.1a
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL 180
PacaCD89.1b
GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆S2∆EC1
GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89.3 (∆EC2) -----------------------------------------------------------PacaCD89 ∆EC1∆EC2 -----------------------------------------------------------PacaCD89 ∆EC1∆TM/C GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89.9 (∆TM/C) GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
│
▼
TM/C
PacaCD89.1a
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA 240
PacaCD89.1b
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆S2∆EC1
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
PacaCD89.3 (∆EC2) ------------------------------------DSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆EC1∆EC2 ------------------------------------DSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆EC1∆TM/C GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------PacaCD89.9 (∆TM/C) GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------│
▼
Tail
PacaCD89.1a
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287
PacaCD89.1b
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆S2∆EC1
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
PacaCD89.3 (∆EC2) LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆EC1∆EC2 LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆EC1∆TM/C -----------------------------------------------GRYLAVQPCVRVG
PacaCD89.9 (∆TM/C) -----------------------------------------------GRYLAVQPCVRVG
PacaCD89 ∆EC1∆TM/C CPGPCHWAGI
PacaCD89.9 (∆TM/C) CPGPCHWAGI

Figure 3.8. Alignment of baboon CD89 splice variants and polymorphisms from animal
#38. Amino acid differences between sequences are bolded and italicized. Paca: Papio
hamadryas anubis.
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┌Mature Peptide
│
▼ │
S1
▼
S2
▼
EC1
PacaCD89.1b
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL 60
PacaCD89.3 (∆EC2)
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89 ∆EC1
MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89 ∆EC1∆EC2
MDPKQTTLLCLVLCLGQRIQAQE------------------------------------PacaCD89.9 (∆TM/C)
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
PacaCD89 ∆S2∆EC1∆EC2 MDPKQTTLLCL------------------------------------------------PacaCD89.1b
PacaCD89.3 (∆EC2)
PacaCD89 ∆EC1
PacaCD89 ∆EC1∆EC2
PacaCD89.9 (∆TM/C)
PacaCD89 ∆S2∆EC1∆EC2

MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT 120
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT
----------------------------------------------------------------------------------------------------------------------MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
------------------------------------------------------------

│
▼
EC2
PacaCD89.1b
GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL 180
PacaCD89.3 (∆EC2)
-----------------------------------------------------------PacaCD89 ∆EC1
GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆EC1∆EC2
-----------------------------------------------------------PacaCD89.9 (∆TM/C)
GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
PacaCD89 ∆S2∆EC1∆EC2 GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
│
▼
TM/C
PacaCD89.1b
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA 240
PacaCD89.3 (∆EC2)
------------------------------------DSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆EC1
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
PacaCD89 ∆EC1∆EC2
------------------------------------DSINQDYTTQNLIRMAVAGLVLVA
PacaCD89.9 (∆TM/C)
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------PacaCD89 ∆S2∆EC1∆EC2 GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVT-----------------------│
▼
Tail
PacaCD89.1b
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287
PacaCD89.3 (∆EC2)
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆EC1
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
PacaCD89 ∆EC1∆EC2
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
PacaCD89.9 (∆TM/C)
-----------------------------------------------GRYLAVQPCVRVG
PacaCD89 ∆S2∆EC1∆EC2 -----------------------------------------------GRYLAVQPCVRVG

PacaCD89.9 (∆TM/C)
PacaCD89 ∆S2∆EC1∆EC2

CPGPCHWAGI
CPGPCHWAGI

Figure 3.9. Alignment of baboon CD89 splice variants and polymorphisms from animal
#39. Amino acid differences between sequences are bolded and italicized. Paca: Papio
hamadryas anubis.
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┌Mature Peptide
│
▼ │
S1
▼
S2
▼
EC1
SomaCD89.1a
MDPKQTTLLCLVLCLGQRIQAQEGDFPTPFISTRSSPVVPWGGSARIQCQAIPDAYLIWL 60
SomaCD89.1b
MDPKQTTLLCLVLCLGQRIQAQEGDFPTPFISTRSSPVVPWGGSARIQCQAIPDAYLIWL
SomaCD89 ∆EC1
MDPKQTTLLCLVLCLGQRIQAQEGDFPTPFISTRSSPVVPWGGSARIQCQAIPDAYLIWL
SomaCD89.9 (∆TM/C) MDPKQTTLLCLVLCLGQRIQAQEGDFPTPFISTRSSPVVPWGGSARIQCQAIPDAYLIWL
SomaCD89 ∆S2 ∆TMC MDPKQTTLLCL------------GDFPTPFISTRSSPVVPWGGSARIQCQAIPDAYLIWL
SomaCD89.1a
SomaCD89.1b
SomaCD89 ∆EC1
SomaCD89.9 (∆TM/C)
SomaCD89 ∆S2 ∆TMC

MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGCYQCRYRIGFSRFRYSDTLELVVT 120
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGCYRCRYRIGFSRFQYSDTLELVVT
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGCYQCRYRIGFSRFRYSDTLELVVT
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGCYRCRYRIGFSRFQYSDTLELVVT
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGCYQCRYRIGFSRFRYSDTLELVVT

│
▼
EC2
SomaCD89.1a
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQYQSGEHPANFSL 180
SomaCD89.1b
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQYQSGEHPANFSL
SomaCD89 ∆EC1
-----------------------------------------------------------SomaCD89.9 (∆TM/C) GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQYQSGEHPANFSL
SomaCD89 ∆S2 ∆TMC GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQYQSGEHPANFSL
│
▼
TM/C
SomaCD89.1a
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVTDSINRDYTTQNLIRMAVAGLVLVA 240
SomaCD89.1b
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVTDSINRDYTTQNLIRMAVAGLVLVA
SomaCD89 ∆EC1
------------------------------------DSINRDYTTQNLIRMAVAGLVLVA
SomaCD89.9 (∆TM/C) GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVT-----------------------SomaCD89 ∆S2 ∆TMC GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALELVVT-----------------------│
▼
TAIL
SomaCD89.1a
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287
SomaCD89.1b
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
SomaCD89 ∆EC1
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
SomaCD89.9 (∆TM/C) -----------------------------------------------GRYLPVQPCVRVGCPGPCHWAGI
SomaCD89 ∆S2 ∆TMC -----------------------------------------------GRYLPVQPCVRVGCPGPCHWAGI

Figure 3.10. Sooty mangabey CD89 splice variant alignment and amino acid
substitutions. Amino acid differences between sequences are bolded and italicized. Soma:
sooty mangabey.
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PacaCD89.1a
PacaCD89.1b
PacaCD89.1c
PacaCD89.1d
PacaCD89.1e

┌Mature Peptide
│
▼ │
S1
▼
S2
▼
EC1
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL 60
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLTWL
MDPKQTTLLCLVLCLGQKIQAQEGNFSTPFISTRSSPVVPWGGSARIQCQAIPDAYLTWL

PacaCD89.1a
PacaCD89.1b
PacaCD89.1c
PacaCD89.1d
PacaCD89.1e

MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFQYSDTLELVVT 120
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
MMLKNSTYEKRGEKLGFWNDTKPEFVIDHMDANKAGRYRCRYRIGLSRFRYSDTLELVVT
MMLKNSTYEKRDEKLGFWNDTTPEFVIDHMDANKAGRYQCRYRIGLSSFRYSGTLELVVT

PacaCD89.1a
PacaCD89.1b
PacaCD89.1c
PacaCD89.1d
PacaCD89.1e

│
▼
EC2
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL 180
GLYGKPSLSADRGPVLMPGENISITCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
GLYGKPSLSVDRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL
GLYGKPSLSADRGPVLMPGENISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSL

PacaCD89.1a
PacaCD89.1b
PacaCD89.1c
PacaCD89.1d
PacaCD89.1e

│
▼
TM/C
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA 240
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINQDYTTQNLIRMAVAGLVLVA
GPVDLNVSGSYRCYGWYNRSPYLWSFPSNALKLVVTDSINRDYTTQNLIRMVVAGLVLVA
GPVDLNASGSYRCYGWYNRSPYLWSFPSNALELVVTDSINQDYTTQNLIRMAVAGLVLVA

PacaCD89.1a
PacaCD89.1b
PacaCD89.1c
PacaCD89.1d
PacaCD89.1e

LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK 287
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
LLAILVENWHSHKALNKEASADVVEPSWSHQMCQPGWTFARTPSVCK
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFARTPSVCK
LLAILVENWHSHKALNKEASADVAEPSWSHQMCQSGWTFARTPSVCK

Figure 3.11. Baboon CD89 polymorphisms. Positions that are different between
sequences are bolded and italicized. Form “a” is found in baboons 35, 36, 38, 7808, 8344,
8170, and 10595 albeit there are differences in some monkeys in the nucleic acid
sequence. Form “b” is found in baboons 39 (two different nucleic acid sequences) and in
baboon 38. The remaining three peptide sequences are deduced from a single baboon: “c”
for baboon 35, “d” for baboon 7808, “e” for baboon 36.
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81700 (Sire) X 10595 (Dam)
AB
AB
14252
AB

15168
AB

15626
BB

16550
AB

8433 (Sire) X 7808
(Dam)
16499
AA

14373
AA

15539
AC

17780
AC

Figure 3.12. Inheritance of CD89 gene sequence variants among baboons in two
pedigreed baboon families. Diagrams above give the baboon numeric designation
assigned by the Southwest National Primate Research Center above the genotypes of
each monkey. Genes are arbitrarily designated A, B and C. Genes A and B differ by a
single nucleotide and do not differ in the amino acid sequence and match the
PacaCD89.1a amino acid sequence of figure 3.11. Gene C encodes a protein matching
PacaCD89.1e of figure 3.11.
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(83.45±6.08% and 99.30±0.58% CD89+ respectively) (Figure 3.13). CD89 staining of
mangabey cells was specific, since an irrelevant isotype matched PE labeled mouse
antibody did not bind to the cells (CD89+ 0.37±0.63). CD16, the IgG low affinity Fc
receptor III, was coexpressed on a majority of mangabey granulocytes with CD89, but
was only expressed on a minority of cells in the monocyte gate, a few of which did not
express CD89. Baboons expressed CD89 on their granulocytes (mean fluorescence
intensity (MFI) = 162.16±37.98), but not on lymphocytes (MFI = 5.58±1.68) (Figure
3.14). A mouse isotype control did not bind to baboon leukocytes (MFI = 7.31±2.96).
Expression of recombinant rhesus macaque CD89 in HeLa cells, IgA binding and effects
of glycosylation inhibition
HeLa cells were transfected with an expression vector for full-length rhesus
macaque CD89 designed to incorporate itself in chromosomes for stable expression.
After antibiotic selection, isolation, expansion and screening, three clones positive for
CD89 cDNA transcripts and exhibiting high CD89+ fluorescence staining were identified
(Figure 3.15). Cells from the positive clones were incubated with mouse isotype control
PE and untransfected HeLa cells incubated with anti-human CD89 PE. All these cells
were negative for fluorescence staining, thus verifying that CD89+ staining of these
clones was specific. Expression of CD89 from these cells was stable, since CD89
expression was consistently detected on these cells for over one year.
Using clones expressing CD89 and untransfected control HeLa cells, binding of
heat aggregated human myeloma proteins and recombinant chimeric rhesus IgA to rhesus
macaque CD89 was assessed (Figures 3.16 and 3.17). Cells were simultaneously stained
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A

B
Granulocytes

R12
R10
R11
Monocytes
Lymphocytes

0

Forward Scatter

1000

100 101 102 103 104
Mouse Isotype FITC

C

D

100 101 102 103 104
CD16- FITC

100 101 102 103 104
CD16- FITC

E

F

100 101 102 103 104
CD16- FITC

100 101 102 103 104
CD16- FITC

Figure 3.13. Sooty mangabey CD89 is expressed on monocytes and granulocytes.
Two-color dot-plots of whole blood leukocytes from a representative sooty
mangabey showing cell population expressing CD89. Forward scatter versus side
scatter plot (A); mouse isotype control PE versus mouse isotype control FITC (B);
CD16 versus CD89 for all leucocytes (C), gated lymphocytes (D), gated
monocytes (E), and gated granulocytes (F).

89

B

A
Granulocytes

R2

R1

Lymphocytes

Figure 3.14. Baboons express CD89 on granulocytes, but not on lymphocytes
from whole blood. Forward scatter versus side scatter dot-plot (A) showing gated
lymphocytes and granulocytes (no defined monocyte populations could be
identified for any of the baboon samples stained for CD89). Histogram of baboon
whole blood leukocytes staining for CD89 (B): green curve = granulocytes, thick
line = lymphocytes, dotted line = total leukocytes stained with PE labeled mouse
isotype control.
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A

B

C

Figure 3.15. Expression of recombinant rhesus macaque CD89 on HeLa cells. (A)
Non-clonal HeLa cells expressing CD89 and (B and C) HeLa cell clones expressing
CD89. HeLa cells were stained with anti-human CD89 PE and 5000 counted by flow
cytometry. Thick solid line = transfected cells, dashed line = untransfected HeLa cells,
dotted line = transfected cells strained with an isotype control.
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IgA1

IgA2

IgM

Anti IgA

A
Anti CD89

IgM

IgA2

B

Figure 3.16. Recombinant rhesus macaque CD89 binds to heat aggregated human
myeloma IgA1 and IgA2 (representative experiment). A: histogram plots of HeLa cells
expressing rhesus macaque CD89 (filled red curves) or control cells (green line) stained
with anti-human CD89 PE and anti-human Igα FITC. B: two-color dot plots of antihuman IgA FITC versus anti-human CD89 PE. 10,000 cells were counted for each assay.
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A

B

100 101 102 103 104
Anti-mouse lambda FITC

10 0 10 1 10 2 10 3 10 4
Anti-mouse lambda FITC

C

D

10 0 10 1 10 2 10 3 10 4
Anti-mouse lambda FITC

10 0 10 1 10 2 10 3 10 4
Anti-mouse lambda FITC

Figure 3.17. Rhesus IgA binds to rhesus macaque CD89. HeLa cells expressing
recombinant rhesus macaque CD89 were incubated with supernatant of J588L cells
expressing recombinant rhesus IgA (containing a mouse Igλ) or control supernatant and
stained with anti-mouse Igλ FITC and anti-human CD89 PE. A: histogram plot of the
HeLa cells expressing CD89 incubated with rhesus IgA (filled), or control supernatant
(dashed line), and untransfected control HeLa cells incubated with IgA (thick line). Twocolor dot plots (C) HeLa cells with IgA supernatant, (B) and (D) HeLa cells expressing
CD89 cells with control supernatant and IgA supernatant, respectively.
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with anti-human CD89 PE and either anti-human Igκ or anti-human Igα to detect bound
antibodies. Human IgA1 and IgA2, but not human IgG or IgM, bound to CD89 (Figure
3.16). IgA binding increased with increased expression of CD89 as indicated by the
positive correlation of MFI for CD89 staining plotted against MFI for bound IgA staining
(Figure 3.16). No correlation exists for MFI of CD89 staining plotted again MFI of
staining for isotypes that did not bind IgM or IgG (Figure 3.16). Multiple experiments
were carried out to test for CD89 binding to NIP specific rhesus IgA. The presence of
recombinant IgA in the supernatant of transfected J558L cells was verified by ELISA
(data not shown). When rhesus IgA binding was tested in the presence of the antigen NIP
(5) BSA, staining against the recombinant antibody was positive for CD89 cells
incubated with IgA supernatant (10.81 ± 8.15), but not for HeLa cells (5.45±3.37) or
CD89 cells incubated with control supernatant (5.00±4.61) (Figure 3.17). Thus, binding
of rhesus macaque IgA to rhesus macaque CD89 was detectable, although IgA was
present at much lower concentrations in the supernatant when compared to the
concentration of the human IgA myeloma protein in its corresponding binding assay.
To assess whether or not rhesus IgA interactions with CD89 were dependent on
IgA binding to antigen, a variation of the binding assay was performed by titrating out the
concentration of NIP (5) BSA incubated with the supernatants (Table 3.4). Binding to
IgA was detectable in the absence of antigen, increased slightly with antigen
concentrations of 1.88-7.5µg/ml and declined with further excess of antigen (15µl/ml).
MFI for staining of bound IgA was significantly less for both controls using
untransfected HeLa cells incubated with IgA supernatant (p = 0.005) and HeLa cells
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Table 3.4. Binding of rhesus macaque CD89 to recombinant rhesus IgA incubated with
different concentrations of antigen, NIP (5) BSA. HeLa cells expressing recombinant
rhesus macaque CD89 or untransfected control HeLa cells were incubated with
supernatant of J588L cells expressing recombinant rhesus IgA (containing a mouse Igλ)
or control supernatant which contained the indicated concentrations of NIP (5) BSA and
stained with anti-mouse Igλ FITC to detect bound rhesus IgA. MFI: mean fluorescence
intensity.
NIP (5) BSA
(µg/ml)

Rhesus IgA &
Rhesus
Macaque CD89
(MFI)

0
1.88
3.75
7.5
15
Mean ± Std

27.6
31.6
28.9
31.3
26.6
29.2 ± 2.2

Control
Supernatant &
Rhesus
Macaque CD89
(MFI)
21.8
20.2
24.3
24.3
21.4
22.4 ± 1.8

Rhesus IgA &
HeLa Cells
(MFI)
22.8
25.7
18.2
18.7
19.0
20.9 ± 3.3
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expressing CD89 incubated with control supernatant (p = 0.005), but not between the two
control groups (p = 0.52) as determined using a paired student T-test.
Fc receptor glycans are often important for expression and immunoglobulin Fc
binding (Drescher et al., 2003). We examined the effects of blocking N-glycosylation
with tunicamycin on rhesus CD89 expression and binding properties, since rhesus
macaque CD89 has N-glycosylation motifs conserved with sites in human CD89
occupied by N-glycans (Figure 3.18). Expression of CD89 was dramatically reduced in
cells treated with tunicamycin (57%-73% reduction) with a disproportionately greater
decrease in ability to bind to human IgA1 and IgA2 (84%-95%).

Splice variants of rhesus macaque CD89
Attempts were made to isolate clones with high expression levels of two rhesus
macaque splice variants: CD89∆EC1, which has the first extracellular domain deleted,
and CD89.9 (CD89 ∆TM/C), which has the transmembrane and cytoplasmic domains
deleted. Despite isolating clones for each variant that produced transcripts, none of the
clones stained for high levels of CD89 expression. The monoclonal antibody used to
detect CD89 expression (A59) binds to the EC2 domain, which is present in both
transcripts; therefore, failure to detect the CD89 isoforms is unlikely to be due to the
absence of the binding epitope. There was some evidence for low level expression of the
resulting isoforms for each of these splice variants. For some clones, low expression
levels were detected by flow cytometry on the cell surface (Figure 3.19).
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IgA1

IgA2

IgM

Anti IgA

Anti CD89

- Transfected with gene for rhesus CD89 HeLa cells
- Transfected HeLa cells with N-glycosylation blocked
- Control untransfected HeLa cells

Figure 3.18. Blocking N-glycosylation reduces expression of recombinant rhesus
macaque CD89 and results in a strong decrease in binding of human IgA1 and IgA2.
HeLa cells were treated with tunicamycin to inhibit the N-glycosylation pathway.
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B
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CD89 PE

100 101 102 103 104
CD89 PE

C

D

10 0 10 1 10 2 10 3 10 4
Mouse Isotype PE

100 101 102 103 104
Mouse IgG1 PE

Figure 3.19. Rhesus CD89 isoforms expressed at low levels in HeLa cells. Two-color dot
plot showing specific staining against CD89 (A, B) and the mouse isotype control (C, D).
Clones for the expression of CD89∆EC1 (A, C), and of CD89∆TM/C (B, D) are shown
from representative clones. MFI of CD89 staining is indicated on the X-axis. MFI of
auto-fluorescence is indicated on the Y-axis indicates.
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While some recombinant human CD89.9 is expressed on the surface of Cos-7
cells, most of the product is secreted into the media (van Dijk, 1996). Therefore, attempts
were made to detect rhesus macaque CD89.9 in the media. Secreted CD89.9 was not
detected by ELISA, but no positive control was available for these experiments (data not
shown). Since CD89.9 was difficult to detect directly, transfected cells were tested for its
expression indirectly by assaying for IgA binding. MFI did not convincingly increase
when cells were stained for bound IgA, but an increase of MFI for CD89 staining of these
cells was observed after incubation with IgA. Therefore, it was hypothesized that cells
expressed low levels of CD89.9 that could bind to HA IgA complexes, which in turn
allowed binding of soluble CD89.9 to unoccupied IgA binding sites. This would result in
an increased concentration of CD89.9 associated with the cells, and hence the observed
increase in MFI for CD89 staining. To test this hypothesis, a similar assay was
performed. HeLa cells expressing full length CD89 were incubated with human IgA and
either media from untransfected HeLa cells or media from cells transfected with the
expression vector for CD89.9. In multiple experiments, greater staining for CD89 was
observed for cells incubated with CD89.9 media compared to cells incubated with control
media (Figure 3.20 A and B). A small but significant decrease in staining for bound IgA
was also observed in some experiments under similar circumstances (Figure 3.20 C and
D). No differences in staining for CD89 were present between CD89.9 media and control
media treated cells when IgM was incubated with cells instead of IgA.
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A

B

C

D

Figure 3.20. Soluble rhesus CD89.9 binds to IgA captured by CD89 on cells and reduces
IgA binding. Incubation of media from cells putatively secreting CD89.9 (black line)
with HeLa cells expressing rhesus CD89 on the plasma membrane results in an increase
in CD89 staining mean fluorescence intensity (MFI) (A, B) and decreased bound IgA
staining MFI (C, D) compared to incubation of media from control HeLa cells which do
not secrete a CD89 isoform (grey line). A, C: histogram plots; B, D: cumulative fraction
plots. Differences were determined to be statistically significant using the KolmogorovSmirnov test (p ≤ 0.001). 10000 cells were counted by flow cytometry for each group.
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Discussion
IgA forms an important defense against pathogens at the mucosal surfaces and is
found at significant concentration in sera where it can interact with CD89 to engage
immune effector functions. IgA/CD89 interactions are important for immune responses to
pathogens including mucosal infections with S. pneumoniae and Bordetella pertussis
(Monteiro and van de Winkel, 2003). CD89 plays a protective role in periodontal disease
and has been shown to mediate the clearance of Porphyomonas gingivalis (Yuan et al.,
2000; Kobayashi et al., 2001, 2003). Interestingly, a polymorphism of CD89 involving a
silent nucleotide substitution has been shown to be associated with aggressive
periodontitis (Kaneko et al., 2003). By contrast, single nucleotide polymorphisms of
CD89 do not appear to be risk factors for allergic asthma (Jasek et al., 2004). CD89
function, concentrations in sera as well as on cells, and glycosylation patterns are altered
in several diseases including HIV-1 infections (Grossetête et al., 1994), alcoholic
cirrhosis (Silvain et al., 1995), ankylosing spondylitis (Montengro et al., 2000) and
Henoch-Schonlein pupura (Haddad et al., 2003). Results from preliminary studies show
that bispecific therapeutic antibodies and other therapeutics targeting CD89 are
potentially efficacious in the treatment of bacterial and fungal infections (Kobayashi et
al., 2004; Tacken et al., 2004) and cancers (Valerius et al., 1997; Stockmeyer 2000;
Sundarapandiyan 2001).
Several studies have examined a possible role for CD89/IgA interactions in the
pathogenesis of IgA nephropathy (IgAN). Also called Berger’s disease, IgAN is a major
cause of end-stage renal failure and the most common form of primary
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glomerulonephritis. Renal damage in IgAN is caused by the deposition of IgA immunecomplexes on mesangial cells and subsequent inflammatory responses. In IgAN patients,
CD89 expression levels are reduced on myeloid linage cells despite normal transcription,
soluble CD89 concentrations are elevated in sera and CD89 is found on mesangial cells
(Launay et al., 1999; Monteiro, 2005). Additionally, transgenic CD89 mice develop
IgAN-like pathogenesis (Launay et al., 1999). A mechanism for IgAN pathogenesis has
been proposed on the basis of the above mentioned observations. Abnormal IgA from
IgAN patients interacts with CD89 on cells, resulting in the release of IgA/CD89
complexes into the circulation. These complexes then bind to mesangial cells through
interaction with an IgA receptor and therefore induce inflammation (Launay et al., 1999;
Monteiro et al., 2002; Monteiro, 2005). To date, the IgA receptor present on mesangial
cells has not been characterized. It might be CD71 (the transferrin receptor) (Monteiro et
al., 2002), some uncharacterized IgA Fc receptor (Barratt et al., 1999) or CD89 (Tsuge et
al., 2003). Although CD89 is not usually expressed on these cells, it has been argued that
under yet to be established conditions its expression is induced and leads to production of
the monocyte chemoattractant protein-1, which plays a role in the inflammatory process
(Tsuge et al., 2003). However, such a model of IgAN pathogenesis has been challenged.
IgA/CD89 complexes have been described in serum of both IgAN patients and healthy
individuals (van der Boog et al., 2003), in discrepancy with reports of these complexes
being unique to IgAN patients (Launay et al., 1999). Injection of human CD89 into
normal mice induces mesangial IgA deposits and mouse IgA is unable to bind human
CD89 (van der Boog et al., 2004). Thus, these findings are in apparent contradiction with
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the results from the CD89 transgenic mouse models studies (Launay et al., 2004).
Clearly, results obtained using mouse models of IgA/Fc receptor interactions must be
interpreted with caution. Indeed, expression of IgA receptors is quite different between
rodents and humans (Decot et al., 2005).
Nonhuman primates are important animal models for biomedical research,
including research that focuses on pathogenesis, vaccine development, transplantation
and development of immunotherapeutics. IgA/CD89 interactions are likely to be
important in several of these studies. For example, macaques are used as a model system
for periodontal disease (Ebersole et al., 2002) in which, as pointed out above, CD89 plays
a role in pathogenesis. Previously, we have identified and partially characterized rhesus
and cynomolgus macaque CD89 (Rogers et al., 2004). Such charcaterization has been
recognized as an important step in the development of animal models for the study of
therapeutic antibodies and IgAN without the limitations that encumber mouse studies
(Woof and Kerr, 2004).
Our further identification and characterization of CD89 in nonhuman primates
shows these molecules to be functionally well conserved with human CD89 and provides
new insights into the function of CD89 in humans as well. Nonhuman primate CD89
molecules share over 80% amino acid sequence identity to human CD89 and over 90%
with each other (Table 3.1). Like macaque and human CD89 genes, baboon and sooty
mangabey CD89 genes have 5 exons and produce multiple splice variants using different
combinations of these exons. These splice variants may result in the production of
functionally distinct CD89 isoforms (Figures 3.4-3.10). Similarly to human and macaque

103

CD89, baboon and sooty mangabey CD89 are expressed on blood leukocytes of the
myeloid lineage only (Figures 3.13 and 3.14). There are different polymorphisms of
human CD89, some of which are associated with increased disease risks (Kaneko et al.,
2003). Baboon and mangabey CD89 molecules are also polymorphic (Figures 3.10 and
3.11). Analysis of two baboon families shows that baboon CD89 gene polymorphisms
follow a classical Mendelian inheritance (Figure 3.12), raising the possibility to identify
polymorphisms associated with disease in these animals through analysis of pedigreed
families.
Human IgA binds to human CD89 at the first extracellular domain (EC1) with
interactions involving residues Y35, R52-N59, H85 and Y86 (Herr et al., 2003). Half of
these residues are substituted in Old World monkeys and in chimpanzees (Figure 3.2).
Baboon and mangabey CD89 substitutions at these residues are nearly identical to those
found in macaques. All of the Old World monkeys have the substitutions R52E, R53K,
K54G, and Y86S. H85 is replaced in baboons and cynomolgus macaques with L85 and in
sooty mangabeys and rhesus macaque with F85. These data suggest that CD89 from all
four Old World species is likely to similarly interact with IgA. To assess nonhuman
primate CD89 interactions with IgA, we chose to express rhesus macaque CD89, since
this species is the most commonly used nonhuman primate for in vivo studies. We
produced three HeLa cell clones expressing high levels of full length recombinant rhesus
macaque CD89. Human IgA1 and IgA2 both bind to rhesus macaque CD89 indicating
that CD89/IgA interactions are indeed conserved between humans and Old World
monkeys (Figure 3.3).
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Rhesus macaques possess a single IGHA gene that encodes the IgA heavy chain,
which is highly polymorphic (Scinicariello and Attanasio, 2001; Scinicariello et al.,
2004). The functional properties of rhesus macaque IgA have not been previously
studied. Therefore, our laboratory has generated a recombinant IgA molecule with
affinity for the hapten NIP, containing rhesus macaque IgA CH1-CH3 domains, a mouse
immunoglobulin light chain and a mouse variable heavy chain domain (Jayashankar,
2004). The deduced amino acid sequences of the recombinant rhesus macaque IgA CH1CH3 domains are shown aligned with IgA CH1-CH3 sequences of humans and other
primates in Figures 3.21-3.23. As depicted in these figures, human IgA residues
responsible for forming interactions with human CD89 are located in the CH2 and CH3
domains. All but two of these residues are conserved in all nonhuman primates. In Old
World monkeys there are substitutions (S46T and E48Q) in the CH3 domain. Therefore,
interactions of different nonhuman primate IgA molecules with CD89 orthologues are
predicted to be similar. Recombinant rhesus macaque IgA is capable of binding to
recombinant rhesus macaque CD89 (Figure 3.17). Human CD89 is a low affinity receptor
and does not bind to monomeric IgA with great efficiency. Affinity for IgA is increased
when IgA binds to antigen and forms immune complexes (increased avidity). When the
antigen of recombinant IgA was titrated out we observed that most of the detected IgA
binding occurred regardless of the presence of antigen with a slight increase at low
concentrations of antigen (Table 3.4). At the highest concentration of NIP (5) BSA-IgA
binding decreased. Such a finding could be interpreted as follows: a) rhesus macaque
CD89 has a relatively high affinity for monomeric IgA; b) addition of antigen at lower
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CH1
Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

10
20
30
40
50
:
:
:
:
:
ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTA
ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTA
ASPTSPKVFPLNLCSTQSD-NVVVACLVQGFFPQEPLNVTWSKSGADVTV
ASPTSPKVFPLSLEGTQSD-NVVVACLVQGFFPQEPLNVTWNKSGAGVTV
ASPTSPKVFPLSLEGTQSD-NVVVACLVQGFFPQEPLNVTWSKSGAGVTV
ASPTSPKVFPLSLEGTQSD-NVVVACLVQGFFPQEPLSVTWNKSGAGVTV

Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

60
70
80
90
100
:
:
:
:
:
RNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCP
RNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNPSQDVTVPCP
INFPPSQDASGGLYTTSSQLTLPAAQCPASESVTCHVEHYTNPSQDVAVPCINFPPSQDASGGLYTTSSQLTLPAAQCPASESVTCHVEHYTNPSQDVAVPCV
INFPPRQDASGGLYTTSSQLTLPAAQCPASESVTCHVEHYTNPRQDVAVPCR
INFPPSQDASSGLYTTSSQLTLPAEQCPASESVTCHVEHYTNPSQDVAVRCR

Figure 3.21. Alignment of human (Hu), rhesus macaque (Mamu), sooty mangabey
(Soma), pig-tailed macaque (Mane) and baboon (Paca) IgA CH1 deduced amino acid
sequences. Residues that do not match human IgA1 residues are unlined. GenBank
accession numbers are: human IgA1 J00220, human IgA2 J00221, Mamu IgA AY29614,
and Soma IgA AY54480. Paca IgA and Mane IgA have not yet been assigned GenBank
accession numbers. The Chinese rhesus macaque IgA sequence shown here is that of the
gene used to produce recombinant IgA.
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CH2
Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

10
20
30
40
50
:
:
:
:
:
-VPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGL
-VP-------------PPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGL
-VPPITP---PC------PSCCEPRLSLRRPALEDLLLGSEANLTCTLTGL
-–PK----PNSC------L-CDEPRLSLRRPALEDLLLGSEANLTCTLTGL
-VPP----PN-C----P-L-CDKPRLSLRRPALEDLLLGSEANLTCTLTGL
GIPP—-P---P-----PS--CCEPRLSLHRPALEDLLLGSEANLTCTLTGL

Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

60
70
80
90
100
:
:
:
:
:
RDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTF
RDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETF
KDPSGATFTWTPSSGKNAVQQSPKRDPCGCYSVSSVLPGCAEPWNNRETF
RDPSGATFTWTPSSGKNAVQQSPERDPCGCYSVSSVLPGCAEPWNNRVTF
RDPSGATFAWTPSSGKNAVQQSPEHDPCGCYSVSSVLPGCAEPWNNRVTF
KDPSGATFTWTPSSGKNAVQQSPERDPCGCYSVSSVLPGCAEPWNNRETF

Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

110
120
:
:
TCTAAYPESKTPLTATLSKS
TCTAAHPELKTPLTANITKS
TCTANHPELETPLTATISKS
TCTANHPELETQLTATISKS
NCTANHPELKTPLTATISKS
TCTANHPELKTPLTATISKS

Figure 3.22. Alignment of human (Hu), rhesus macaque (Mamu), sooty mangabey
(Soma), pig-tailed macaque (Mane) and baboon (Paca) IgA CH2 deduced amino acid
sequences, including the IgA hinge regions. Residues in human IgA1 as well as
corresponding residues in other IgA molecules that make contact with human CD89 are
shaded (Herr et al., 2003). Residues that do not match human IgA1 residues are unlined.
GenBank accession numbers are: human IgA1 J00220, human IgA2 J00221, Mamu IgA
AY29614, and Soma IgA AY54480. Paca IgA and Mane IgA have not yet been assigned
GenBank accession numbers. The Chinese rhesus macaque IgA sequence shown here is
that of the gene used to produce recombinant IgA.
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CH3

Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

10
20
30
40
50
:
:
:
:
:
GNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELP
GNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELP
GNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPEDVLVRWLKGTEQLP
GNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPEDVLVRWLKGTEQLP
GNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPEDVLVRWLKGTEQLP
GNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPEDVLVRWLKGTEQLP

Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

60
70
80
90
100
:
:
:
:
:
REKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPL
REKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPL
RDKYLTWESRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPL
RDKYLTWESRKEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPL
RDKYLTWESRKEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPL
RDKYLTWESRKEPNQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPL

Hu Igα1
Hu Igα2
Mumu Igα
Soma Igα
Mane Igα
Paca Igα

110
120
130
:
:
:
AFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY
AFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY
AFTQKTIDRLAGKPTHVNVSV
AFTQKTIDRLAGKPTHVNVSV
AFTQKTIDRLAGKPTHVNVSV
AFTQKTIDRLAGKPTHVNVSV

Figure 3.23. Alignment of human (Hu), rhesus macaque (Mamu), sooty mangabey
(Soma) and pig-tailed macaque (Mane) and baboon (Paca) IgA CH3 deduced amino acid
sequences. Residues in human IgA1 as well as corresponding residues in other IgA
molecules that form the surface interface with human CD89 are shaded (Herr et al.,
2003). Residues that do not match human IgA1 residues are unlined. GenBank accession
numbers are: human IgA1 J00220, human IgA2 J00221, Mamu IgA AY29614, and Soma
IgA AY54480. Paca IgA and Mane IgA have not yet been assigned GenBank accession
numbers. The Chinese rhesus macaque IgA sequence shown here is that of the gene used
to produce recombinant IgA.
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levels resulted in IgA-immune complexes that bound with slightly higher affinity, but at
higher concentration with excess antigen; c) IgA antigen binding sites were saturated and
could not form larger immune complexes.
Differential glycosylation is characteristic of CD89 on different cells types and
during certain types of pathogenesis (Monteiro et al., 1992). Human CD89 can have Nglycans at four of the six N-gylcosylation motifs (N44, N58, N120 and N156) (Herr,
2003). The other two sites are N165 and N177. All six of these N-glycosylation motifs
are conserved in nonhuman primates. Additionally, macaque and baboon CD89molecules
have a seventh site at N4 that is absent in humans, chimpanzees and sooty mangabeys
(Figure 3.2). Notably, N58 is found at the CD89/IgA interaction interface. Blocking of Nglycosylation greatly reduced the expression of rhesus macaque CD89 from HeLa cells
and led to a greater decrease in IgA binding, indicating that N-glycans are important for
both CD89 expression and interactions with IgA (Figure 3.18).
Alternative splice variants of human CD89 were identified over a decade ago. At
least two isoforms are known to be produced (Monteriero and van de Winkel, 2003). The
expression of these two isoforms is modulated by inflammatory cytokines (Togo et al.,
2003). However, neither the expression nor the function of the majority of these splice
variants has been determined. Transfection of the genes for two alternative splice variants
of rhesus macaque CD89 (CD89∆EC1 and CD89.9) into HeLa cells results in only very
low expression on the cell surface (Figure 3.19).
The CD89∆EC1 splice variant has not been described in humans and would not
be expected to be able to bind to IgA, since the domain responsible for IgA binding
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(EC1) is deleted. The remaining domain (EC2) may play some as yet unknown functional
roles. CD89 is most closely related to killer-inhibitory/activatory (KIR/KAR)-related
immunoreceptors, Ig-like transcripts, as well as the leukocyte and
monocytes/macrophage Ig-like receptors (Monteiro and van de Winkel, 2003). These
molecules typically share about 35% identity with CD89 (Monteiro and van de Winkel,
2003). We have identified a putative pig KIR gene located upstream of the pig CD89
gene in a contig encoding an immunoglobulin-like domain. This domain is up to 42%
identical to the EC2 domain of CD89 from different species. The homology of KIR/KAR
molecules with CD89 suggests that they have some functions in common with CD89
EC2.
CD89.9 is a splice variant also found in humans and has a deletion of the exon
encoding the transmembrane and cytoplasmic domains. This deletion results in the
addition of an alternative tail from the translation of several codons found at the 5’ end of
the EC2-TM/C introns (Dijk et al., 2006). Recombinant CD89.9 is mostly found in
extracellular secretions and has been speculated to possibly contribute to CD89 deposits
found on mesangial cells in IgAN (Dijk et al., 1996; Monteiro et al., 2002). Although
CD89.9 can bind to IgA, it has not been determined yet whether or not it is produced in
vivo and what its functional role maybe in health individuals. Here, we observed that
media from cells transfected with a rhesus macaque CD89.9 expression vector could
enhance CD89 cell surface staining on cells already expressing CD89 only in the
presence of IgA. In addition, an apparent inhibition of IgA binding was observed. On the
basis of these observations, it is reasonable to propose that CD89.9 may be produced in
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vivo and may function under normal physiological conditions to modulate IgA activation
of CD89 by blocking IgA binding. A single IgA molecule can bind to two CD89
molecules. Therefore, CD89.9 may act to prevent the initial binding of IgA to cells as
well as bind to IgA already bound to a single CD89 molecule to block cross-linking and
signal transduction through interaction with another membrane bound CD89 molecule. It
would be of interest to know if this splice variant is expressed in species other than
primates. As of yet similar splice variants have not been described in other species. The
putative pig CD89 gene that we have identified has a EC1-TM/C intron 5’ sequence
similar to that of primates. CD89 sequences from pig and nonhuman primates are
conserved (data not shown). In addition, a polyA tail motif (AATAAA) is present in the
pig intron downstream of the stop codon, further supporting the presence of a similar
splice variant in pigs.
Although the functions of IgA and CD89 are incompletely understood, it is clear
that these molecules play roles in both protective immunity and autoimmunity. The
presence of CD89 with similar expression and function profiles in four nonhuman
primates strongly supports the development of animal models to study IgA and CD89
functions as well as to evaluate therapeutics.

111

Acknowledgements
The authors thank the late Dr. Harold McClure (Yerkes National Primate Research
Center) for rhesus macaque and sooty mangabey blood samples, and Drs. Jerilyn Pecotte
and Dr. Kathy Brasky (Southwest National Primate Research Center) for providing
cynomolgus macaque and baboon blood samples. This work was supported in part by
NIH grants RR10755 and RR00165, by the Research Program Enhancement from the
GSU Office of Research and Sponsored Programs and by the Georgia Research Alliance.
Support for Kenneth A. Rogers was provided by the Molecular Basis of Disease program
at Georgia State University.

112

CHAPTER 4
Molecular Characterization of IgD in Mammals: Immunoglobulin Heavy Constant
Delta (IGHD) Genes in Dogs, Chimpanzees and Four Old World Monkey Species
The content of this chapter have been published as: Rogers et al., Immunology 2006;
118:88-100.

Keywords: Immunoglobulin heavy constant delta, IgD, Nonhuman primates, Dog, B cell
receptor
Summary
Antibodies are adaptor molecules that neutralize pathogens and link humoral and
cellular defense mechanisms. IgD, one of the five antibody classes present in mammals,
is expressed as an antigen receptor on naïve B cells. The functional role that IgD plays in
the immune response is still poorly understood, but the recent characterization of
immunoglobulin heavy constant delta genes (IGHD) in a variety of species challenges the
view that IgD is of minor importance and is not present in many animals. On the basis of
serological studies, IgD appears to be expressed in the majority of mammalian species
examined. To confirm, at the molecular level, that IgD is present in different species, we
cloned and sequenced IGHD cDNA from dogs and five nonhuman primate species
(chimpanzee, rhesus macaque, cynomolgus macaque, baboon and sooty mangabey). Our
results show that in all six species, IgD heavy chains possess three immunoglobulin
domains and a long hinge region encoded by two exons. Only the hinge region of
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nonhuman primates is similar to the human hinge region, with conservation of Oglycosylation sites and multiple charged residues at opposing ends. The preservation of
IgD in primates, dogs and previously characterized species suggests an important
functional role for IgD, possibly involving binding to a receptor. The high degree of
similarity existing between the structural features of human and nonhuman primate IgD
suggests that nonhuman primates are suitable for in vivo studies designed to define the
role that IgD plays in the immune response.

Introduction
Immunoglobulin D (IgD) is the least understood of the five antibody classes
found in mammals, both from a functional and evolutionary perspective. On the surface
of naïve B cells, IgD functions as an antigen receptor in apparent redundancy with IgM.
Indeed, IgM heavy chain gene (IGHM) knockout mice appear to be healthy, with only a
slight reduction of their B cell compartment (Lutz et al., 1998). IgD is also present in a
secreted form, with sera concentrations (40µg/ml in adults) considerably less than those
of IgG, IgA and IgM (Preud’homme et al., 2000). Attempts to identify the function of the
secreted form have languished in part due to the difficulty of obtaining purified IgD
(Preud’homme et al., 2000). Initially described in 1965 as a human myeloma protein
(Row and Fahey, 1965), IgD was subsequently characterized in humans, mice and rats at
both the protein and genetic levels (Rowe and Fahey, 1965; Mushinki et al., 1980;
Putnam et al., 1981; White et al., 1981; Sire et al., 1982; Zhao and Hammarström, 2003).
The presence of IgD in nonhuman primates was firmly established soon after that of
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human IgD (Martin et al., 1976). Putative IgD molecules were also identified in other
species including chicken, rabbit, dog and tortoise (Fiebig and Ambrosius, 1976; Eskinazi
et al., 1977; Sire et al., 1977; Wilder et al., 1979; Chen et al., 1982; Yang et al., 1995).
Additional studies failed to identify IgD either at the protein or the genetic level in other
species (swine, cows, sheep, duck and African clawed frog) as well as in the same species
(chicken and rabbit) (Knight and Tunyaplin, 1995; Butler et al., 1996; Naessens, 1996;
Zhao et al., 2000; Lundqvist et al., 2001). The finding that mouse and human IgD are
structurally different argued against a conserved IgD function (White et al., 1985). These
combined observations contributed to the speculation that IgD evolved recently, was
repeatedly deleted in different species, and lacks a major function. However, results from
recent studies indicate that IgD plays an important role in the immune system
(Preud’homme et al., 2000). IgD expression is differentially regulated from that of IgM
(Loder et al., 1999), and antigen binding properties differ for IgM and IgD due to
differences in their hinge regions (Løset et al., 2004). Antigen cross-linking of IgD on B
cells leads to a stronger and more prolonged signal than that of IgM (Kim and Reth,
1995), and in IgD deficient mice affinity maturation is slower than that of normal mice
(Roes and Rajewsky, 1993).
Analysis of newly described immunoglobulin heavy constant delta genes (IGHD)
has greatly altered and expanded the understanding of IgD biology and evolution. Until
the late 1990’s, only human and mouse DNA sequences were available in addition to a
partial rat sequence. Even with this paucity of genetic information, it is apparent that
IGHD properties are quite divergent between species. The human IGHD consists of eight
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exons: one encoding the first immunoglobulin domain (CH1), two encoding 58 amino
acids of an extended hinge region (H1 and H2), two encoding the second and third
immunoglobulin domains (CH2 and CH3), one encoding a hydrophilic secretory tail
(CH-S), and two encoding the membrane tail (M1and M2) (White et al., 1985). By
contrast mouse and rat IGHD have only 6 exons (CH1, a single hinge exon, CH3, CH-S,
M1 and M2) (Mushinski et al., 1980; Sire et al., 1982; Zhao and Hammarström, 2003).
The human IgD hinge region is characterized by a highly O-glycosylated N-terminal end
encoded by H1 and a highly charged C-terminal end encoded by H2. The rodent IgD
hinge region is shorter and appears to be structurally unrelated to the human hinge (Sire
et al., 1982). In 1997, Wilson et al. described an IGHD in channel catfish, which contains
seven tandem immunoglobulin exons and lacks any hinge exon. IGHD has since been
identified in Atlantic cod, Japanese flounder, carp, Atlantic salmon, Atlantic halibut,
rainbow trout, fugu and zebra fish. These genes also encode IgD heavy chains without
hinge regions and consist of various numbers of tandem immunoglobulin domain
encoding exons, which for some species are repeated in clusters (Hordvik et al., 1999;
Stenvik and Jørgensen, 2000; Bengtén et al., 2002; Hordvik, 2002; Hirono et al., 2003;
Saha et al., 2004; Srisapoome et al., 2004; Danilova et al., 2005; Hansen et al., 2005;
Savan et al., 2005). The fish IgD heavy chains are characterized by the fusion of their Nterminal end with the CH1 of IgM, which results in unique chimeric molecules. Recently,
IGHD of cow, sheep, pig and horse have been sequenced. Their exon configuration is
similar to that found in humans (Zhao et al., 2002; Zhao et al., 2003; Wagner et al.,
2004). With the exception of the pig IgD, which has the H2 exon spliced out (Zhao et al.,
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2003), in ungulates the IgD hinge regions are all encoded by two exons. However, their
hinge regions are dissimilar to those of humans and rodents in sequence. Interestingly,
pig IGHD transcripts can have the IgM CH1 fused to their 5’ end as described in fish
(Zhao et al., 2003). Together, these data demonstrate that IGHD has an ancient origin, is
distributed widely across vertebrate taxa, and is structurally diverse particularly within
the hinge region.
Despite the early recognition of the presence of IgD both on B-cells and as a
secreted protein in nonhuman primates (Voormolen-Kalova et al., 1974a; VoormolenKalova et al., 1974b; Martin et al., 1976; Finkelman and Scher, 1979; Black et al., 1993),
IgD has not been studied in these animals at the genetic level. In pioneering studies of
IgD function, injection of anti-IgD antiserum into rhesus macaques was shown to
enhance antibody responses to antigen in an adjuvant-like manner and lead to
hypergammaglobulinemia, indicating a role for IgD in regulation of humoral responses
(Pernis, 1975; Martin and Leslie, 1979). Because of their similarities to humans,
nonhuman primates are commonly used as models to understand pathogenesis for a
variety of human diseases and to develop therapeutic and preventive approaches
(Kennedy et al., 1997; Carlsson et al., 2004). Although IgD in nonhuman primates
appears well conserved with human IgD based on serology (Black et al., 1993), more
detailed studies are required to determine the extent to which this is so, particularly in
light of the divergence of IgD seen in other species. A dog immunoglobulin with IgD-like
properties, including B cell surface expression and lack of cross-reactivity with
antibodies against the other dog isotypes, has been identified (Yang et al., 1995). As
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pointed out by Naessens (1996), conclusive evidence that this immunoglobulin is indeed
canine IgD, such as cross-reactivity with known anti-IgD antibodies, is still lacking.
Hence, the presence of IgD in dogs remains to be established, particularly since it has
previously been proposed that IgD may have been deleted from many mammals
(Naessens, 1996; Stenvik and Jørgensen, 2000).
The human IgD hinge region has structural features in common with the hinge
region of IgA, including a repetitive sequence. It has been suggested that this repetition is
possibly responsible for the genetic instability and diversification of the IgA hinge region
(Flanagan et al., 1984). If this is correct, the hinge regions of IgD from species closely
related to humans might be expected to be highly divergent and polymorphic. On the
other hand, the O-glycans of the human hinge are responsible for forming interactions
with an IgD receptor expressed on human CD4+ and CD8+ T cells (Tamma and Coico,
1992; Rudd et al., 2001). If the human IgD receptor has orthologues in nonhuman
primates and it is important for survival, then the hinge region of nonhuman primates
may be well conserved with that of human IgD. Therefore, we have sequenced IGHD
from chimpanzee, rhesus macaque, cynomolgus macaque, baboon and sooty mangabey.
We have also sequenced dog IGHD, thus confirming the presence of IgD in carnivora,
and expanding the growing body of evidence that IgD is present in most mammals and
likely to be functionally important.
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Materials and methods

Blood samples and RNA extraction
Total RNA was extracted from heparinized whole blood of two rhesus macaques
(Macaca mulatta), three cynomolgus macaques (Macaca fascicularis), two baboons
(Papio hamadryas anubis) and one sooty mangabey (Cercocebus torquatus), whereas
total RNA was extracted from isolated PBMC of two chimpanzees (Pan troglodytes) and
one dog (Canis familiaris) using the QIAamp RNA Blood Mini Kit (Qiagen Inc.,
Valencia, CA). PBMC were isolated from whole blood by Histopaque®-1077 (SigmaAldrich Corp., St. Louis, MO) centrifugation. All animals used were healthy. Macaques
and baboons samples were from animals housed at the Southwest National Primate
Research Center San Antonio, TX. The sooty mangabey and the chimpanzees, Tika and
Manuel, were housed at the Yerkes National Primate Research Center, Emory University,
Atlanta, GA. Whole dog blood was purchased from Harlan Bioproducts for Science, Inc.,
Madison, WI.

Amplification, cloning and sequencing of immunoglobulin D heavy chain cDNAs
RNA was reverse transcribed into cDNA using oligo d(T)17 primers, followed by
primer extension with AMV reverse transcriptase (Roche Diagnostic Corp., Indianapolis,
IN). PCR amplification of cDNA was performed with Expand High Fidelity polymerase
(Roche Diagnostic Corp.). Primers for amplification of primate IGHD were designed on
the basis of the human sequence assuming conserved homology between primates. The

119

forward primer IgD7 (5’-CGGATGTGTTCCCCATCATATCAG-3’) is located in the 5’
end of the human CH1 exon (16-39nt). Two reverse primers were used with IgD7, IgD3
(5’-ACCCAGAAGTGTTCACCTCACG-3’) located in the center of the CH3 exon (135156nt) and IgD13 (5’-AGCTGACTTCTAGGCTCCGGCT-3’) located at the 3’ end of
CH3 exon (303-324nt). Canine primers were designed from DNA sequences of a contig
(GenBank accession number NW_140211) predicted to encode an IgD heavy chain-like
protein. The canine forward primer K9IGHDF1 (5'- ATCGTCACTTCTGCTCCCCTTG
-3') is located in the canine IgD CH1 exon (12-33nt). The canine reverse primer
K9IGHDB6 (5'- AGCAAAAAGGCAAGGGGCTG -3') is located in a region upstream
of a polyadenylation signal and downstream of the M2 exon. After initial denaturation at
95°C for 10 min, cDNAs was amplified for 40 cycles, with each cycle consisting of 94°C
for 1 min, 56°C for 1 min and 72° for 1 min 30 sec. A final step at 72°C for 10 min was
used to ensure complete extension. Primers IgD7 and IgD13 yield a human product of
1110bp and primers IgD7 and IgD3 yield one of 942bp. All reactions were performed in
at least two independent reverse transcriptions PCR to verify product sequences. At least
10 clones were sequenced for each animal of the primate species and six clones were
sequenced for dog. An additional primer set was used to amplify the baboon IgD hinge
region exons and the immediate surround nucleotides (BGDF 5’AGTACAAATGCACCGTCAAGCAT-3’ and BGDR 5’CGAAGCAGGTGAAGGTGACTTTG-3’).
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Cloning of the amplified gene sequences
For cloning, 100µl of a reverse transcription PCR was run on a 1% agarose gel.
The specific band of interest was excised from the gel and purified using a QIAquick®
Gel Extraction Kit (QIAgen, Inc., Valencia, CA). The cDNA was ligated into TopoTA
vector and transformed into Top10 Esherichia coli (Invitrogen Corp., Carlsbad, CA).
Plasmid DNA was purified using a FastPlasmid® Mini kit (Eppendorf, Inc., Hamburg,
Germany) and screened on a 1% agarose gel after digestion with EcoRI to confirm the
correct size of the DNA fragments. All DNA sequences were determined using the
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA)
on an ABI 3100 Genetic Analyzer (PerkinElmer, Inc., Wellesley, MA). The forward and
reverse M13 primers were used for the sequencing. For the canine DNA fragments, an
additional primer, K9IGHDB2 (5'- TGATCCAGGTGAGGAGGATGTCAG -3'), located
in the CH3 exon, was used.

Analysis of DNA sequences
Overlapping regions were identified and sequences were edited using the
MacVector software program (Accelrys Inc., San Diego, CA). Sequences were aligned
with each other and other known IGHD using the CLUSTAL function of the
MEGALIGN part of the LASERGENE software package (DNASTAR Inc., Madison,
WI). ImMunoGeneTics (IMGT) standardized nomenclature and numbering has been used
to show and discuss data based on human reference sequences (Lefranc and Lefranc,
2001). The GenBank accession numbers for the IGHD sequences of the various species
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used for analysis which were previously available are human K02875-K02883, horse
AY631942, cow AF411240, pig AF411239 and AY228508, sheep AF411238, rat
AY148494 and AY148495, and mouse V00786-V00788 and J00450,. The GenBank
accession numbers for the IGHD sequences described in this study are chimpanzee
DQ297173-DQ297174, baboon DQ297175-DQ297176, cynomolgus macaque
DQ297177-DQ297178, rhesus macaque DQ297179-DQ297181, sooty mangabey
DQ297182-DQ297184 and dog DQ297185.

Results
Chimpanzee IGHD
We cloned and sequenced IGHD using total RNA of PBMC from two different
chimpanzees. Tika and Manuel’s IGHD were sequenced using the primers IgD7 and
IgD3, which amplify a 942bp product with a sequence encoding amino acids from the
CH1 position 7 to the CH3 position 52. Tika’s IGHD was also amplified using the primer
pair IgD7 and IgD13 allowing for sequencing through the 3’ terminus of the CH3 and
yielding a 1110bp product. Attempts to sequence Manuel’s IGHD with this latter primer
pair were unsuccessful. The region amplified for both animals had identical sequence
except for a single G/C difference in the CH1 codon 14 at position 3, which is silent.
Through screening of GenBank for matches with the chimpanzee mRNA sequences
IGHD, the genomic sequence was identified on a contig from the chimpanzee
chromosome 14 (NW_115908). The nucleotide sequence of the contig has 99.4% identity
to that of the cDNA, with a G in the third position of CH1 codon 14. In the contig
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sequence three nucleotide differences from the cDNA sequences are present: an insertion
of C at CH2 codon 16 between positions 2 and 3, which results in a reading frame shift; a
silent A to C substitution of CH2 codon 24 position 3; and a missense A to C substitution
of CH3 codon 106 at position 3 resulting in a coding change from glutamate to aspartate.
All exons had the anticipated boundaries and were of equivalent sizes to the human
counterparts. Besides the CH1-3 identified by reverse transcription PCR, we identified an
exon for the secretory tail and the first exon for the transmembrane tail from the contig
(Figures 4.1 and 4.2).
The chimpanzee IGHD deduced amino acid sequence, which is 98.1% identical to
that of human IGHD, is shown aligned with IGHD of other species in Figure 4.2. All
cysteines responsible for inter- and intra- chain disulfide bonds found in human IGHD
are conserved in the chimpanzee (CH1 positions 15, 28 and 84; CH2 positions 2, 31 and
90; CH3 positions 27 and 88). Similarly, the three N-glycosylation motifs (CH2
asparagine 66 and CH3 asparagines 49 and 100) are conserved between humans and
chimpanzees. The human IgD N-terminal portion of the hinge is highly O-glycosylated
(Putnam et al., 1981). Identified sites of O-glycosylation in human IgD hinge include H1
encoded residues S8, S9, T12, T25, T26, T30 and T31. All of these O-glycosylation sites
are present in chimpanzee IgD with the exception of T25, which is replaced by an
arginine in chimpanzee.
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Figure 4.1. Chain diagram of human, chimpanzee and dog IGHD genes. Numbers indicate nucleotides in exons or introns.
Domains which have not been identified are indicated by dashed lines.
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Figure 4.2. (Following pages) Alignment of IgD heavy chain deduced amino acid sequences for
each domain: CH1 (A), hinge H1 (B) and H2 (C), CH2 (D), CH3 (E) and transmembrane (F).
Mouse and rat hinge is encoded by a single exon. Pig H2 is spliced out of the mature mRNA and
its deduced sequence is denoted in italics case to reflect this (Zhao et al., 2003). B) Glycines in
the middle of the hinge, potentially contributing to flexibility, are underlined. O-glycan sites in
human H1 and the corresponding conserved residues in nonhuman primates are bolded and
italicized. A, C, D, and E) N-glycosylation motifs (NXS or NXT where X is not proline) are
bolded and italicized. Cysteines that form disulfide bonds within immunoglobulin domains and
between immunoglobulin chains are bolded and underlined. F) Amino acid of the conserved
antigen receptor transmembrane motif (CART) are underlined and bolded. Mangabey.1 and
mangabey.2 in D are two sequence variants. Numbering is based on IMGT numbering for human
IgD heavy chain and disregards insertions and deletions found in other species. GenBank
accession numbers are given in the methods sections.
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A
IgD CH1

1
20
40
|
|
|
Human
APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTV
Chimpanzee
APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTPVTV
Baboon
DVFPIISVCELPKDNSPVVLACLITGYNPKSVTV
Mangabey
DVFPIISACQLPKDNSPVVLACLITGYNPKSVTV
Rhesus
DVFPIISACQLPKDNSPVVLACLITGYNPKSVTV
Cynomolgus
DVFPIISACQLPKDNSPVVLACLITGYNPKSVTV
Dog
ASRESSLLLPLVSGCKVPKNGEDITLACLAKGPFLDSVRV
Horse
SLEDTAVIPLFSECKAPKEDDVVSLACLVKGYFPEPVQV
Cow
EGESHLRVFPLVSCVSSPSDESTVALGCLARDFVPNSVSF
Sheep
ESESHPKVFPLVSCVSSPSDENTVALGCLARDFMPNSVSF
Pig
ESQSAPNLYPLVSCVSPPSDESLVALGCLARDFLPSSVTF
Mouse NFTICLAGDKKEPDMF-LLSECKAPEENEKINLGCLVIGSQP--LKI
Rat
APEKEPDLF-LSSECKAPNQNEHVNVSCMAIGVQP--LTL
41
60
80
|
|
|
Human
TWYMGT----QSQPQRTFPEIQRRDSYYMTSSQLS---TPLQQWRQG
Chimpanzee TWYMGT----QSQPQRTFPEIQRRDSYYMTSSQLS---TPLQQWRQG
Baboon
TWHLGT----QIQNQIMFPETER-EGSYTTSSQLAP-TPLLSQQHQG
Mangabey
TWHLGT----QIQNQIMFPETER-EGSYMTSSQLAP-TPPLSQQHQG
Rhesus
TWHLGT----QIQNQIMFPETER-EGSYTTSSQLAP-TPPLSQQHQG
Cynomolgus TWHLGT----QIQNQTMFPETER-EGSYTTSSQLAP-TSPLSQQHQG
Dog
TTGPES----QAQMEKTTLKMLK-IPDHTQVSLLS------TPWKPG
Horse
TWEPEM----QNQKPWTFPAMKK-GQEYIHVFSLT------TWWKPG
Cow
SWKFNNST-VSSERFWTFPEVLR-DGLWSASSQVVLPSSSAFQGPDD
Sheep
SWKLNNST-VSSERFWTFPEVLR-DGLWSASSQVALHSSSAFQG-TD
Pig
SWNYKNSSKVSSQNIQDFPSVLR-GGKYLASSRVLLPSVSIPQDPEA
Mouse
SWEPKK----SSIVEHVFPSEMR-NGNYTMVLQVT---VLASEL-NL
Rat
AWEP-------TLPSTVFSGKNK-D-EYITILQVS---VPAPNL-SP
81
100
|
|
Human
EYKCVVQHTASKSKKE-IFRWP
Chimpanzee EYKCVVQHTASKSKKE-IFRWP
Baboon
EYKCTVKHTPSNTNQEKTFRWP
Mangabey
EYKCTVKHIPSDTNKAKTFRWP
Rhesus
EYKCTVKHTPSDTSKEKTFRWP
Cynomolgus EYKCTVKHTPSNTNNEKTFRWP
Dog
LHYCEAIRKDNKEKLKKAIHWP
Horse
SHSCTVHHKASSFRKKMTFQEP
Cow
YLVCEVQHPKGGKTVGTVRVVPR
Sheep
GYLCEVQHPKGGKTVGTTRVVPR
Pig
FLVCEVQHPSGTKSVSISGP
Mouse
NHTCTINKP---KRKEKPFKFP
Rat
NLTCTITNTS--KKKSKTFKLP

Figure 4.2. A.
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B
IgD Hinge H1
1
20
|
|
Human
ESPKAQASSVPTAQPQAEGSLAKATTAPATTRNT
Chimpanzee ESPKAQASSVPTAQPQAEGSLAKATRAPATTSNT
Baboon
ESPKAQYPSVPTVQPQAEGGLSKATRPPATNRNT
Mangabey
ESPKAQYPSVPTVQPQAEGGLSKATRPPATNRNT
Rhesus
ESPKAQYPSVPTVQPQAEGGLSKATRPPATNRNT
Cynomolgus ESPKVQYPSVPTVQPQAEGGLSKATRPPATNRNT
Dog
ASWETAIS-LLTHAPSR---PQDHTQAPSMARVS
Horse
ASWAPQ------RTSALPVTSKEPTPAPTTLRKS
Cow
ASTPT—-P-T-TPLPSLISGSEGSNKAVSTQSSP
Sheep
VSASTLTP-T-TLAPSLKSRSEGSSKAVTTQSSP
Pig
ASRQLPAP-AGTPGPTL---STVSTKALTTPRIPA
Mouse
-SWDSQSSKRVTPTLQAKNHSTEATKAITTKKDIE
Rat
ETRNSQSSKKANPTPQAKNHYIEATKPTATKNIVG

C
IgD Hinge H2
1
20
|
|
Human
GRGGEEKKKEKEKEEQEERETKTP
Chimpanzee GRGGEEKKKEKEKEEQEERETKTP
Baboon
GR--REKENEEEKEQQEG-ETKTP
Mangabey
GR--REKEDEEEKEQQEG-ETKTP
Rhesus
GR--REKEDEEEKEQQEG-ETKTP
Cynomolgus GR--REKDDEEEKEQQEG-ETKTP
Dog
VPPTSHTQTQAQ-EPGCPVDTILR
Horse
EPSTRHTQPETQK-PRIPVDTPLK
Cow
ALTTSHRQTEAQT-LACPKE-PCR
Sheep
VPATSHSQTEAPT-LACPKD-PCR
Pig
-RSTVRGQPGAQT-QE-PPEGPRG

Figure 4.2. B and C.

127

D
IgD CH2
Human
Chimpanzee
Baboon
Mangabey.1
Mangabey.2
Rhesus
Cynomolgus
Dog
Horse
Cow
Sheep
Pig

1
20
40
|
|
|
ECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKD
DCPSHTQPLGVYLLPPAVQDLWLRDKATFTCFVVGSDLKD
ECPSHTQPLGVYLLPPALQDLWFRDKVTFTCFVVGSDLQD
ECPSHTQPLGVYLLPPALQDLWFRDKVTFTCFVVGSDLQD
ECPSHTQPLGVYLLPPALQDLWFRDKATFTCFVVGSDLQD
ECPSHTQPLGVYLLPPALQDLWFQDKVTFTCFVVGSDLQD
ECPSHTQPLGVYLLPPALQDLWFQDKAIFTCFVVGSDLQD
ECWNHTHPPSLYMLRPPLRGPWLQGEAAFTCLVVGDDLQK
ECQSHTHPPSIYLLHPPLQGLWLKGEATFTCLVVGDDLKD
ECQNHTQAPRVHLLPPTPQGLWLLDKAEFTCLATGEAPLD
ECQNHTQAPSVRLLPPPPQGLWLLDKAEFTCLATGEALLD
-CQNHTRPPSVYLLLPPLQGLWLRAEATFTCLAVGQDLQE

41
60
80
|
|
|
Human
AHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRS
Chimpanzee AHLSWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRS
Baboon
AHLSWEVAGKVPKGDMEEGPLEQHSNGSQSQHSRLALPRS
Mangabey.1 AHLSWEVAGKVPKGGMEEGPLEQHSNGSQSQHSRLALPRS
Mangabey.2 AHLSWEVAGKVPEGGMEEGPLEQHSNGSQSQHSRLALPRS
Rhesus
AHLSWEVAGKVPKGGMEEGPLEQHSNGSQSQHSRLALPRS
Cynomolgus AHLSWEVAGKDPKGGMEKGPLEQHSNGSQSQHSRLALPRS
Dog
AHLSWEVAGAPPSEAVEERPLQEHENGSQSWSSRLVLPIS
Horse
AHLSWELSERSNGMFVESGPLEKHTNGSQSRSSRLALPRS
Cow
AHFSWEVNGQPHGGALEEG-PTRHINSSWSQSSRLALPRS
Sheep
AHFSWEVNGQPHGGAVEER-PTSHMNGSWSHSSRLALPRS
Pig
ARLSWAVAEDPQGGRMEEG-PTEHTNGSWSLSSRLALPRS
81
100
|
|
Human
LWNAGTSVTCTLNHPSLPP-QRLMALREP
Chimpanzee LWNAGTSVTCTLNHPSLPP-QRLMALREP
Baboon
LWNAGTSVTCTLNHPSLPS-QKLMALREP
Mangabey.1 LWNAGTSVTCTLNHPSLPS-QKLMALREP
Mangabey.2 LWNAGTSVTCTLNHPSLPS-QKLMALREP
Rhesus
LWNAGTSVTCTLNHPSLPS-QKLMALREP
Cynomolgus LWNAGTSVTCTLNHSSLPS-QKLMALREP
Dog
LWASGANITCTLSLPSMPSQVVSAAAREH
Horse
SWAMGTSVTCKLSYPNLLSSMEVVGLKEH
Cow
LWASGSNVTCTLSSPGLQSPVTLTAQREH
Sheep
LWASGSNVTCTLSGPGLRSPVSLTAQREH
Pig
SWAAGAPVTCRLSGPGLRSLVTAEARREH

Figure 4.2. D.
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E
IgD CH3

1
20
40
|
|
|
Human
AAQAPVKLSLNLLASSDP---PEAASWLLCEVSGFSPPNILLM
Chimpanzee AAQAPVKLSLNLLASSDP---PEAASWLLCEVSGFSPPNILLM
Baboon
AAQAPVRLSLNLLASSDP---PEAASWLLCEVSDFSPPNILLM
Mangabey
AAQAPVRLSLNLLASSDP---PEAASWLLCEVSDFSPPNILLM
Rhesus
AAQAPVRLSLNLLASSDP---PEAASWLLCEVSDFSPPNILLM
Cynomolgus AAQAPVRLSLNLLASSDP---PEAASWLLCEVSDFSPPNILLM
Dog
AARAPSSLNVHALTMP------RAASWFLCEVSGFSPPDILLT
Horse
AASAPRSLTVHALTTPGLNASPGATSWLQCKVSGFSPPEIVLT
Cow
AASVPGNLTLRTVTAPG----PFSPAWLLCEVSGFSPVDILLT
Sheep
AASVPGNLTLRTLTTPG----PFSPAWLLCEVSGFSPVDILLT
Pig
AALAPSNLAVRVLTAPGPLAFTKAASWLLCEVSSFSPLDILLT
Mouse
AMAPSNLTVNILTTSTH---PEMSSWLLCEVSGFFPENIHLM
Rat
AMAPSNLNVNILTTFTH---HEMSSWLMCEVSGFYPEDIHLW
41
60
80
|
|
|
Human
WLEDQREVNTSGFAPARPPPQPRSTTFWAWSVLRVPAPPS
Chimpanzee WLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPS
Baboon
WLEDQREVNTSWFATTHPTPQPGSTMFWAWSVLRVPGPTS
Mangabey
WLEDQREVNTSWFATTHPTPQPGSTMFWAWSVLRVPGPTS
Rhesus
WLENQREVNTSWFATTHPTPQPGSTMFWAWSVLRVPGPTS
Cynomolgus WLEDQREVNTSWFATTHPTPQPGSTMFWAWSVLRVPGPTS
Dog
WIKDQIEVDPSWFATAPPMAQPGSGTFQTWSLLRVLAPQG
Horse
WLEGQREVDPSWFATARPTAQPGNTTFQTWSILLVPTIPG
Cow
WLEGQQEVEPSQFATAHTTAQAGRASSHTWSVLRVSSPLD
Sheep
WLEGQQEVEPSQFATAHTTAQSGHASFHTWSVLHVSSPLD
Pig
WLEGQQEVDPSWFATARPAAQPGNPTFRTWSVLRVPASPG
Mouse
WLGVHSKMKSTNFVTANPTAQPGG-TFQTWSVLRLPVALS
Rat
WLSAQTKMDPINFVTAQPVRQSGD-KFQIWSVLRLPVALS
81
100
|
|
Human
PQPATYTCVVSHEDSRTLLNASRSLEVS
Chimpanzee PQPATYTCVVSHEDSRTLLNASRSLEVS
Baboon
PQPATYTCVVSHEDSRTLLNASRSLEVS
Mangabey
PQPATYTCVVSHEDSRTLLNASRSLEVS
Rhesus
PQPATYTCVVSHEDSRTLLNASRSLEVS
Cynomolgus PQPATYTCVVSHEDSRTLLNASRSLEVS
Dog
PHPPTYTCVVRHEASRKLLNTSWSLDS
Horse
PPTATYTCVVGHEASRQLLNTSWSLDTG
Cow
HAGATYTCVVSHEASRTLLNGSCSLDT
Sheep
HVGSTYTCVVSHEASRTLLNGSCSLDTG
Pig
HQDATYTCVVGHEASRTLLNASWRLDTG
Mouse
SSLDTYTCVVEHEASKTKLNASKSLAIS
Rat
PSLDTYTCVVEHEASQTKLNASKSLEIS

Figure 4.2. E
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F
IgD TM
Human
Chimpanzee
Dog
Horse
Cow
Sheep
Pig
Mouse
Rat

Figure 4.2. F.

1
20
40
|
|
|
YLAMTPLIPQSKDENSDDYTTFDDVGSLWTTLSTFVALFILTLLYSGIVTFIKVK
DLAMTPLIPQSKDENSDDYTTFDDVGSLWTTLSTFVALFILTLLYSGIVTFIKVK
GLTMTPPAPQSHDESSGDSMDLEDASGLWP---TFAALFVLTLLYSGFVTFLKVK
GLAMTPE---SKDENSDDYADLDDAGSLWL---TFMALFLITLLYSGFVTFIK
GLATWPPW--SQDESSDDGTDVEDASPLWL---TFLALFLVTVVYGGFVTFIKVK
GLATWPPW--SQDESSDDSADAEDASPLWL---TFLALFLATVVYSGFVTFIKVK
GLATLTPG--SQDEGSDDYVDLEDAGRLWL---TFTVLFLVTLLYSGFVTFLKVK
GIVNTIQHSCIMDEQSDSYMDLEEENGLWPTMCTFVALFLLTLLYSGFVTFIKVK
GMVDTIPNSCIRDEQTDSYVDLEEENGLWPTLCTFVALFLLTLLYSGFVTFIKVK
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IGHD mRNA transcripts in Cercopithecoidea
With the same strategy used to clone and sequence chimpanzee IGHD, we
identified IGHD transcripts for four Old World monkey species commonly used in
biological research. IGHD were sequenced for two rhesus macaques, three cynomolgus
macaques, two baboons and one sooty mangabey. Amplification of monkey IGHD cDNA
with the primer pair IgD7 and IgD13 resulted in an 1107bp product for all four species.
Because IGHA in macaques and baboons is highly polymorphic (Scinicariello and
Attanasio, 2001; Scinicariello et al., 2004), multiple animals were used for some of the
species to allow for identification of potentially high levels of IGHD polymorphisms in
these species. A single IGHD sequence was present for each species, except sooty
mangabey, which had two sequences in one animal that varied at five nucleotides
resulting in two amino acid substitutions. As discussed below, polymorphisms of IGHD
appear to be less extensive than those of IGHA in nonhuman primates.
The deduced amino acid sequences for each species are shown in Figure 4.2. The
percent identities of the Old World monkey sequences with those of the human and
chimpanzee (in parentheses if different) sequences are 72% baboon, 77% (78%) sooty
mangabey, 77% rhesus macaque and 76% cynomolgus macaque. The percent identities
between Old World monkeys are higher: 96% baboon-sooty mangabey, 97% baboonrhesus macaque, 94% baboon-cynomolgus macaque, 98% sooty mangabey-rhesus
macaque, 96% sooty mangabey-cynomolgus macaque and 97% rhesus macaquecynomolgus macaque (Table 4.1). The transcripts encoded all expected domains: CH1,
hinge, CH2 and CH3. In the Old World monkeys, CH1 is two amino acids longer than
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Table 4.1. Range of percent identities for deduced amino acid sequences between the IgD
heavy chain domains of different mammalian phyla. Groups used are based on
representative species for which IGHD has been identified and include: hominoids
(human and chimpanzee); cercopithecoidea (baboon, mangabey, rhesus macaque and
cynomolgus macaque); primates (combined cercopitheocoidea and hominoids);
Laurasiatheria (dog, horse, pig, sheep and cow); rodents (mouse and rat). * For the
described species of rodents, IgD does not encode a CH2 domain.

HumanChimpanzee
HominoidsCercopithecoidea
Within
Cercopithecoidea
PrimatesLaurasiatheria
PrimatesRodents

CH1
98.9

Hinge
96.6

CH2
97.2

CH3
99.1

CH1-3
98.1

57.7-58.8

61.8-65.5

84.3-89.8

88.9-90.7

71.5-77.7

91.8-95.9

96.4-100

93.5-99.1

99.1-100

93.8-98.4

21.6-32.0

13.2-19.6

48.6-55.6

51.4-60.2

27.3-42.4

15.5-18.7

23.5-31.4

N/A*

47.2-51.9

12.9-32.3
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the hominoid CH1 (excluding any differences in the first six amino acid which are
encoded by nucleotides prior to where our forward PCR primer annealed), while the Old
World monkey hinge is three amino acids shorter than the hominoid IgD hinge. These
differences result in Old World monkey IgD heavy chains being one amino acid shorter
in their described CH1-CH3 portion than is found in chimpanzee and human IgD heavy
chain. Comparing hominoids to Old World monkeys, CH1 of Old World monkeys lacks
arginine 60, has an insertion of proline and threonine between S71 and T72, and an
insertion of lysine between E96 and I97. Within the carboxy-terminal half of the hinge
region, three amino acids present in human and chimpanzee IGHD are absent in the Old
World monkeys: G3, G4 and R19. All N-glycosylation motifs and cysteines involving
inter- and intra-chain disulfide bonds in humans are conserved in Old World monkey
IgD. Cynomolgus macaques have additional potential N-glycosylation sites at CH1 N50
and CH2 N93. These position are not N-glycosylated in any of the other know
mammalian IgD. CH1 N50 is also present in pig and the other Old World primates and
CH2 N93 is present in all the primates examined. However, in these species, neither is
followed by the N-glycosylation consensus sequence. Human O-glycosylation sites in the
first half of the hinge are partially conserved in the Old World monkeys; H1 encoded
residues S9, T12, T25 and T30 are conserved, but S8, T26, T31 are proline, arginine and
asparagine respectively in Old World monkeys.
Unexpectedly, in addition to the 1107bp inserts from the RT-PCR clones, 1044bp
clones were isolated from all four Old World primate species. These clones have the
same sequence as the larger product but, inferring a similar intron-exon arrangements and
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boundaries as found in humans and chimpanzees, with an absent H2 exon. This H2
deletion was present in clones from PCR products of both IgD3 and IgD13, and IgD7 and
IgD13 primer sets. In two of the three cynomolgus macaques examined, all of the clones
sequenced had the H2 deletions. Conversely, the clones of the third cynomolgus macaque
included the H2 exon. A single clone for each of the other species (baboon, rhesus
macaque and sooty mangabey) was sequenced that lacked the H2. In addition to clones
that were verified by sequencing, clones for each species with inserts of size
corresponding to the H2 deletion product were observed on 1% agarose gels. No clones
missing the H2 exon were observed for chimpanzee clones or human clones when the
same primer sets were employed. Besides the two primer pairs described, we also
designed a primer set (BGDF and BGDR) flanking the hinge to amplify small PCR
fragments. These primers were tested with cDNA of two different baboons than those
reported here and produced primarily fragments of the size expected for the IgD∆H2
product when visualized as bands on an agarose gel. The bands for the product with a
complete hinge were faint. These experiments likely under represent the full-length hinge
product, because PCR amplification would favor the smaller IgD∆H2 product, which was
nearly half the size of the product with H2.

Dog IGHD
We performed reverse-transcription PCR on dog PBMC total RNA using primers
K9IGHDF1 and K9IGHDB6 derived from sequences within a contig (NW_140211) that
had a high percent identity with IGHD of other species. The resulting 1468nt product
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consisted of seven exons (CH1, H1, H2, CH2, CH3, M1 and M2) encoding a 416 amino
acids polypeptide (Figure 4.2), and a portion of the 3’ untranslated region. Comparison
with the genomic sequence shows the dog IGHD spans 8.25kb and all the introns follow
the GT…AG rule with the possible exception of the H2/CH3 intron, which does not
begin with GT in the contig sequence. The cDNA sequences agree with the dog contig
for all but two nucleotides. Residues corresponding to human IgD CH1 positions 56 and
63 are methionine and glutamate in the contig, but are lysine and aspartate respectively in
our clones. All cysteines that form intra- and inter-chain disulfide bonds in humans IgD
heavy chains are conserved in the dog IgD heavy chain. An additional cysteine is present
in the dog H2 at position 16. The predicted molecular weight of the unglycosylated
transmembrane protein is 45.409 kDa, and without the transmembrane domain is
39.836kDa. There are four potential N-glycosylation sites in the dog IgD heavy chain. Nglycosylation sites at CH2 N66 and CH3 N100 are sites conserved with other mammalian
IgDs. The N-glycosylation site at CH2 N4 is shared with artiodactyls and the Nglycosylation site at CH2 N87 is also present in cow and sheep. Dog IgD heavy chain
amino acid identities with horse, pig, cow and sheep are similar to those seen between
these species. CH1 and the hinge are least conserved, while CH2, CH3 and
transmembrane domains are more conserved. Residues of the conserved antigen receptor
transmembrane (CART) motif are present in the dog IgD transmembrane domain with the
exception of T31, which is also absent in the other species of the Laurasiatheria group,
i.e. pig, cow, sheep and horse (Campbell et al., 1994). Dog IgD is most similar to horse
IgD for CH1, hinge, CH2 and CH3 with percent identities of 40.2%, 37.3%, 57.8% and
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67.3%, respectively. Dog IgD TM is most similar to that of pig and sheep with 62%
identity to each. The percent identity of dog IgD CH1-CH3 with that of primates is 39%
(human 39.3%, cynomolgus 38.7%, mangabey 38.6%, rhesus 38.7% and baboon 38.5%).

Phylogenetic analysis and comparative analysis of IgD heavy chains
To gain further insight into the evolution of IGHD, additional analysis of IGHD in
mammals was performed. A phylogenetic tree was constructed from IgD CH1-CH3 of
different mammals (Figure 4.3). The relationship between taxa corresponds to accepted
phylogeny, with the exception of that of the Old World monkeys.
The human IgD H1 may have originated from IgM CH2 (Putnam et al., 1981).
Therefore, we compared the amino acid sequences from IgD H1 and IgM CH2 of
different species. Human H1 is 35.3% identical to a portion of human IgM CH2 (R46T79). The H1 of the chimpanzees and Old World monkeys have 32.4% identity with the
same portion of IgM CH2, but the percent identity was lower when dog or mouse IgM
CH2 was used for comparison. IgD H1 S8 and T26 in humans in this scenario would
derive from IgM CH2 S53 and T71 respectively. However, with the exception of humans,
IgD H1 S8 is only conserved in chimpanzees and IgD H1 T26 is replaced by an arginine
in all the examined nonhuman primate species. IgD H1 A22 of hominoids is substituted
with S22 in all Old World monkeys which aligns with the conserved IgM CH2 S67. IgD
H1 of species other than primates have less than 17% amino acid identities with IgM
CH2.
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Figure 4.3. Phylogentic relationships of mammalian IgD heavy chains. Neighbor joining
tree constructed from the deduced amino acid sequences of mammalian IgD domains
CH1-CH3 created using the CLUSTAL X method. Mangabey.1 and mangabey.2
represent two sequence variants. Accepted phylogenetic relationships between the
different species are present in the tree except for Old World monkeys, which likely
result from the high conservation of IgD within these species. The values shown
represent the number of occurrences of branches over 1,000 bootstrap resamplings of the
data sets.

137

In previously characterized IGHD sequences, different exons are conserved at
different degrees. Table 4.1 summarizes the overall trends in deduced amino acid
conservation observed between groups of mammals for the CH1-CH3 exons. As
reported by others (Wagner et al., 2004), the CH1 and the hinge exons are the least
conserved. CH3 is the most conserved exon. In rodents, IgD CH2 is absent, but otherwise
CH2 is conserved nearly as well as CH3 for other mammals. IGHD is well conserved in
primates, both within the Old World monkey and hominoid groups, and between the two
groups. Comparing Old World monkeys with hominoids, the IgD domain conservation is
CH3>CH2>hinge>CH1. IgD CH3 is conserved 100% between baboon, mangabey and
cynomolgus monkeys. The IgD hinge region of rhesus and mangabey is identical. The
secretory tail (CH-S) of IgDs is poorly conserved between species. Of all the IgD
domains, CH-S has the lowest percent identity between chimpanzees and humans
(77.8%; chimpanzee CH-S: YVTDRGPVK versus human CH-S: YVTDHGPMK).

Disscussion
Here, we have sequenced IGHD cDNA from five nonhuman primate species and
from dog. Through comparison of these sequences and previously available IGHD
sequences, we have examined issues related to the evolution of IgD and gained insight
into structural IgD features that are most likely involved in functional properties. In
agreement with what previously known about IgD, CH3 is the most conserved domain
among the different species (Table 4.1). In contrast, the hinge region has diversified

138

extensively between different mammalian groups, but is well conserved within primates.
Hence the hinge region may have evolved unique functional roles in primates.
Despite the importance of nonhuman primates in research, the immunoglobulin
heavy chain constant regions of these species are only partially characterized. Sequences
of genes are currently available for only a few antibody classes, mainly IgG and IgA, and
are limited to a few species (Ueda and Kawamura, 1992; Calvas et al., 1999;
Scinicariello and Attanaio, 2001; Attanasio et al., 2002; Scinicariello et al., 2004).
Furthermore, corresponding immunoglobulin Fc receptors, which are responsible for
initiating cellular immune responses to antibody bound antigens, generally have not been
characterized for nonhuman primates beyond identification by cross-reactive antibodies.
The biology of humans and mice with regards to Fc receptors is often quite different
(Takai, 2005). Therefore, nonhuman primates may provide useful alternative models to
study antibody/Fc receptor interactions. Mice lack a homologue of the human IgA Fc
receptor I (Takai, 2005), but homologues are present in macaques (Rogers et al., 2004).
In nonhuman primates, IgA is highly polymorphic and sequence differences from the
human counterpart may result in modifications of their functional properties
(Scinicariello and Attanasio, 2001; Scinicariello et al., 2004). Overall, few studies have
been performed to evaluate the functional properties of nonhuman primate antibodies, in
part because of their incomplete molecular characterization.
Understanding of IgD has lagged compared to other immunoglobulin classes, but
evidence has mounted over the past years for distinct roles played by IgD in the immune
response. When immunized with a model antigen, the antibody repertoire of IgD+IgM-
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mice differs from that of the IgD+IgM+ mice by VH gene usage, degree of affinity
maturation, and reduced isotype switching to the IgG2a subclass (Han et al., 2004). Both
secretory and membrane bound IgD can bind to IgD receptors found on T cells of
humans and mice (Amin et al., 1991; Rudd et al., 1995). In contrast to Fc receptors for
IgE, IgG and IgA, these IgD receptors, identified over a decade ago, have remained
poorly characterized making it difficult to assess their true function. In mice, antigen
specific responses involving the cognate interactions of T and B cells are enhanced by the
combined presence of IgD on B cells and up regulation of the IgD receptor on CD4+ T
cells (Wu et al., 1999). IgD can activate the alternate complement pathway (Spiegelberg,
1989). Despite the low concentration of IgD in normal sera, IgD serum concentrations are
elevated under some circumstances (Preud’homme et al., 2000). For example, increased
serum IgD levels appear early and persist in HIV infections (Raiteri et al., 1991). IgD
levels also increase in humans with atopy (Peng et al., 1991). Pathogen-specific IgD can
be produced in response to infection (Preud’homme et al., 2000). IgD makes up 3-10% of
immunoglobulins in nasal, lacrimal and parotid glands, and in IgA deficient individuals
IgD increases to 34-57% of the total immunoglobulins at these locations (Brandzaeg et
al., 1991). Elevated levels of serum IgD are characteristic of an autosomal recessive
disorder, hyper IgD and periodic fever syndrome (HIDS), which is caused by mutations
in the mevalonate kinase gene (Centola et al., 1998). Although symptomatic attacks in
HIDS patients do not correlate to IgD serum levels, attacks are marked by high levels of
IL1, IL6 and TNF-α, the same cytokines induced by incubation of normal PBMC with
IgD, suggesting a possible link between IgD and HIDS pathology (Drenth et al., 1996).
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Our findings show IgD structure of nonhuman primates and dog is similar to that
found in human, horse and artiodactyls (cow and sheep). Three CH domains and a long
hinge are present in all the examined primates and in dog. By contrast, mouse and rat IgD
have no CH2, although a mouse pseudo-exon related to CH2 has been described
(Mushinski et al., 1980; Sire et al., 1982; Richards et al., 1983). Our results cannot
establish whether or not the dog immunoglobulin identified by Yang et al. (1995)
corresponds to the one that would be produced from dog IGHD; however, our data is
compatible with this possibility. The calculated molecular weight of dog IgD CH1-CH3
domains is 40kDa. A complete IgD heavy chain including glycans at its four Nglycosylation sites, the heavy chain variable domain and a secretory tail (which we did
not identify) would be expected to be of a greater molecular weight. This would be
consistent with the reported molecular weight of 55kDa of the putative dog IgD heavy
chain found in sera (Yang et al., 1995).
N-glycosylation is an important feature of all immunoglobulin molecules
including IgD. All the N-glycosylation sites found in humans are conserved in nonhuman
primates. In humans, the N-glycosylation site at CH2 N66 is necessary for the association
of IgD heavy chains to form a complete antibody and for secretion from the endoplasmic
reticulum (Gala and Morrison, 2002). The N-glycosylation site at CH3 N49 is
characteristic of all the examined primates and not found in IgD of the other species.
Cynomolgus macaque IgD has additional N-glycosylation motifs present at CH1 N50 and
CH2 N93. Mice possess an IgD receptor different from that of humans, which is
expressed on CD4+ T cells and is specific for N-linked glycans on murine IgD (Adachi
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and Ishizaka, 1986; Amin et al., 1991). It is unknown if similar IgD receptors are present
in other species, but possible N-glycan sites are present in dog IgD that might provide
points of interaction with such an IgD receptor.
The structure of the immunoglobulin hinge regions is critical for their function; it
gives antibodies the flexibility needed to bind antigen and provide sites of interaction
with Fc receptors and complement. The IgD hinge is quite diverse in structure between
species. Rodents have a shorter IgD hinge encoded by a single exon. The hinge regions of
dog and chimpanzee are encoded by two exons. Old World monkey IgD hinge regions
similarly have two distinct segments that are highly conserved with those of hominoids,
including the large number of lysine and glutamate residues of the C-terminal portion.
These charged residues may favor the formation of an α-helix structure and act to
separate the two hinge segments by repulsion (Sun et al., 2005). The IgD hinge region is
the longest of that found in all human antibody isotypes and, besides the IgG3 hinge, is
the only other immunoglobulin hinge encoded by multiple exons (Lefranc and Lefranc,
2001). The dog IgD hinge region is structurally distinct from the corresponding primate
regions and is related more closely to that of ungulates; it does not have a highly charged
second domain. The second half of the dog hinge region contains a cysteine which is at a
conserved position with cysteines found in the hinge regions of sheep and cow. In the
latter two species a second cysteine is also present in the IgD H2. It is possible that these
cysteines in the IgD hinge regions of dogs, sheep, and cows are involved in forming
inter-heavy chain disulphide bonds as described for the cysteines of IgG hinge regions.
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Structurally, IgD and IgA1 hinges of humans share common features. IgA1 is the
only other immunoglobulin with O-glycosylation in its upper hinge. As previously
demonstrated for IgA, the flexible arms of IgD Fab can be separated by a wide angle thus
resulting in an average antibody conformation similar to that of a T-shape in contrast to
the more typical immunoglobulin Y-shape (Løset et al., 2004; Sun et al., 2005).
Comparable to the hinge of IgD, IgA of different mammals is highly variable in length
and amino acid sequence. IgD H2 is high repetitive. It has been suggested that the
repetitive genetic structure of the IgA hinge region has led to its evolutionary instability
(Flanagan et al., 1984). Indeed, the hinge of two mouse species has diverged 25% in the
mere 4-8 millions since the two species have separated (Osborne et al., 1988). Old World
monkeys, unlike humans, have only a single IGHA that encodes a short hinge more like
the human IgA2 hinge without multiple O-glycosylation sites (Scinicariello et al.,2004).
The IgA hinge within rhesus macaques is highly polymorphic (Scinicariello et al.,2004).
By contrast, nonhuman primate IgD amino acid substitutions were found only in a sooty
mangabey at two positions in CH2. More importantly, the hinge is highly conserved
between primates; rhesus macaque and sooty mangabey IgD hinge regions are identical.
Therefore, the hinge region of IgD appears to be less variable and evolutionarily more
stable than the hinge region of IgA in nonhuman primates.
In humans, three glycine residues encoded at the start of H2 contribute to IgD
hinge segmental flexibility (Sun et al., 2005). Though conserved in chimpanzee, the
glycines at H2 positions 3 and 4 are deleted in Old World monkeys. Loss of these
glycines may be compensated for by a glycine dyad created by a glycine substitution next
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to a conserved glycine in IgD H1 and by another glycine substitution in the middle of IgD
H2. Besides being important for IgD receptor interactions (Rudd et al., 1995), the Oglycans of the hinge contribute to structural rigidity (Sun et al., 2005). We predict that
IgD H1 O-glycosylation is reduced in nonhuman primates. At equivalent positions of the
human O-glycan sites, IgD of chimpanzee has one substitution and IgD of Old World
monkeys have three substitutions. In Old World monkeys, only IgD H1 S22 offers a
potential O-glycosylation site not found in human IgD H1. Dog IgD hinge is not well
conserved with that of primates. Hence, if present, dog IgD O-glycosylation is quite
different.
In mangabey, baboon, rhesus macaque and cynomolgus macaque, we identified
IGHD clones in which the hinge region that corresponds to the hominoid H2 exon was
deleted. These transcripts (IgD∆H2) may be the result of 1) an artifact of the reverse
transcription PCR, 2) a polymorphism encoded by a second IGHD gene or allele or 3)
alternative splicing events. Several lines of evidence argue against the first possibility.
Under the same PCR conditions, and using the same primer sets, IgD∆H2 transcripts
were niether found in any of the chimpanzee clones, nor in control experiments using
human RNA. The percentage of clones for each transcript varied between animals.
Multiple primer pairs produced IgD∆H2 clones. The deletion was always exact so that it
maintained the reading frame. Finally, alignment of the hinge regions and CH3 were
compared and no unusual sequences with high identity were found that might be
conducive to PCR jumping. The latter two possible explanations remain to be tested and
are not necessarily exclusive. For example, an allelic variant in the intron between H1
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and H2 could alter splicing. Pig IGHD has an H2 exon that is spliced out because of a
branchpoint mutation in the H1-H2 hinge intron (Zhao et al., 2003). When a single T
nucleotide is introduced into this sequence, pig IGHD transcripts include H2. Zhao et al.
(2003) speculated that some transcripts with H2 might be produced normally in pigs,
although none of their clones included the H2 exon. Future studies will be needed to test
whether or not these primates express IgD without the H2 portion of the molecule, as
such a difference may have profound effects on antigen binging properties.
The origin of the hinge in IgD is still an open question. Fish IgD have no hinge
(Wilson et al., 1997; Hordvik et al., 1999; Stenvik and Jørgensen, 2000; Bengtén et al.,
2002; Hordvik, 2002; Hirono et al., 2003; Saha et al., 2004; Srisapoome et al., 2004;
Danilova et al., 2005; Hansen et al., 2005; Savan et al., 2005). Putnam et al. (1981) have
made the case that the human IgD N-terminal half of the hinge (H1) may have originated
from a duplication of the IGHM CH2 domain, since human IgD H1 residues have a
significant percent identity with those conserved between IgM CH2 of different species.
Complementing this hypothesis is evidence that IGHM and IGHD are closely related and
have exchanged genetic material in the past. Such evidence includes the probable
origination of IGHD from an ancient duplication of IGHM (Zhao and Hammarström,
2003), and the demonstration that a duplicated IGHM CH1 replaced the original IGHD
CH1 in artiodactyls (Zhao et al., 2003). IgD H1 of primate appear to have a common
origin, and nonhuman primate IgD H1 has a 32.4% identity with the same section of
human IgM CH2 that has a 35.3% identity to human IgD H1. Such supports the
hypothesis for a possible IgM CH2 origin of the primate IgD H1. This hypothesis does
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not fit as well for species other than primates, which possess IgD hinges with less than
17% amino acid identities with IgM CH2. If the hypothesis is correct, then it would seem
likely that IgD hinge regions arose in evolution three or more times, once for rodent
hinge, once for primate hinge, and once for Laurasiatheria hinge. Additionally, the H2 of
primates appears to be unique and may have yet another origin.
As anticipated on the basis of cross-reactivity obtained with anti-human
antibodies, IgD deduced amino acid sequences of nonhuman primates are well conserved
among the examined primates and humans. By contrast, dog IgD is not as well
conserved, and it is not surprising that the available anti-IgD raised against IgD of other
species do not cross-react with dog IgD. IgD CH1 and CH2 domains compared to CH3
and transmembrane domains are less conserved at the amino acid levels. This would
seem to indicate that the IgD CH1 and CH2 domains are less critical for functional
properties of IgD that are conserved across species, although these domains may have
important species-specific functions. For example, in human IgD, these domains contain
cysteines necessary for integrity of the quaternary structure. CH1 C15 forms bonds with
the immunoglobulin light chains and CH2 C2 forms the only covalent bond between
heavy chains. These cysteines are conserved in nonhuman primates and in dog.
IgD CH1 of artiodactyls shares a high degree of conservation with CH1 of IgM as
a result of the IGHM CH1 having replaced the original IGHD CH1 (Zhao et al., 2002;
Zhao and Hammarström, 2003). Our data are in agreement with the hypothesis that the
IgD CH1 replacement with IgM CH1 in artiodactyls was recent. Dog IgD CH1 is not
highly conserved with the published dog IgM CH1 protein sequence (14.3% identity)
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(McCumber and Capra, 1979). Horse IgD CH1 is not highly conserved with IgM CH1
(Wagner et al., 2004). Therefore, the genetic event leading to the replacement of the
original IgD CH1 in artiodactyls occurred after the evolution of carnivora, perissodactyla
and cetartiodactyla as distinct phyla.
The IGHD M1 and M2 exons encoding the transmembrane domain are highly
conserved between all species examined reflecting the importance of the transmembrane
domain that they encode in establishing interactions with the B cell receptor associated
signaling chains. As expected, dog IGHD maintains the M1 and M2 exon arrangement
seen in other species. Presumably, this is also the case for chimpanzee IGHD for which
we could not identify the M2 (because of the incomplete resolution of the chimpanzee
contig sequence). Importantly, the dog and chimpanzee transmembranes domains
contain the CART motif found in antigen receptors described by Campbell et al. (1994).
This motif is involved in forming interactions with the B cell receptor signaling
polypeptides (Campbell et al., 1994).
Knowledge at the genetic level of IgD in species other than human and rodents
has only begun to accumulate recently, and has demonstrated that IgD is widespread
throughout vertebrates and is extremely diverse. Despite this diversity, IgD is
surprisingly well conserved between nonhuman primates. In contrast to the view that IgD
function as a BCR is redundant with IgM and that secreted IgD is unimportant, this high
degree of conservation indicates that IgD may have valuable biological roles as yet
unappreciated. Future studies should include the molecular characterization of IgD
receptors and the determination of whether or not IgD receptors are a common feature of
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mammals, thus leading to a clear definition of the roles that IgD plays in the immune
response. The IgD sequences identified here would be valuable in such endeavors.
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CHAPTER 5
Immunoglobulin G (IgG) Fc Receptor III Homologues in Nonhuman Primate Species:
Genetic Characterization and Ligand Interactions

Summary
Immunoglobulin Fc receptors are glycoproteins that bind to immune complexes
through interactions with the Fc regions of specific antibody subclasses to initiate or
inhibit the defense mechanisms of the leukocytes on which they are expressed. The
human IgG low affinity Fc receptor III (CD16) can initiate phagocytosis and antibodydependent cell-mediated cytotoxicity. CD16 has two isoforms, CD16a expressed on
natural killer cells, monocytes as well as macrophages, and CD16b expressed on
neutrophils. CD16a associates with either FcR γ or TCR ζ signal molecules to transduce
activation signals. Although the development of therapeutic IgG molecules usually
involves testing in nonhuman primates, the Fc receptors in these species have not been
studied. Therefore, we have identified and characterized CD16 homologues in rhesus
macaques, cynomolgus macaques, baboons and sooty mangabeys. Similar to humans,
CD16 expression was detected on a lymphocyte subpopulation, on monocytes, and on
neutrophils of sooty mangabeys. By contrast, CD16 was detected only on a lymphocyte
subpopulation and on monocytes in macaques and baboons. In each nonhuman primate
species, we identified a single CD16 gene encoding a protein at least 91% identical to
human CD16a and a TCR ζ gene predicted to encode a protein with a conserved
transmembrane domain necessary for CD16a association. A recombinant nonhuman
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primate CD16 generated in HeLa cells interacted with human IgG1 and IgG2. By
contrast, human CD16 binds to IgG1 and IgG3. Similar to human CD16, the monoclonal
antibody 3G8 was able to block IgG binding to nonhuman primate CD16. Inhibition of
nonhuman primate CD16 N-glycosylation enhanced IgG binding. Differences in
interaction with IgG subclasses and in cells type expression should be considered when
using these species for in vivo evaluation of therapeutic antibodies.

Introduction
Fc receptors are plasma membrane glycoproteins that bind to the Fc region of one
or a few classes of antibodies. Cross-linking of antibody Fc receptors by antibodyopsonized antigen complexes initiates cellular immune responses including phagocytosis,
antibody-dependent cell-mediated cytotoxity (ADCC), respiratory burst, release of
cytokines and inflammatory mediators, and antigen presentation (Ravetch and Bolland,
2001). Fc receptors are therefore crucial for the destruction and clearance of pathogens
and tumors. Different Fc receptors with specificity for each of the five classes of
antibodies (IgM, IgD, IgA, IgE and IgG) have been identified in mammals. Human IgG
Fc receptors include FcγRI, FcγRII, and FcγRIII, which differ for cell type distributions
and affinity for the four subclasses of human IgG (Ravetch and Bolland, 2001). Human
FcγRIII, also known as CD16, is specific for IgG1 and IgG3 (Tamm and Schmidt, 1997).
Humans express two 97% identical FcγRIII isoforms, CD16a and CD16b,
encoded by separate genes consisting of two immunoglobulin-like domains and a tail
region linking the protein to the plasma membrane (Ravetch and Perussia, 1989; Gessner
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et al., 1998). CD16a is expressed on monocyte subpopulations, macrophages, natural
killer cells, select γδ T cells, and can be induced on glomerular mesangial cells (Lanier et
al., 1985; Ravetch and Kinet, 1991; Radeke et al., 1994; LaFont et al., 2001). Because
CD16a is the only Fc receptor expressed on natural killer cells and is responsible for IgG
initiated ADCC, it has been called the ADCC receptor (Ahmad and Menezes, 1996;
Mandelboim et al., 1999). The CD16a complex consists of three polypeptide chains: one
unique ligand binding chain and two signaling chains. The ligand binding chain (CD16a
or FcγRIIIa) spans the plasma membrane and has a short cytoplasmic tail. In humans, the
signaling chains of the complex are composed of either a homodimer or a heterodimer of
FcRγ and TCR ζ that are required for efficient assembly, transport of the receptor from
the endoplasmic reticulum to the plasma membrane and retention on the plasma
membrane (Lanier et al., 1989; Anderson, 1990; Gessner et al., 1998). FcRγ is also a
necessary component of the FcεRI and FcγRI complexes (Ra, 1989; Ravetch and
Bolland, 2001). TCR ζ, expressed in T cells and natural killer cells, is also a component
of the T cell receptor complex (Weissman et al., 1989). In contrast to CD16a, CD16b is
not associated with signaling chains. The CD16b isoform, exclusively expressed on
neutrophils and eosinophils that have been exposed to IFN-γ (Hartnell et al., 1992;
Ravetch and Bolland, 2001), is linked to the outer plasma membrane by a glycosyl
phosphatidylinositol (GPI) link, and modulates cellular responses through interactions
with the other neutrophil Fc receptors (Scallon et al., 1989; Jones and Brown, 1996).
Association of the FcRγ signaling chain dimer with CD16a may contribute to a higher
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ligand affinity of CD16a compared to CD16b (Miller et al., 1996). No orthologues for
CD16b have been identified in nonhuman species.
Nonhuman primates are widely used in biomedical research. The complex
mechanisms of action and pharmacokinetics of therapeutic antibodies, usually IgG1 or
IgG2 molecules, are routinely evaluated in these species (Yang et al., 1999a; 1999b;
Hahn et al., 2001; Hinton et al., 2003). Potential therapeutic cytokines and cytokine
receptors are tested in nonhuman primates, and there is interest in extending these studies
to immunoglobulin-cytokine fusion proteins as has been done in mice (Evans et al., 1994;
Munn et al., 1996; Hérodin et al., 2003). Macaques represent the accepted model for HIV
vaccine development and AIDS pathogenesis (Hirsch and Lifson, 2000). CD16a is
critical for natural killer cell targeted destruction of HIV infected cells through ADCC,
although the relative importance of this mechanism in vivo is debated (Ahmad and
Menezes, 1996). Recently, a small study in SIV-infected macaques indicated that
sustained ADCC correlates with delayed onset of AIDS pathogenesis (Banks et al.,
2002). Xenograft rejection, also studied in nonhuman primates, is in part mediated
through IgG directed ADCC via CD16 (Schaapherder et al., 1994; Watier et al., 1996;
Cozzi et al., 2005; Rood et al., 2006). Nonhuman primates are widely used in testing
monoclonal antibodies designed to prevent allograft rejection (Cosimi et al., 1990; Kirk
et al., 1999; Kanmaz et al., 2004; Kawai et al., 2004; Koyama et al., 2004; Schuler et al.,
2004).
CD16 homologues in nonhuman primates remain uncharacterized, and the
premise that IgG/CD16 interactions in these species mimic those in humans has not been
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fully evaluated. In the present study, we have identified nonhuman primate homologues
of the human CD16 α chain and one of its associated signaling chains, TCR ζ, by
sequencing these genes in four of the species most frequently used in biomedical
research: rhesus macaque, cynomolgus macaque, baboon and sooty mangabey.
Furthermore, we generated a recombinant nonhuman primate CD16 expressed on
mammalian cells, and assessed its binding ability to the various IgG subclasses.

Materials and methods
Samples
Heparinized blood samples were collected from healthy animals of each of the
following species: rhesus macaque (Macaca mulatta), cynomolgus macaque (Macaca
fascicularis), baboon (Papio hamadryas anubis), and sooty mangabey (Cercocebus
torquatus). Rhesus macaque and baboon samples were from animals housed at the
Southwest National Primate Research Center San Antonio, TX. The samples from
cynomolgus macaque and sooty mangabey were from animals housed at the Yerkes
National Primate Research Center, Emory University, Atlanta, GA. Animal blood was
collected under approval of the appropriate institutional review committees.

Determination of CD16 expression on blood leukocytes
Blood from 4 rhesus macaques, 7 cynomolgus macaques, 4 baboons and 4 sooty
mangabeys was collected in EDTA Vacutainer® tubes (Becton, Dickinson and Co., San
Jose, CA) by venipuncture under anesthesia. Leukocyte expression of CD16 on macaque
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cells was analyzed by three-color flow cytometry analysis using cy-chrome conjugated
anti-human CD16 (clone 3G8), phycoerythrin (PE)-conjugated anti-human CD89 (clone
A59) and fluorescein isothiocyanate (FITC)-conjugated anti-human CD3 (clone SP34)
(Becton, Dickinson and Co.). SimultestTM Control γ1/γ2 (Becton, Dickinson and Co.) was
used to detect non-specific binding of mouse IgG to cells. Since cy-chrome conjugated
anti-human CD16 was found to be poorly cross-reactive with baboon and sooty
mangabey leukocytes, baboon and sooty mangabey leukocytes were analyzed by staining
with anti-human PE conjugated CD16 PE (clone 3G8) and FITC conjugated anti-human
CD3 (clone SP34). Additionally, sooty mangabey leukocytes were stained with CD89PE
and CD16 FITC. Staining of whole blood was done using a standard procedure. Briefly,
100µl of blood was incubated with 20µl of each antibody in the dark at room
temperature. Erythrocytes were lysed with 2ml of BD PharM Lyse (Becton, Dickinson
and Co.), washed 3 times with PBS and fixed with 1% paraformaldehyde. 10000 events
were counted by flow cytometry.

Amplification of nonhuman primate CD16 and TCR ζ cDNA
Total RNA was extracted from whole blood using the QIAamp RNA Blood Mini
Kit (Qiagen, Inc., Valencia, CA), and reverse transcribed into cDNA using oligo d(T)17
primers, followed by primer extension with the AMV reverse transcriptase (Roche
Diagnostic Corp., Indianapolis, IN). PCR amplification of the cDNA was performed with
Expand High Fidelity polymerase (Roche Diagnostic Corp.) with the appropriate primer
pair. Primers for amplification of primate CD16 were designed from the human sequence
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assuming conserved homology between primates. The forward primer FCG3aF (5’ATGTGGCAGCTGCTCCTCCCA-3’) encodes the first 7 amino acids of CD16. The
reverse primer FCG3aR (5’-TCATTTGTCTTGAGGGTCCTT-3’) encodes the last 6
amino acids and the stop codon. TCR ζ and FcR γ primers were likewise designed. The
forward primer TCRZ3F (5'ATGAAGTGGAAGGCGCTTTTCAC-3') encodes the first 7
amino acids of TCR ζ. The reverse primer TCRZ3B (5'-TTAGCGAGGGGGCA-3')
encodes the last 3 amino acids and the stop codon of TCR ζ. The FcR γ forward primer
FCRgamF (5'-ATGATTCCAGCAGTGGTCTTGCT-3') binds at the start codon, whereas
the reverse primer FcRgam4 (5'-CTACTGTGGTGGTTTCTCATGCTTC-3') binds at
stop codon and together amplify the complete gene. After initial denaturation at 95°C for
10 min, the cDNAs were amplified for 40 cycles, with each cycle consisting of 94°C for
1 min, 56°C for 1 min and 72° for 1 min 30 sec. A final step at 72°C for 10 min was used
to ensure complete extension. For amplification of the signaling chains the step at 72ºC
was reduced to 30 sec. All reactions were performed in at least two independent reverse
transcriptions PCR to verify product sequences. For CD16 of each nonhuman primate
species 10 clones were sequenced from each of two independent PCR reactions.

Cloning of the amplified gene sequences
For cloning, 50µl of a reverse transcription PCR was run on a 1% agarose gel.
The specific band of interest was excised from the gel and purified using a QIAquick®
Gel Extraction Kit (QIAgen, Inc.). The cDNA was ligated into pCR2.1 vector and
transformed into Top10 Esherichia coli (Invitrogen Corp., Carlsbad, CA) followed by
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expansion of select white colonies grown on media containing X-gal. Plasmid DNA was
purified using a Wizard®plus Minipreps kit (Promega Corp., Madison, WI). The samples
were screened on a 1% agarose gel after digestion with EcoRI to confirm the correct size
of the DNA fragments. At least two clones from each PCR were sequenced. All DNA
sequences were determined using the BigDye® Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) on an ABI 3100 Genetic Analyzer (PerkinElmer,
Inc., Wellesley, MA).The forward and reverse M13 primers were used for sequencing.
Overlapping regions were identified and sequences were edited using the MacVector
software program (Accelrys Inc., San Diego, CA). Sequences were aligned with each
other and other published sequence using the CLUSTAL function of the MEGALIGN
part of the LASERGENE software package (DNASTAR Inc., Madison, WI).

Construction of nonhuman primate CD16 expression vectors
Full length nonhuman primate CD16 genes were first PCR amplified from
cDNAs ligated into the pCR2.1 vector using forward and reverse primers FCG3FHinb
(5'-AGATAAGCTTGATATGTGGCAGCTGCTCCTCCCA-3') and FCG3RBam
(5'-TCTAGGATCCTCATTTGTCTTGAGGGTCCTT-'3), which add Hind III and
BamHI restriction sites 5’ and 3’ of the full length cDNA, respectively. CD16 fragments
from clones with the correct sequence were released from vector by sequential digestion
with Hind III and BamHI, cleaned up on a 1% agarose gel, and ligated into the Hind III
and BamHI digested expression vector pcDNA3.1 (+) (Invitrogen Corp.) to create
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pcCD16 vectors. CD16 expression vectors were then cloned into Top10 E. coli and
colonies screened by sequencing with primers T7 and T7 reverse.
To improve the stability of the expression vectors in transfected cells, part of the
pcDNA3.1 constructs were amplified (containing cDNA of nonhuman primate FcγIIIRa,
a cytomegalovirus promoter, a bovine growth hormone polyadenylation signal, and a f1
origin) and inserted into the vector pLSXN (Becton, Dickinson and Co.), which contains
long terminal repeats for integration into chromosomes. pLSXN contains a neomycin
resistance gene, which allows for transfectant selection. Insertion of a pcDNA-CD16
fragment into pLXSN was carried out by amplifying with primers PcHp (5’CTGCTGTTAACCGTTAGGGTTAGGCGTTTTGCG-3) and PcSa (5’ACTTTGTCGACGCTCAGCGGCCGGCCATCGATCCACAGAATTAATTCGCGTT‘3). The resulting fragment was then digested with Hpa I and Sal I and pLXSN digested
with Hpa I and Xho I. The two fragments were then ligated together to form pLXSNCD16.

Generation of recombinant CD16 by transfection of expression vectors into HeLa cells
Large quantities of vector for transfection were prepared using EndoFree®
Plasmid Maxi kits (Qiagen Inc.). Twenty µg of expression vector was added to HeLa
cells suspended in 250µl of Dulbecco’s modified Eagle medium (DMEM) at 14×106
cells/ml. After ten min of incubation on ice, cells were electroporated by one pulse using
the power supply set to 300V, 25mA, and 25W and the Electroporator II (Invitrogen
Corp.) set to 1000µF and ∞Ω, according to the manufacturer’s recommendations. Cells
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were then incubated at room temperature for ten min and grown in 10ml of DMEM 10%
FCS in 5% CO2 at 37°C. Antibiotic G418 (400µg/ml) was added to cell 72 hours post
transfection to obtain stable transfectants.
Once cells recovered, an initial screen for successful transfections was carried out
by flow cytometry. Adherent cells were removed from flasks with 90% confluent growth
using 0.25% trypsin/2.21 EDTA in Hank’s Balanced Saline Solution for 10 min. Cell
number and viability was assessed using trypan blue exclusion on a hematocrit. PBS
washed cells (0.5 ×106) were stained by incubation with 5µl of cross-reactive
phycoerythrin-conjugated (PE) mouse anti-human CD16 clone 3G8 or mouse isotype
control (Becton, Dickinson and Co.) for 30 min at 4º C. Unbound antibody was then
removed with three washes of 200ul of PBS. Finally, cells were fixed with 200µl of 1%
paraformaldehyde and analyzed using a FACSCalibur flow cytometer (Becton, Dickinson
and Co.).

Clonal expansion
Selection and expansion of clones was performed following identification of
successful transfections as indicated by positive stain for CD16 and a positive reverse
transcription PCR for CD16. To isolate single clones, cells were diluted serially into 96
well microtiter plates. Cells were grown in 100µl of DMEM 10% FCS with G418
400µg/ml which was 50% fresh media and 50% conditioned media collected from flasks
of untransfected HeLa cells and filtered with a 0.2µm filter. Each well was examined by
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microscopy to identify wells with a single cell. Clones were subsequently expanded in
wells of increasing size until cell numbers were sufficient to screen for CD16 expression.

Purification of nonhuman primate IgG
Nonhuman primate IgG was purified from serum from each species. Briefly,
200µl of serum diluted 1:1 in Pierce ImmunoPure® IgG binding buffer was incubated
with 200µl ImmunoPure® Plus immobilized protein G for 30 min at room temperature
(Pierce Biotechnology, Inc., Rockford, IL). The mix was then transferred to a 0.45µm
filter tube and centrifuged for 2 min at 6g and the filtrate discarded. Following four
washes with PBS at a (pH 7.2) and 10 min incubation at room temperature with Pierce
ImmunoPure® IgG elution buffer, the tube was spun for 2 min and the filtrate collected.
Finally, the filtrate was dialyzed against water using Spectral/Por® cellulose ester
MWCO 50,000 (Spectrum Laboratories, Inc., Ft. Lauderdale, FL), first with two
incubations at room temperature for 1 hour each and then overnight at 4ºC with the buffer
being changed each time. Purity of IgG was verified by a reducing SDS PAGE and the
concentration checked by spectrophotometry at 280nm. IgG was frozen at -80ºC prior to
use.

IgG subclass ELISA
ELISA was used to verify the purity and identity of the human IgG myeloma
proteins used in the CD16 binding assays. Microtiter plates were coated with human
myeloma proteins (IgG1, IgG2, IgG3, or IgG4) (Binding Site Ltd., Birmingham, UK) or
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purified total nonhuman primate IgG from the four species. After incubation at 4ºC
overnight, the plate was blocked with 5% FCS diluted in PBS at 37ºC for 30 min. After
washing, anti-human IgG1 (clone SG-16), IgG2 (clone HP-6014), IgG3 (clone HP-6050),
or IgG4 (clone SK-44) were added to the plate and incubated for 1 hr at 37ºC (SigmaAldrich Corp., St. Louis, MO). Following washing to remove unbound antibody, HRPlabeled goat anti-mouse IgG (H+L) was added to the plate and incubated for 1hr at 37ºC
(KPL, Inc., Gaithersburg, MD). The washed plate was developed by addition of
ABTS/H2O2 followed by addition of stop solution, and its absorbance measured at 405nm
using an automated Benchmark microplate reader (Bio-Rad Laboratories, Inc., Hercules,
CA).

Immunoglobulin binding assay
Binding of immunoglobulin to CD16 was assessed by flow cytometry using
antibodies that were heat aggregated at 63ºC for 1hr. Human myeloma proteins IgG1,
IgG2, IgG3, IgG4, IgA1, IgA2, IgM (Binding Site Ltd.) or IgE (Serotec Inc, Raleigh,
NC) with immunoglobulin κ light chain as well as purified nonhuman primate IgG from
different species were added to 0.5×106 cells at 20µg/ml and incubated for 1 hr at 4ºC.
PBS washed cells were then stained with 5µl of either FITC-conjugated mouse antihuman kappa or FITC-conjugated mouse IgG3 control for 30 min at 4ºC (Invitrogen
Corp.). In addition, in some experiments cells were stained using FITC-goat anti-human
IgG (Invitrogen Corp.). For dual labeling experiments, mouse anti-human CD16 PE was
added as well. Cells were washed and analyzed by flow cytometry as described above.
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The ability of mouse monoclonal antibody 3G8 to block IgG binding was performed by
first incubating harvested HeLa cells and mangabey CD16 expressing cells (0.5×106
cells/tube) with 20µl of 3G8 or control mouse myeloma IgG1 at different concentrations
(0.5, 0.25, 0.125 and 0 mg/ml) for 30 min at 4ºC. Afterwards cells were washed 3 times
with PBS and IgG binding tests carried out as described above except that human
myeloma antibodies were added at 40µg/ml. For N-glycosylation blocking experiments,
tunicamycin was added to half of the cell cultures at 1µg/ml 30 hr prior to harvesting
cells. Tunicamycin blocks the addition of N-glycans to proteins by inhibiting the transfer
of N-acetylglucosamine-1-phosphate to dolicholmonophosphate.

Results

CD16 expression on macaque leukocytes
Although CD16 has been used as a marker of natural killer cells in nonhuman
primates (Reimann et al., 1994), CD16 expression on neutrophils has not been reported in
these species. To determine whether or not CD16 is expressed on neutrophils in macaque
species, whole blood from four rhesus and seven cynomolgus macaques was stained for
flow cytometry analysis with anti-human CD16 Cy-Chrome, anti-human CD89 PE and
anti-human CD3 FITC (Figure 5.1 C-H). Previously, it was determined that CD89 is
expressed on macaque monocytes and granulocyte populations including neutrophils and
eosinophils (Rogers et al., 2004). Anti-human CD16 clone 3G8 was used because it binds
to human CD16a natural killer cells on and human CD16b on neutrophils. CD16+
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Figure 5.1. (Next page) CD16 expression on nonhuman primate leukocytes.
Representative two-color dot-plots of whole blood leukocytes from nonhuman primates
stained for CD16 expression. A) forward scatter versus side scatter plot with leukocytes
gates indicated, B) staining with mouse isotype controls, C-N) gated leukocyte
populations (C, F, I and L granulocytes; D, G, J and M lymphocytes; E, H, K and N
monocytes) stained for CD16 and either CD89 or CD3. CD16 expression was examined
for rhesus macaques (C, D and E), cynomolgus macaques (F, G and H), baboons (I, J and
K) and sooty mangabeys (L, M and N). At least 10000 cells were counted for all plots.
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leukocytes were 6.76±1.04% (mean± standard deviation) for rhesus macaque and
11.02±3.55% for cynomolgus macaque of the total peripheral blood leukocyte
population. CD89+ granulocytes (Figure 5.1 C and F) and CD3+ lymphocytes (Figure 5.1
D and G) from both macaque species were CD16-. CD16- cells constituted 11.75±4.28%
of rhesus macaque and 15.31±7.64% of cynomolgus macaque lymphocytes (Figure 5.1 D
and G). 14.67±4.66% of rhesus macaque and 28.40±14.00% of cynomolgus monocytes
were CD16+ (Figure 5.1 E and H). CD89+CD16+ monocytes accounted for less than 1%
of total leukocytes and constituted 29.81±9.71% of rhesus macaque and 8.84±8.26% of
cynomolgus macaque monocytes.
Three-color analysis was attempted for four baboons and four sooty mangabeys as
done above for the macaques, but cy-chrome conjugated anti-human CD16 was not
sufficiently cross-reactive. Whole blood from four baboons was stained with anti-human
CD16 PE and anti-human CD3 FITC (Figure 5.1 I-K). In baboons, CD16+ cells
constituted 3.97±0.94% of the peripheral blood leukocytes. Seventy percent of the CD16+
cells were found within the lymphocyte gate and accounted for 11.92±6.95% of the
lymphocyte population (Figure 5.1 J). CD16+ cells in baboons were CD3-. Most of the
remaining CD16+ cells fell within the monocyte gate where 21.38±13.71 of the cells were
CD16+ (Figure 5.1 K). CD16+ cells made up 44.42±12.27% of sooty mangabey peripheral
blood leukocytes (Figure 5.1 L-N). Within the lymphocyte gate 6.70±1.97 of the cells
were CD16+CD3- and 0.65±0.62% were CD16+CD3+ (Figure 5.1 N). In the monocyte
gate 25.61±13.43% of the cells were CD16+ (21.85±12.86% CD16+CD89+) (Figure 5.1
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M). The majority of the sooty mangabey granulocytes were CD16+, with 72.51±14.29%
staining CD89+CD16+ (Figure 5.1 L).

Cloning and sequencing of nonhuman primate CD16 genes
Cloned and sequenced cDNA of rhesus macaque, cynomolgus macaque, baboon
and sooty mangabey was obtained through reverse transcription of total RNA isolated
from whole blood followed by amplification performed using primers complementary to
CD16 gene sequences located at the 5’ and 3’ ends of the coding region. The primers
were designed to be complementary to the genes for both human CD16 isoforms. To
verify that both human CD16 genes could be amplified with the primers, human CD16
cDNA was amplified, cloned and sequenced. All sequences from clones amplified using
total RNA from human whole blood matched the CD16b isoform allele FCGR3B*02
(GenBank accession number AJ581669), likely a result of CD16b transcripts
outnumbering CD16a transcripts. Therefore, we stimulated THP-1 monocytic cells with
PMA in the absence of estrogen to induce expression of CD16a. Amplification of cDNA
from these cells yielded clones all matching a reported CD16a sequence (GenBank
accession number X52645), thus validating our strategy to amplify both human CD16
isoforms. This strategy was then used to amplify CD16 from a single animal of each of
four nonhuman primate species.
For all four nonhuman primate species, a single PCR band was present which
represented a CD16 transcript with the complete reading frame encoding 254 amino
acids, equivalent in size to human CD16. All nonhuman primate CD16 clones bore
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greater sequence homology to human CD16a than CD16b. In nonhuman primates,
residues at positions that differ between human CD16a and CD16b were conserved with
human CD16a, including Gly147, Tyr158 and Phe203 (Figure 5.2). Phe203 is substituted
by a Ser in CD16b and is critical to the expression of CD16b as a GPI linked protein on
human neutrophils (Kurosaki and Ravetch, 1989). Single sequences were obtained for
rhesus macaque, baboon and sooty mangabey CD16, whereas two sequences differing by
a single amino acid (Lys25 or Arg25) were obtained for cynomolgus macaque CD16
(GenBank accession numbers DQ423376-DQ423380). All cysteines involved in forming
intra-chain disulfide bonds in human CD16 are conserved in nonhuman primates (C47,
C89, C128 and C172). Human CD16 (GenBank accession number CAA34755) has Nglycosylation motifs at Asn 56, Asn 63, Asn 92, Asn 180, and Asn 187. These motifs are
conserved in nonhuman primate CD16 molecules, with the exception of Asn 92. An
additional motif is present in nonhuman primates at Asn 82. Rhesus macaque and
cynomolgus macaque CD16 amino acid sequences exhibit 91.7% and 91.3% identity to
the human CD16a, respectively. The rhesus macaque CD16 amino acid sequence shows
99.6% identity to the corresponding cynomolgus macaque sequence. Baboon and sooty
mangabey CD16 have identical amino acids sequences and share 92.5% identity with
human CD16a, 98.4% identity with rhesus macaque and 98.0% identity with cynomolgus
macaque. Therefore, CD16 sequences are highly conserved in nonhuman primates with
only three residues distinguishing the African species (baboons and mangabeys) from the
Asian species (macaques) (an Asp/Glu substitution at position 122, a Val/Met
substitution at position 229 and a Ser/Arg substitution at position 238).
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Figure 5.2. (Next page) Alignment of CD16 amino acid sequences of rhesus macaque,
cynomolgus macaque, baboon, and sooty mangabey and humans. Nonhuman primate
sequences were deduced from cDNA of whole blood. Human CD16a and CD16b
sequences are from GenBank (accession numbers CAA34753 and J04162). Amino acid
differences between human CD16a and nonhuman primate sequences are underlined. The
mature peptide begins at residue 18 as indicated by the arrow. Two vertical arrows
indicate the boundaries of exon S2, which is spliced out of one isolated rhesus macaque
transcript. Potential N-glycosylation sites and cysteines involved in disulfide bonds are
bolded. Shaded amino acids indicate amino acids in human CD16 that interact with
human IgG1 (Sondermann et al., 2000). Domains of the protein are indicated by arrows.
The sequence of MafaCD16.2 was found to match an unpublished GenBank sequence
(accession number AF485815). MafaCD16.1 is an experimentally isolated variant of
CD16 differing at residue position 25. Hu: human; Soma: sooty mangabey; Paca: baboon;
Mamu: rhesus macaque; Mafa: cynomolgus macaque. S1 and S2: signal peptide; Ig:
immunoglobulin; Tm: transmembrane. Star indicates the amino acid critical for binding
to monoclonal antibody 3G8.

Mature Peptide
↓
Ig1 domain
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↓
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HuCD16a
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSG
HuCD16b
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQWFHNENLISSQASSYFIDAATVDDSG
MamuCD16
MWQLLLPTALLLLVSAGMRAEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTRWFHNESLISSQTSSYFIAAARVNNSG
MafaCD16.1 MWQLLLPTALLLLVSAGMRAEDLPRAVVFLEPQWYRVLEKDRVTLKCQGAYSPEDNSTRWFHNESLISSQTSSYFIAAARVNNSG
MafaCD16.2 MWQLLLPTALLLLVSAGMRAEDLPKAVVFLEPQWYRVLEKDRVTLKCQGAYSPEDNSTRWFHNESLISSQTSSYFIAAARVNNSG
PacaCD16
MWQLLLPTALLLLVSAGMRAEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTRWFHNESLISSQTSSYFIAAARVNNSG
SomaCD16
MWQLLLPTALLLLVSAGMRAEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTRWFHNESLISSQTSSYFIAAARVNNSG
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HuCD16a
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HuCD16b
EYRCQTNLSTLSDPVQLEVHVGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSY
MamuCD16
EYRCQTSLSTLSDPVQLEVHIGWLLLQAPRWVFKEEESIHLRCHSWKNTLLHKVTYLQNGKGRKYFHQNSDFYIPKATLKDSGSY
MafaCD16.1 EYRCQTSLSTLSDPVQLEVHIGWLLLQAPRWVFKEEESIHLRCHSWKNTLLHKVTYLQNGKGRKYFHQNSDFYIPKATLKDSGSY
MafaCD16.2 EYRCQTSLSTLSDPVQLEVHIGWLLLQAPRWVFKEEESIHLRCHSWKNTLLHKVTYLQNGKGRKYFHQNSDFYIPKATLKDSGSY
PacaCD16
EYRCQTSLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDSIHLRCHSWKNTLLHKVTYLQNGKGRKYFHQNSDFYIPKATLKDSGSY
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Expression of sooty mangabey/baboon CD16 and identification of nonhuman primate
TCR ζ chains
To characterize the ligand interactions of nonhuman primate CD16, the sooty
mangabey gene was selected for expression in HeLa cells. The expression vector
pLXSN-CD16 encoding mangabey CD16 was transfected into HeLa cells. These cells do
not express Fc receptors and have been previously used to generate recombinant Fc
receptors (Renedo et al., 2001; Rogers et al., 2004). Transcription of the introduced
CD16 gene was determined by reverse transcription PCR. CD16 expression was assessed
by staining with a PE conjugated anti-human CD16 and a mouse isotype control.
Screening by reverse transcription PCR identified 9 clones which were positive for CD16
transcription. One clone resulted in high CD16 expression as determined by flow
cytometry (mean fluorescence intensity MFI=1445.22) (Figure 5.3). Anti-CD16 staining
was specific, since staining of untransfected HeLa cells (MFI= 8.12) and staining of the
clone with a mouse isotype control (MFI =11.91) was low.
Mangabey CD16 expression was unexpected in HeLa cells without cotransfection
with a signaling chain vector, because human CD16 requires coexpression of FcRγ or
TCRζ for efficient expression (Hibbs et al., 1989; Kurosaki and Ravetch, 1989; Lanier et
al., 1989). To address whether or not HeLa cells express either signaling chain, reverse
transcription PCR was performed. FcR γ transcripts were amplified successfully using
RNA isolated from THP-1 cells (positive control), but not RNA isolated from HeLa cells.
By contrast, reverse transcription PCR for TCR ζ yielded a band for the T cell line Hut78 cells and a band of lesser intensity for HeLa cells. Cloning and sequencing of the band
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Figure 5.3. HeLa cells expressing high levels of recombinant sooty mangabey CD16.
Histogram plot showing fluorescence of HeLa cells stained for the presence of
recombinant mangabey with anti-human CD16 PE detected by flow cytometry. Filled
curve-mangabey CD16 clone (MFI=1445.22), dotted line- HeLa cell control (MFI=8.21)
and, solid line-clone stained with an antibody isotype control (MFI=11.91). 10000 events
were counted per sample.
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as well as a real time RT-PCR confirmed that TCR ζ is transcribed in HeLa cells albeit at
levels lower than those found in Hut-78 cells. These results indicate that high levels of
CD16 in HeLa cells may be permissible as a result of endogenous TCR ζ expression.
In contrast to human TCR ζ, mouse TCR ζ acts to down regulate CD16 as a result
of a substitution of Leu 46 with Ile 46 in the transmembrane domain (Kurosaki et al.,
1991; Arase et al., 2001). Therefore, TCR ζ cDNA from rhesus macaque, cynomolgus
macaque, baboon and sooty mangabey was cloned and sequenced (Figure 5.4) (GenBank
accession numbers DQ437667, and DQ437669, DQ437663 and DQ437665). Importantly,
Leu 46 is conserved in Asian and African species. In baboons and sooty mangabeys the
transmembrane domain and surrounding residues are completely conserved, whereas two
substitutions (Ile41Leu and Val53Ala) are present in macaques. This conservation
suggests that in mangabeys and boaboons CD16 and TCR ζ may associate similarly to
what is observed in humans.
The percent identities of the deduced amino acid sequences compared with the
human TCR ζ sequence for rhesus macaque, cynomolgus macaque, baboon and
mangabey are 92.7%, 95.1%, 96.3% and 96.3%. The amino acid identity between the two
macaque species is 98.2%. Baboon and mangabey deduced amino acid sequences are
100% identical, although there are differences at the nucleotide level. The
baboon/mangabey amino acid sequence shares 97.0% identity with rhesus macaque and
98.8% identity with cynomolgus macaque. All TCR ζ chains from the nonhuman
primates have an Asn and a Gln inserted between residues 131E and 132R of the
corresponding human TCR ζ. As a result, nonhuman primate TCR ζ chains are two amino
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Signal Peptide

Extracellular
→ domain
→ Transmembrane domain

Cytoplasmic
→ Tail

Human
Baboon
Mangabey
Rhesus
Cynomolgus
Mouse

MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSA
MKWKALFTAAILQAQFPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSA
MKWKALFTAAILQAQFPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSA
MKWKALFTAAILQAQFPITEAQSFGLLDPKLCYLLDGILFLYGVILTALFLRAKFSRSA
MKWKALFTAAILQAQFPITEAQSFGLLDPKLCYLLDGILFLYGVILTALFLRAKFSRSA
MKWKVSVLACILHVRFPGAEAQSFGLLDPKLCYLLDGILFIYGVIITALYLRAKFSRSA
#
$
!

Human
Baboon
Mangabey
Rhesus
Cynomolgus
Mouse

DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDK
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNALQKDK
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNALQKDK
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNALQKDK
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNALQKDK
ETAANLQDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQQRRRNPQEGVYNALQKDK
*
2nd ITAM
1st ITAM

Human
Baboon
Mangabey
Rhesus
Cynomolgus
Mouse

MAEAYSEIGMKGE--RRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MAEAYSEIGMKGENQRRRGKGHDGLYQGLSTATKDTYDALHMQTLPPR
MAEAYSEIGMKGENQRRRGKGHDGLYQGLSTATKDTYDALHMQTLPPR
MAEAYSEIGMKGENQRRRGKGHDGLYQGLSTATKDTYDALHMQTLPPR
MAEAYSEIGMKGENQRRRGKGHDGLYQGLSTATKDTYDALHMQTLPPR
MAEAYSEIGTKGE--RRRGKGHDGLYQGLSTATKDTYDALHMQTLAPR
+
+
3RD ITAM

Figure 5.4. Alignment of TCR ζ deduced amino acid sequences. ITAM= immunoreceptor
tyrosine activation motif (italics with conserved tyrosine and leucine/isoleucines bolded).
Other features are underlined and indicated by symbols which appear below the position of
the feature: # = cysteine involved in TCR ζ dimerization, $ = aspartic acid which pairs with a
charged residue of associated ligand binding chain (Lanier et al., 1991), + = lysine and
glycine residues in human peptide that bind GTP and GDP (Franco et al., 1994), * =
glutamine spliced into a variant that disrupts a G coupled protein binding motif, which
includes 2 prolines prior and 1 after the glutamine (Atkinson et al., 2003). != position 46 of
leucine critical for human CD16 association (Kurosaki et al., 1991). GenBank accession
numbers for humans and mice are AL031733 and BC052824, respectively.
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acids longer than their human counterpart (166 amino acids as compared to 164). In addition
to the 164 amino acid TCR ζ polypeptide, humans also produce a 163 amino acid
polypeptide that results from the splicing out of the codon encoding Gln 101 (Atkinson et al.,
2003). Splice variants were isolated for all four nonhuman primate species that were 165
amino acids long as a result of the same splicing event (GenBank accession numbers
DQ437668, DQ437670, DQ437664 and DQ437666).

Mangabey CD16 binding to immunoglobulins
Binding assays were performed to determine the ability of mangabey CD16 to
bind the different human and antibody subclasses and polyclonal nonhuman IgG. Heat
aggregated myeloma proteins with an Ig κ light chain or polyclonal Ig were incubated
with control HeLa cells or mangabey CD16 expressing cells followed by staining against
bound antibody and analysis by flow cytometry.
Purity and identity of myeloma proteins was verified by ELISA using IgG
subclass specific antibodies (data not shown). All tested subclass specific antibodies did
not cross-react with purified nonhuman primate species’ IgG. The staining for human
IgG subclasses on mangabey CD16 expressing cells as measured by MFI was: IgG2
(131.78) and IgG1 (75.98) >> IgG3 (17.68) > IgG4 (10.05) (Figure 5.5). Staining of
control HeLa cell for each subclass was as follows: IgG2 (10.75), IgG1 (10.16), IgG3
(14.08), and IgG4 (9.73). Staining of mangabey CD16 expressing cells using a FITC
conjugated mouse antibody isotype control was negative (12.73). These results indicate
that mangabey CD16 binds human IgG2 and IgG1 and only slightly binds IgG3, but not
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Figure 5.5. Binding of human IgG subclasses to recombinant mangabey CD16 expressed
on HeLa cells. Human myeloma immunoglobulins of different subclasses all with Igκ
light chain were incubated with HeLa cells expressing mangabey CD16; bound
immunoglobulins were detected with anti-human Igκ FITC (IgG1: solid line MFI =
75.98, IgG2: filled MFI = 131.78, IgG3: dashed line MFI = 17.68, IgG4: thin line MFI
=10.05). As negative control, cells were stained with a mouse FITC isotype control
(dotted line MFI = 12.73). 10000 cells were counted per sample. MFI= mean
fluorescence intensity
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IgG4. These results were independently verified using FITC conjugated goat anti-human
immunoglobulin γ (data not shown). No staining for heat-aggregated human IgA1
(11.53), IgM (13.34), or IgE (7.75) was detected, nor for heat aggregated polyclonal
mouse IgG (10.31). Polyclonal IgG from sooty mangabey and baboon bound to CD16 as
detected by both FITC conjugated mouse anti-human immunoglobulin κ and FITC
conjugated goat anti-human immunoglobulin γ (Figure 5.6). Similarly, binding was
observed for purified polyclonal IgG of rhesus macaques and cynomolgus macaques.

IgG binding correlates with expression of sooty mangabey CD16 and is blocked by
monoclonal antibody 3G8
Taking advantage of the variation in CD16 expression levels among different
cells of the clone, IgG binding was correlated to CD16 expression. This was done by
incubating HeLa cells expressing recombinant CD16 as well as untransfected HeLa cells
with each of the four human IgG subclasses, followed by staining with PE conjugated
anti-human CD16 clone 3G8 and FITC anti-human immunoglobulin κ. 3G8 is an
antagonist of IgG binding to human CD16 (Hibbs et al., 1994). As observed on dot plots
of MFI for anti-human immunoglobulin κ versus MFI for anti-human CD16, there was a
positive correlation between bound IgG and receptor level for the human subclasses IgG2
and IgG1 (Figure 5.7). As expected, no correlation was observed when using IgG3, IgG4
and IgA1. To ascertain whether or not a similar antagonist effect might exist for
mangabey CD16, regression analysis was performed plotting anti-human
immunoglobulin κ MFI versus anti-human CD16 MFI using different Ig subclasses.
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B

C
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Figure 5.6. Binding of sooty mangabey (A & B) and baboon (C & D) IgG to HeLa cells
expressing recombinant mangabey CD16. (A & C) detection of bound IgG with goat antihuman IgG FITC to mangabey CD16: filled (baboon MFI = 992.63, sooty mangabey
MFI = 325.87), control HeLa cells: dotted line (baboon IgG MFI = 29.44, sooty
mangabey IgG MFI = 37.17) and goat anti-human IgG bound in the absence of IgG to
mangabey CD16: solid line (baboon MFI = 61.20, sooty mangabey MFI = 24.93). (B &
D) detection of bound IgG with anti-human Igκ FITC to mangabey CD16: filled (baboon
IgG MFI = 62.04, sooty mangabey MFI = 24.46) and in the absence of IgG (baboon MFI
= 7.67, sooty mangabey MFI = 7.69). MFI = Mean fluorescence intensity. 10000 events
were counted per sample.
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Figure 5.7. Binding of human IgG1 and IgG2 increases with increased expression of
mangabey CD16 on HeLa cells. Following incubation with human myeloma
immunoglobulins, which all have Igκ light chains, cells expressing recombinant
mangabey CD16 were stained with anti-human CD16 PE and anti-human Igκ FITC.
Density dot plots for IgG1 (a), IgG2 (b), IgG3 (c), IgG4 (d) and IgA1 (e). 1000 cells were
counted by flow cytometry for each sample.
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A significant negative correlation (R2= -0.97, P=0.006) was present, thus indicating that
IgG competes with the anti-human CD16 clone 3G8 for binding to mangabey CD16.
These results also suggest that IgG did not completely saturate receptor binding sites at
the concentration used. To verify that 3G8 blocks mangabey CD16 preventing binding of
IgG, IgG binding experiments were repeated with cells that were first incubated with
unlabeled 3G8 at different concentrations. Incubation of cells with 3G8 prior to addition
of human IgG resulted in reduced binding of human IgG1 and IgG2 to mangabey CD16
(Figure 5.8). By contrast, incubation with a mouse antibody of irrelevant specificity prior
to addition of human IgG did not alter the ability of mangabey CD16 to bind to human
IgG1 and IgG2.

Effects of blocking N-glycosylation on the expression and ligand binding of CD16
Human and mangabey CD16 have conserved glycosylation motifs. Therefore, Nglycosylation of mangabey CD16 was blocked to assess the effects on IgG binding. Antihuman CD16 staining with monoclonal antibody 3G8 of tunicamycin treated cells
decreased 15.43-17.47% compared to untreated cells. Previously, it has been shown that
3G8 binding to human CD16 is unaltered by glycosylation and that blocking Nglycosylation of human CD16 results in a modest decrease in its expression (Drescher et
al., 2003). Thus, the decrease in staining for mangabey CD16 likely represents a similar
decrease in receptor expression. By contrast, staining for bound IgG increased for both
IgG1 and IgG2 when N-glycosylation was blocked. Adjusting for the decrease in receptor
expression, the increase in bound IgG1 and IgG2 ranged from 110% to 129.5% between
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Figure 5.8. Monoclonal antibody 3G8 (Mouse Anti-human CD16) blocks binding of
human IgG1 and IgG2 to recombinant mangabey CD16 expressed on HeLa cells.
Different concentrations of 3G8 were incubated with HeLa cells expressing mangabey
CD16 (diamonds) or with control HeLa cells (squares). Additionally mangabey CD16
expressing cells were incubated with an irrelevant mouse IgG1 control (triangles). Next,
cells washed of unbound antibody were incubated with either human IgG1 (solid shapes)
or human IgG2 (outlined shapes). Finally, washed cells were stained with FITC labeled
anti-human Ig κ to detect bound human IgG. 10000 cells for each condition were read by
flow cytometry and the mean fluorescence intensity (MFI) plotted against the
concentration of monoclonal antibody 3G8 or mouse IgG1.
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different experiments. The increase in IgG binding did not favor either isotype over the
other. Staining for bound IgG3 and IgG4 was not significant regardless of Nglycosylation.

Discussion
Animal model studies of Fc receptor/antibody interactions have and will continue
to yield useful insights into humoral immune responses, since only in vivo testing can
mimic the complexities of the immune system. Mice have been used extensively for this
purpose and have provided fundamental information about the function of Fc receptors.
However, mice have no homologue of CD16b (Gessner et al., 1998). Mice do possess
CD16a, but this molecule does not appear to be a true orthologue of human CD16a
because its extracellular region, responsible for binding to IgG, is more conserved with
mouse FcγRII (Hughes, 1996). In addition, mouse FcγRIII is expressed on mast cells,
whereas human mast cells do not express this receptor (Tkaczyk et al., 2004). A second
mouse receptor (CD16-2), which may be more homologous to human CD16a, has been
recently identified (Mechetina et al., 2002). However, this receptor has not yet been
studied extensively. Nonhuman primates, which are widely used in immunological
research and are more closely related to humans than mice, may be suitable models to
study Fc receptors and related therapeutic strategies. Considering the importance of
CD16 in immune responses and the use of nonhuman primates to evaluate human
therapeutics which may bind CD16, we have identified and characterized CD16 ligand
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binding chains and potentially associated signaling chains (TCR ζ) in rhesus macaques,
cynomolgus macaques, baboons, and sooty mangabeys.
The presence of CD16 on nonhuman primate natural killer cells and monocytes
was determined through staining of lymphocytes with cross-reactive anti-human CD16
(Reimann et al., 1994; Munn et al., 1996; Sopper et al., 1997). Indeed, CD16 is
recognized as one of the most reliable marker for phenotyping natural killer cells in
macaques, while CD56, an informative marker for NK cells in humans, is not (Carter et
al., 1999). However, these studies do not provide information on the expression of CD16
on nonhuman primate neutrophils. Using flow cytometry and the anti-human CD16 clone
3G8, which cross-reacts with both human CD16 isoforms, we confirmed the presence of
CD16 on nonhuman primate natural killer cells and monocytes in agreement with
previous reports. We did not observe many CD3+CD16+ cells in any of the examined
animals suggesting that most T cells in these nonhuman primate species do not usually
express CD16. In humans, γδ T cells can express CD16, but these are a minority of the T
cell population and expression of CD16 on these cells may generally remain low until
cells are properly stimulated (LaFont et al., 2001). It remains to be determined whether or
not nonhuman primates have γδ T cells that can express CD16. In two of the sooty
mangabeys a little over 1% of the cells in the lymphocyte gate stained CD3+CD16+. For
all other animals examined the percentage of CD3+CD16+ cells was below 1% and
comparable to the number of nonspecifically stained cells observed using mouse isotype
control antibodies. Macaque and baboon granulocytes failed to stain positive for CD16.
These results suggest the possibility that macaques and baboons may lack an orthologue
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of human CD16b. Alternatively; any such orthologues may not be expressed at high
levels on peripheral blood granulocytes in healthy animals or have diverged sufficiently
so as to be undetectable by antibodies against the human receptor. In contrast, sooty
mangabey granulocytes stained positive for CD16 on their cell surface.
Employing RT PCR capable of amplifying genes of both human CD16 isoforms,
we identified a single gene homologue for each nonhuman species. These genes code for
polypeptides that share at least 91% amino acid identity with human CD16, and more
closely resemble human CD16a than CD16b. In particular, all genes from nonhuman
primates possess a phenylalanine at position 203 like human CD16a. In human CD16b
this residue is replaced with a serine that dictates the truncation and GPI linking of the
protein to the plasma membrane (Kurosaki and Ravetch, 1989). The similarity of
nonhuman primate CD16 with human CD16a is consistent with detection of CD16 on
nonhuman primate NK cells and monocytes. We did not identify a nonhuman primate
gene similar to the human CD16b gene. Differences in promoter regulation of the single
CD16 gene identified in sooty mangabey may allow for its expression on granulocytes as
well as monocytes and NK cells. The absence of CD16 on neutrophils from macaques
and baboon suggests the absence of a CD16b gene homologue and requires further
research. Humans may lack expression of CD16 on neutrophils without any apparent
health problems (de Haas et al., 1995). Thus, CD16b does not appear to be essential for
effective immune responses, although it can modulate phagocytosis (Bredius et al.,
1994). Based on the high sequence homology of the two human CD16 genes, it appears
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that the second gene arose recently from duplication of the original CD16 gene. This
would explain why CD16b homologues have not been identified in other species.
CD16a is part of a larger complex that includes a signaling chain dimer with an
immunoreceptor tyrosine activation motif. Human CD16a expression requires association
with a signaling chain dimer of FcRγ, TCRζ or a heterodimer of the two (Lanier et al.,
1989; Anderson, 1990; Gessner et al., 1998). In mice, by contrast, increased expression
of TCR ζ in NK cells down regulates CD16 expression (Arase et al., 2001).
This species difference may be explained by differences in the TCR ζ transmembrane
domain. Kurosaki et al. (1991) have shown that the Leu/Ile substitution at position 46 in
the transmembrane domain of mouse TCR ζ causes the loss of the association of this
signaling chain with CD16. We found that Leu 46 is conserved in all four nonhuman
primate species. However, macaques exhibit substitutions that may influence the
interactions with CD16. HeLa cells expressing TCR ζ, but not FcRγ, were able to express
mangabey CD16. TCR ζ is normally only expressed in T cells and NK cells, because it is
encoded by a gene controlled by a tissue-restricted promoter (Rellahan et al., 1994). We
also observed that when transient transfection was performed, mangabey and cynomolgus
macaque CD16 expression was greater in a T cell line, HUT 78, than in HeLa cells that
have lower levels of TCR ζ (results not shown). Thus, nonhuman primate CD16 may be
positively regulated by TCRζ, similar to human CD16.
Results from mutational analysis and antibody epitope mapping show that the
CD16 membrane proximal immunoglobulin-like domain interacts with the lower hinge
and CH2 domain of the IgG Fc region (Hibbs et al., 1994; Shields et al., 2001). Further
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refinement of this model is based on the crystal structure of a human IgG1 fragment
bound to soluble Fc gamma RIII (Sondermann et al. 2000). The crystal structure reveals
that a single FcγRIII receptor binds asymmetrically to the two chain of a single IgG1 Fc
fragment. Using the numbering of Sondermann et al. (IMGT unique numbering of CH2
immunoglobulin domain; LeFranc and LeFranc, 2001), IgG1 residues crucial for binding
FcγRIII include Leu 234(4)-Ser 239(9), Asp 265(35), Ser 267 (37), Glu 269 (39), Ala 327
(97)-Ala 330 (100), and Ile 332 (102). In addition, the N-glycan at Asn 297 (67) is
important (Sondermann et al., 2000). Numbering from the start of the preprotein, the
CD16 residues forming contact with IgG1 are Ile 106-Trp 108, Trp 131-Ala 135, His
137-Thr 140, Asp 147-His 153, Arg 173, and Val 176-Lys 179 (Sondermann et al.,
2000). The majority of the human CD16 residues important for binding IgG are
conserved in nonhuman primate CD16 molecules. In all four nonhuman primate species
Ala 135, His 153, and Val 176 are substituted with Leu, Glu, and Ile, respectively. In
addition, Asp 147 is Gly in all nonhuman primate CD16 molecules as is found in human
CD16a.
To assess nonhuman primate CD16/IgG interactions, we generated recombinant
sooty mangabey CD16 in HeLa cells. The recombinant sooty mangabey CD16 was
capable of binding to human IgG1 and IgG2, but not human IgG3 and IgG4. Despite the
strong conservation of the mangabey CD16 sequence with the human CD16 sequence,
mangabey and human CD16 differ in their ability to bind human IgG subclasses. Human
CD16 binds to IgG1 and IgG3, but only weakly to IgG2 and IgG4 (Tamm and Schmidt,
1997). Mangabey CD16/IgG interactions are specific as indicated by the positive
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correlation of cells labeled for both CD16 and bound IgG (Figure 5.7). Similarly,
monoclonal antibody 3G8, an antagonist of IgG binding to human CD16, blocks binding
to mangabey CD16 (Figure 5.8). These results indicate that the IgG binding site for
mangabey CD16 is likely conserved with the human CD16 binding site as the sequence
homology suggests, but only a few amino acid substitutions may be sufficient to allow
for binding to IgG2. Failure to detect sooty mangabey CD16 binding to IgG3 could
represent a limitation of the assay used. The myeloma IgG3 could have failed to form
heat aggregates. However, under such circumstances, a low level of monomeric IgG3
binding to the receptor might then be anticipated. Alternatively, sooty mangabey CD16
may have low affinity for IgG3.
The IgG1 motif LLGGP located in the lower hinge is particularly important for
binding to CD16 (Chappel et al., 1991; Tamm and Schmidt, 1997). In IgG2 this motif is
replaced by VAGP. Mutational analysis shows that the entire IgG2 lower hinge motif
must be replaced with that of the IgG1 motif to allow binding to CD16. Mutations of
IgG1 in its motif are detrimental to binding affinity (Chappel et al., 1991). The motif
LLGGP is encoded by all four IgG subclasses genes in baboons, rhesus macaques,
cynomolgus macaques, pigtail macaques and sooty mangabeys with the exception of
baboon IgG2 and pigtail macaque IgG4 (Attanasio et al., 2002; Scinicariello et al., 2004;
and our unpublished results). Here, we have shown that recombinant mangabey CD16 is
capable of binding to rhesus macaque, cynomolgus macaque, baboon and sooty
mangabey IgG. Currently, purified nonhuman primate IgG1, IgG2, IgG3 and IgG4 are
not available and therefore could not be tested in binding assays. Based on the
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conservation of the IgG1 motif in most of these IgG molecules, it is expected that all four
subclasses bind CD16. However, IgG/CD16 interactions have been shown to be complex
and involve residues outside of the IgG lower hinge (Shields et al., 2001). Radaev and
Sun (2001) found that small peptides with the sequences matching those of the lower
hinge of human IgG1, IgG2 and IgG4 all have similar affinities for human CD16 and
concluded that additional IgG features, such as hinge length, are important. Human IgG3
contains the LLGGP motif, yet we did not detect its binding to mangabey CD16.
Therefore mangabey CD16/IgG interactions are likely to also involve additional IgG
subclass differences.
The N-glycan of human CD16 at Asn 180 is in close proximity of other residues
that interact with the Fc fragment of IgG1 (Sondermann et al., 2000). Glycosylation
inhibition and mutation of Asn 180 to Glu results in increased affinity of CD16 for
monomeric IgG, whereas mutations at other CD16 N-glycan sites have no effect
(Dreshcer et al., 2003). CD16a of monocytes, macrophages and NK cells have different
affinities for IgG as a result of differential glycosylation (Edberg and Kimberly, 1997).
Hence, cells can modulate binding to IgG through modification of the Asn 180 N-glycan.
CD16 of nonhuman primates have the Asn 180 glycosylation motif. Inhibition of Nglycosylation with tunicamycin resulted in a modest increase of human IgG binding to
mangabey CD16, just as is reported for human CD16 (Drescher et al., 2003). As is the
case for other molecules, CD16 glycosylation may be altered during inflammation to
modulate affinity to IgG and hence activation through CD16 (Drescher et al., 2003). Our
data support the possibility that such a mechanism is also possible in nonhuman primates,
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although it is unclear how important this would be in the context of the types of increased
binding affinity we observed. Testing of this hypothesis will require examination of
CD16 affinity and glycosylation changes under inflammatory conditions which would be
more physiologically relevant than a total inhibition of glycosylation.
The extensive use of nonhuman primates in immunological studies makes it
important to understand how their antibody responses compare to those of humans. To
achieve this goal it is not only vital to study nonhuman primate antibodies directly, but
also to understand how they interact with the various components of the immune system.
Therapeutics that may directly interact with Fc receptors include monoclonal antibodies,
immunoglobulin fusion proteins as well as small drugs being developed to inhibit Fc
receptor function (Radaev and Sun, 2001). Our results are therefore critical for the proper
interpretation of results from studies performed in nonhuman primates.
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Epilogue: Nonhuman Primate CD16 and Testing of Therapeutic Antibodies

Does the IgG Fc receptor III (CD16) play a role in determining the efficacy of
therapeutic antibodies and other therapeutics? How would the human/nonhuman primate
differences in CD16 expression profiles and binding characteristics influence testing of
therapeutics in nonhuman primates?
Many therapeutic antibodies and other therapeutics containing the Fc region from
antibodies are either approved for use or are being developed for use in humans for
sundry medical conditions. Use of therapeutic antibodies is rapidly increasing with 19
FDA approved molecules and over 150 in development (Kim et al., 2005). These
molecules primarily are of the IgG isotype. Therefore, engineering and evaluation of
these molecules must take into account potential interactions with CD16. In some clinical
applications it is desirable to engage Fc receptor induced cellular effector mechanisms,
for example when trying to target ADCC to cancer cells (Carton et al., 2004), whereas in
others it is preferable that Fc receptors not be engaged, for example when using anti-CD3
monoclonal antibodies to prevent transplant rejection (Cole et al., 1997; Li et al., 2005).
Anti-tumor therapeutics are usually IgG1 molecules and thus bind to Fc receptors (Carton
et al., 2004). By contrast, IgG2 is a preferred subclass for anti-CD3 monoclonal
antibodies (Cole et al., 1997). Clearly, the IgG subclass of each potential therapeutic
immunoglobulin must be selected on the basis of its ability to engage Fc receptors.
Indeed, understanding IgG/CD16 interactions may improve the prognostic value of
monoclonal antibody treatment. Multiple alleles exist for both isoforms of human CD16.
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CD16a isoforms have either a valine or a phenylalanine at position 158, the former
having higher affinity for IgG (Koene et al., 1997). Therapeutic success rates are higher
in individuals homozygous for the CD16 valine 158 allele receiving rituximab for
follicular lymphoma or Waldenstrom’s macroglobulinemia compared to individuals
either heterozygous or homozygous for the phynylalanine 158 allele who receive similar
treatment (Carton et al., 2004; Weng and Levy, 2003; Treon, 2005). Immunoglobulinfusion molecules, a class of therapeutics, typically consist of a biological active molecule
(such as a cytokine or cytokine receptor) attached to the IgG Fc portion which includes
the hinge region and the CH2 and CH3 domains (Kim et al., 1998). Incorporation of the
immunoglobulin Fc in these molecules has the advantage of extending their half-life and
allowing for multimeric presentation. However, often it is desirable that these molecules
not interact with IgG Fc receptors, including CD16, as such interactions would result in
unwanted biological activities (Kim et al., 1998). Other therapeutics being considered are
peptidyl inhibitors that mimic IgG to block IgG receptors including CD16. These
molecules would be potentially beneficial for treating autoimmune diseases, as for
example rheumatoid arthritis, which are triggered by autoantibodies activating
inflammatory cellular responses through Fc receptors (Radaev and Sun, 2001).
We found that CD16 in nonhuman primates is expressed on some cells types in
common with those on which human CD16 is expressed, and nonhuman primate CD16
homologues do not always interact with the same IgG subclasses as human CD16. It
would be imperative to consider these differences in monoclonal antibody safety studies
in nonhuman primates. For example, studies of IgG2 monoclonal antibodies in these
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animals may over estimate toxicity, because IgG2 may trigger CD16 directed NK cell
ADCC responses that would not occur in humans (where IgG2 does not interact with
CD16). On the other hand, neutrophil responses to IgG1 would also differ. In baboons
and macaques CD16 seems to be absent from neutrophils. Therefore, IgG1 antibodies
might trigger immune responses in human neutrophils that would not be uncovered from
testing in nonhuman primates. While expression of CD16 on neutrophils of sooty
mangabeys is more similar to what observed in humans, our data suggest that the
mangabey receptor may be similar to the human isoform found on other cell types
(CD16a) than the isoform found on human neutrophils (CD16b). These isoform differ in
the transmembrane and cytoplasmic regions, hence in cell signaling capacities. Therefore,
sooty mangabey and human IgG activation of neutrophils through CD16 is likely to be
different.
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CHAPTER 6
Conclusions
Our defenses against pathogens and malignancies comprise a complex array of
interacting cells and molecules that makeup our immune system. At the beginning of
vertebrate evolution, the adaptive portion of the immune system budded from the older
innate immune system and diversified. Antibodies, the quintessential component of the
adaptive humoral immune system, act as adaptor molecules that link targets of the
immune system to immune effector responses. As previously discussed, antibodies are
highly diverse and are divided into classes and subclasses characterized by different
functional properties, which result from differences in the structure of the constant
regions. These functional properties are still not completely defined. To fully understand
antibody function, it is necessary to characterize the other components of the immune
system with which antibodies interact. Because the immune system of nonhuman
primates most closely resembles that of humans, and because nonhuman primates are
widely used for biomedical research, we characterized immunoglobulins and
immunoglobulin Fc receptors in these species.
In mammals there are five classes of antibodies (IgM, IgD, IgG, IgA, and IgE),
each of which is represented in humans. We have studied selected aspects of three classes
of antibodies: IgA, IgD and IgG. IgA, the antibody class produced most copiously, is
dominant in the mucosae, where it represents the frontline defense against pathogens, and
is a major component of sera. IgD, along with IgM, is responsible for the initial
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recognition of antigens and activation of B cells in adaptive humoral immune responses
as part of the B cell receptor. IgG is the most abundant antibody in sera and is
recognized as the most important antibody for systemic adaptive immunity. The
characterization of structure/function relationships related to these classes of antibodies
as well as the characterization of differences between species, especially humans and
nonhuman primates, is incomplete. In this study, we have identified and characterized
nonhuman primate IgD. In addition, we have extended our previous work on nonhuman
primate IgA and IgG by defining the interactions of these two immunoglobulin isotypes
with their specific Fc receptors.
While the role of IgA at mucosal surfaces is partially understood, the role of IgA
in sera is mostly undefined. In the last decade, the discovery and characterization of a
human IgA Fc receptor (CD89) has provided a context to understand the functions of
serum IgA. Early studies of this receptor suggested its participation in activating cellular
effector functions, including antibody-dependent cell-mediated cytotoxicity, phagocytosis
and respiratory burst, as well as release of cytokines and inflammatory mediators. Results
from recent studies point out that CD89 can also provide down regulation and activation
signals to other Fc receptors, helping to explain the anti-inflammatory properties of IgA.
Because of the lack of a reliable in vivo model system, research on IgA/CD89
interactions has been limited. At the onset of this project, no animal homologues of CD89
were known, despite extensive searches performed in mice (it is now established that
mice most likely have lost the CD89 gene). Thus, we have characterized CD89
homologues in rhesus macaques, cynomolgus macaques, baboons and sooty mangabeys.
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Nonhuman primate and human CD89 molecules are expressed on the same cell types and
are highly conserved with each other (Figure 6.1). Furthermore, similar to what is known
for humans, the four nonhuman primate species produce several different CD89 splice
variants. By contrast, CD89 splice variants have not been identified in other mammalian
species. By generating and using in binding studies recombinant rhesus macaque CD89
expressed on the cell surface of HeLa cells, we have determined that rhesus macaque
CD89 can bind both human IgA subclasses and that its expression is dependent on Nglycosylation (Figure 6.1). Recombinant rhesus macaque IgA generated in our laboratory
is also able to bind rhesus macaque CD89. These results indicate that IgA function is
conserved between humans and nonhuman primates, thus validating the use of these
animal models to study the functional properties of IgA in vivo.
IgD has been a neglected class of antibodies and little is know about its functions
outside of its role as a B cell receptor. Because of its apparent redundancy with IgM, even
the B cell receptor related function of IgD has been treated dismissively until recently.
IgD is also present as a secreted protein in serum, although it is only found at
comparatively low concentrations under most physiological conditions. Although IgD
receptors were described in mice and humans over a decade ago, they remain poorly
characterized. In stark contrast, important advances have been made in the
characterization of Fc receptors for IgG, IgE and IgA. The faltering progress on IgD
receptors has engendered a degree of uncertainty over the true function of these receptors.
Nonetheless, there has recently been a resurgence of interest in IgD. IgD previously was
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Table 6.1. Human and nonhuman primate expression of CD89 and CD16 on different
leukocyte populations and antibody subclasses binding patterns of each receptor. NT not

CD89

tested, hu: human, rh: rhesus macaque, NHP: nonhuman primate.

Human

Rhesus
Macaque

Cynomolgus
macaque

Baboon

Sooty
Mangabey

Lymphocytes
Monocytes

+

+

+

+

+

Granulocytes

+

+

+

+

Antibody
Subclasses

huIgA1,
huIgA2
NK
cells, γδ
T cells

+
huIgA1,
huIgA2,
rhIgA

NT

NT

NT

NK cells

NK cells

NK cells

NK cells

Monocytes

+

+

+

+

+

Granulocytes

+

-

-

Antibody
Subclasses

huIgG1,
huIgG3

NT
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thought to be expressed in only a very limited number of mammals. The recent discovery
of IgD in additional species has sharply challenged this view. We have characterized IgD
in chimpanzees, rhesus macaques, cynomolgus macaques, baboons, sooty mangabeys and
dogs, thus contributing information that will aid to shed light on IgD functions. IgD is
expressed at high levels in certain pathogenic conditions including myeloma, hyper IgD
and periodic fever syndrome, atopy, and HIV infection. Characterization of IgD in
macaques, the accepted model for HIV, will make it possible to better explore the
significance of elevated IgD in AIDS patients. It is our hope and intent that the
characterization of nonhuman primate IgD be used to identify and characterize the IgD
receptor. Only nonhuman primate IgD hinge regions are structurally similar to the
corresponding human region, which is known to be responsible for interactions with the
human IgD receptor. Structural similarities exist between the hinge region of nonhuman
primate IgD and IgA, including a repetitive sequence which for IgA has been
hypothesized to contribute to genetic instability. Sequence information on nonhuman
primate IgD allows us to address this hypothesis. Our laboratory has previously found
that IgA is highly polymorphic in nonhuman primates, showing that there is sufficient
evolutionary human-nonhuman primate separation to allow for diversification of the IgD
hinge. The strong conservation of the human-nonhuman primate IgD hinge region does
not support the hypothesis that a repetitive genetic sequence is the most important factor
influencing the diversity of the hinge region. Other factors that may have influenced
hinge region diversity include selective pressure due to the existence of bacterial
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proteases that cleave IgA molecules at the hinge region and possibly important conserved
functions of the IgD hinge region, as for example interactions with an IgD receptor.
In humans, two genes encode the two isoforms of the IgG Fc receptor III (CD16).
These isoforms differ from each other by only 3% in amino acid sequence, but are
functionally distinct as a result of differences in cell type distribution and in how they are
anchored to the plasma membrane. CD16a is present on monocytes, macrophages, and
natural killer cells, contains a complete transmembrane domain that associates with a
signaling chain, and is essential for directing natural killer cells antibody-depended cellmediated cytotoxicity. CD16b is expressed on neutrophils and activated eosinophils, and
is attached to the plasma membrane by a GPI-link, thus being truncated and not directly
associated with signaling chains. Therefore, CD16b is thought to function in cooperation
with other Fc receptors. No homologues for human CD16b have been described in other
species. Because of the major role that CD16 plays in the immune response, we have
identified and characterized nonhuman primate CD16 homologues. Identification of these
homologues is especially important in view of the increasing use of nonhuman primate
models to test therapeutic antibodies as well as strategies to control xenograft rejection.
We profiled peripheral blood leukocytes for CD16 expression by flow cytometry with a
cross-reactive anti-human CD16 monoclonal antibody (Figure 6.1). Traditionally, CD16
has been used to phenotype nonhuman primate natural killer cells with cross-reactive
anti-human CD16 antibodies. However, there are no published reports on the expression
of these molecules on nonhuman primate granulocytes. CD16 is undetectable on the cell
surface of rhesus macaques, cynomolgus macaques and baboons, although it is expressed
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on natural killer cells and some monocytes. Surprisingly, CD16 was detected on sooty
mangabey neutrophils as wells as natural killer cells and a few monocytes from this
species. Genetic analysis of CD16 mRNA in nonhuman primates confirms the absence of
CD16b in rhesus macaques, cynomolgus macaques, and baboons. Indeed, all the
transcripts isolated from these three species appear to be more related to CD16a. The
same was true of transcripts isolated from sooty mangabey. In disagreement with results
obtained by flow cytometry in sooty mangabeys, genetic analysis shows only presence of
CD16a related transcripts in this species. Sooty mangabey CD16 transcripts differ only
at the genetic level from the corresponding baboon transcripts. Indeed, the deduced CD16
amino acid sequences are identical in sooty mangabeys and baboons. Macaque CD16
deduced amino acid sequences are also highly conserved with baboon/mangabey CD16
sequences. The differences in the expression profile of sooty mangabey CD16 when
compared to other nonhuman primate species could be explained on the basis of a
differential regulation of the expression of the identified sooty mangabey CD16 gene,
which in turn would be the result of differences in promoter elements responsible for
restrictive tissue type expression. Alternatively, as demonstrated in humans, sooty
mangabeys may possess a second CD16 gene.
To assess IgG/nonhuman primate CD16 interactions, we generated a high
expression recombinant sooty mangabey CD16 HeLa cell clone. The resolved crystal
structure of a human CD16/IgG1 Fc complex and mutational studies have determined
important residues of interaction on both molecules. The majority of residues that in
humans are responsible for Fc interaction are conserved in nonhuman primate CD16
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molecules. A few human-nonhuman primate substitutions are conserved in all four
nonhuman primate species. Therefore, we could predict that the binding properties of
nonhuman primate CD16 molecules are similar to those of human CD16. Indeed, our
results show that recombinant mangabey CD16 is capable of binding heat-aggregated
polyclonal IgG from rhesus macaques, cynomolgus macaques, baboons and sooty
mangabeys. The recombinant CD16 molecule also binds heat-aggregated human IgG1
and IgG2 (Figure 6.1). However, this molecule does not appreciably bind the other
human antibody classes. These results indicate that the subclass interaction properties of
sooty mangabey/baboon CD16 (and probably macaque CD16) differ from the
corresponding human properties. Such a finding has important implications for the testing
of therapeutic antibodies in these species. IgG2 therapeutics tested in these animals are
likely to be able to activate cells, ex. NK cells, which would not be activated in humans.
On the other hand, interactions with IgG1 molecules would be different for human and
nonhuman primate neutrophils, at least for the three species in which CD16 is not
expressed in neutrophils. While efficacy studies of therapeutic antibodies ultimately must
be carried out in humans, trials in nonhuman primate species are especially important for
evaluation of safety. Without considering the differences existing between human and
nonhuman primate CD16, there is a potential to overestimate or underestimate health
risks and therapeutic values of monoclonal antibodies or other molecules containing
antibody Fc regions.
Use of nonhuman primates in biomedical research is based on the premise that
these species are physiologically similar to humans. As biomedical research becomes
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more technical and more dependent on refined molecular targeting, it has necessary to
clearly delineate the distinctions of these species from humans. Our characterization of
nonhuman primate immunoglobulins and Fc receptors shows presence of conserved
traits, e.g. IgD structure and CD89/ligand interaction, and non-conserved traits, e.g.
aspects of CD16 expression and CD16/ligand interactions. The study of the immune
system and immune responses in nonhuman primates is likely to lead to new insight into
human biology and human diseases.
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Appendix A
Supplemental Information Related to the Identification of IgD in Nonhuman
Primates and Dogs: Additional Considerations
Because of the advent of the various genome projects and increasing availability of
genetic information though GenBank and other community databases, it has become possible
to access large amounts of genetic information. The Human Genome Project was officially
launched in 1990 and completed in April 2003 when two simultaneous reports on the
completion of the human genome sequencing were released in Science and Nature.
Sequencing of genomes of other species, including several mammals, is in various stages of
completion. 2005 marks the official release of the complete chimpanzee genome, and the dog
genome is also soon to be released. The information obtained through the Human Genome
Project is expected to further our understanding of diseases, thus leading to new cures. Just as
the Human Genome Project is expected to advance human medicine, the Dog Genome
Project is expected to advance veterinarian medicine. Considering the intimate relationship
existing between the immune system and disease, it is then reasonable to exploit the
information available from the various genome projects to understand the biological role of
IgD. Therefore, in the next few pages, we will use sequence information from different
genome projects to answer biological questions related to IgD genes.
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Is the chimpanzee immunoglobulin heavy chain (IGH) locus similar to the human locus?
What can we learn about the evolution of human immunoglobulins?
Upon identifying a contig from GenBank that encodes the chimpanzee IGHD
(accession number NW_115908), we examined the contig for flanking genes and the
exon/intron arrangement of IGHD. This revealed that chimpanzee IGHD is flanked by IGHM
and IGHG3 (the genes encoding the immunoglobulin heavy chains of IgM and IgG3) on the
contig. This is the same gene arrangement as is found in the human immunoglobulin heavy
chain locus.
As it is characteristic of all described IGHD genes, the IGHM gene is found upstream of the
IGHD gene (Figure A.1). The intergenic space between chimpanzee IGHM and IGHD is
6.195kb, slightly larger that the intergenic distance of the human orthologues (6.049 kb based
on GenBank contig NC_00014). Comparing the predicted IGHM transcript with sequences
available through GenBank, we found a Gnomon predicted mRNA (accession number
XM_522973) constructed from the same contig. Such a Gnomon agrees with our prediction,
except that it contains additional nucleotides 5’ of the expected CH1 exon boundary. The
chimpanzee IGHM gene is structured as the human gene, with four exons encoding the CH1CH4 domains followed by two exons encoding the transmembrane domain and the
cytoplasmic tail. Figure A.2 shows the alignment of the deduced amino acid sequence of
chimpanzee IGHM with that of two human IGHM alleles (IGHM*01 and IGHM*03). As
expected, all cysteines involved in disulfide bonds within the immunoglobulin domains and
linking the four chains of IgM are preserved in the chimpanzee. Five N-glycosylation sites
are present at positions identical to those found in the human IgM heavy chain. A few amino

Human Chromosome 14q32.33 (GenBank accession NC_000014)

CH2
90

312

CH3
245

336

CH4
179

318

105
392

M1
1744

6

M2
173

116

236
6

Poly A

CH1

Poly A

5’

6049

6

Chimpanzee Chromosome 14 (GenBank accession NW_115908)

CH2
90

312

CH3
245

336

CH4
179

318

107
392

6

M1
1975

M2
173

116

Poly A

CH1

Poly A

5’

6195

237
6

6

Figure A.1. Chain diagram of human and chimpanzee IGHM genes . Numbers indicate nucleotides in exons or introns.
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CH1

Human*01
GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITLSWKYKNNSDISSTRGFPSVL
Human*03
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Chimpanzee GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFSWKYKNNSDISSTRGFPSVL
▼
CH2
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Chimpanzee RGGKYAATSQVLLPSKEVMQGTDEHVVCKVQHPNGNKEKNVPLPVTAELPPKVSIFVPPR

Human*01
DGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTS
Human*03
DGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTS
Chimpanzee DGFFGNPRSSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKQSGPTTYKVTS
▼
CH3
Human*01
TLTIKESDWLGQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKST
Human*03
TLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKST
Chimpanzee TLTIKESDWLSQSVFTCRVDHRGLTFQQNASSMCSPGPDTAIRVFAIPPSFASIFLTKST

Human*01
KLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGER
Human*03
KLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGER
Chimpanzee KLACLVTDLTTYDSLTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGER
▼
CH4
Human*01
FTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPAD
Human*03
FTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPAD
Chimpanzee FTCTVTHTDLPSPLKQTISRPKEVALHRPDVYLLPPAREQLNLRELATITCLVTGFSPAD

Human*01
VFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCV-AHEAL
Human*03
VFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEAL
Chimpanzee VFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVVAHEAL

Human*01
PNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY
Human*03
PNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY
Chimpanzee PNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY
Tail of Membrane bound IgM
M1
▼M2
Human
GEVSADEEGFENLWATASTFIVLFLLSLFYSTTVTLFKVK
Chimpanzee GEVSADEEGFENLWATASTFIVLFLLSLFYSTTVTLFKVK

Figure A.2. Alignment of chimpanzee and human IgM heavy chains. The chimpanzee
(Chimp) IGHM deduced amino acid sequence were obtained through analysis of a contig on
chromosome 14 (GenBank accession number NW_115908) and compared with two human
alleles IGHM*01 (GenBank X14940) and IGHM*03 (GenBank X57331). Chimpanzee
IGHM is most like human allele IGHM*03, indicating that this allele maybe more ancestral.
The tail of the membrane bound form of IgM is identical for all the sequences. Amino acid
differences are underlined. Arrowheads indicate the start of each domain encoded by separate
exons. Potential N-glycosylation sites and cysteines involved in disulfide bonds are italicized
and bolded. Dashes indicate deleted residues.
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acid substitutions are found in each of the CH domains, but no substitutions are located in the
secretory tail, the transmembrane domain and cytoplamic tail.
The chimpanzee sequence is more conserved with IGHM*03 than with IGHM*01.
The chimpanzee IGHM shares 96.0% amino acid identity with IGHM*01 and 97.1% identity
with IGHM*03. Chimpanzee IGHM has a phenylalanine at CH1 position 40 , serine at CH2
position 87 and a valine at CH4 position 93 as is the case for human IGHM*03, whereas
human IGHM*01 has a leucine at the first position, a glycine at the second position and a
deletion at the latter position. This finding suggests the possibility that the human allele
IGHM*03 may represent a more ancestral allele, whereas and IGHM*01 may represent a
derived allele. Therefore, we examined such a possibility. At the nucleotide level, the
chimpanzee identities with the respective human alleles IGHM*01 and IGHM*03 are 97.4%
and 98.1%, respectively. There are 30 nucleotide substitutions in chimpanzee IGHM when
compared to human IGHM. Of these substitutions, 26 are different from both human alleles
and the remaining 4 are only different from IGHM*01. It is possible that these substitutions
may have arised from two mutation events, once in the chimpanzee gene and once in
IGHM*01, but this is highly unlikely for all four positions. The Chimpanzee Sequencing and
Analysis Consortium (2005) has reported that the error rate for assignment of human single
nucleotide polymorphisms (SNPs) as ancestral (on the basis of their presence in the
chimpanzee sequence) is estimated at ~1.6% overall and 12% when the chimpanzee sequence
occurs at a TG and human polymorphisms are CG and TG. Indeed, CpG dinucleotides are
hotspots for deamination of C to yield T (Hwang and Green, 2004). Thirty % of the
chimpanzee IGHM substitutions are at a CG/TG dinucleotides compared to the 12.5% that
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would be expected by unbiased random mutation of the gene. Only one of the four
chimpanzee substitutions differing from a single human allele is a CG/TG substitution (this
substitution is TG in the chimpanzee sequence and IGHM*03). Together, these data suggest
that the human allele IGHM*03 may be ancestral. Further analysis of other primate IGHM
sequences is required to determine whether IGHM*01 is likely derived or possibly originates
from an ancestral polymorphism.
A putative chimpanzee IGHG3 was found ~90kb downstream of IGHD (Figure A.3).
This intergenic distance is larger than that found in humans, (65 kb between IGHD and
IGHG3). Due to the incomplete resolution of the contig sequence, the center portion of
the IGHG3 sequence encoding part of the hinge region, CH2 and the 5’ end of CH3 could
not be examined (Figure A.3 and A.4). The last exon encoding the second half of the
transmembrane domain and cytoplasmic tail could not be identified. It is likely that the
contig sequence terminates prior to this portion of the chimpanzee IGHG3. Despite the
incomplete sequence, it is clear that the gene, if functional, would be classified as
IGHG3. Indeed, two complete hinge exons and a portion of a third exon encoding amino
acids identical to those of the human IgG3 heavy chain can be identified. In humans, the
IgG hinge region is the most defining characteristic of the IgG subclasses, and only the
human IgG3 subclass has a hinge encoded by multiple exons, the number of which varies
depending on the allele (LeFranc and LeFranc, 2001). Additionally, as is the case for
human IGHG3, the chimpanzee gene is found downstream of IGHD. In the chimpanzee
IgG3 CH1, CH3 and available portion of the hinge region, all cysteines involved in inter-
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Chimpanzee Chromosome 14 (GenBank accession NW_1159908)
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Figure A.3. Chain diagram of human and chimpanzee IGHG3 genes. Numbers indicate nucleotides in exons or introns.
Domains that have not been identified are indicated by dashed lines.

236

237

Figure A.4. (Next Page) Alignment of chimpanzee and human IgG3 heavy chains.
Chimpanzee (Chimp) IGHG3 derived amino acid sequences were obtained through
analysis of GenBank sequences including a contig on chromosome 14 (accession number
NW_115908), from which IGHG3 had not previously been identified, and two partial
mRNA sequences denoted as allele A1 (GenBank AF300434) and allele A2 (GenBank
AF300435). Human alleles of the IgG3 heavy chain exist with varying numbers of hinge
exons (H1, H2, H3 and H4). Although incomplete, the available chimpanzee sequences
also vary in number of hinge exons. Therefore multiple IgG3 alleles with varying
numbers of hinge exon repeat may represent polymorphisms of a common ancestor of
both primate species. Amino acid differences are underlined. Arrowheads indicate the
start of each domain encoded by separate exons. Potential N-glycosylation sites and
cysteines involved in disulfide bonds are italicized and bolded. Dashes indicate residues
absent in the sequences, whereas asterisks indicate unresolved sequences from the contig.
Sequences are compared to the human allele IGHG3*03 (GenBank X03604). The tail of
the membrane bound form of IgG3 is composed of exons M1 and M2. Only M1 is shown
here since the chimpanzee contig did not extend through to the M2 exon.
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CH1
Human
ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
Chimp Contig ASTKGPSVFPLAPCSRSTSEGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
Chimp A1
AVLQSS
Chimp A2
AVLQSS
▼
H1
▼
Human
GLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSC
Chimp Contig GLYSLSSVLTVPSSTFGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSC
Chimp A1
GLYSLSSVVTVPSSSLGTQTYICNVDHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSC
Chimp A2
GLYSLSSVVAVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSC
H2
▼
H3
▼
H4
▼
CH2
Human
DTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDT
Chimp Contig DTPPPCPRCPEPKSCDTP******************************************
Chimp A1
DTPPPCPRCP------------------------------APELLGGPSVFLFPPKPKDT
Chimp A2
DTPLPCPRCP------------------------------APELLGGPSVFLFPPKPKDT
Human
LMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLH
Chimp Contig ************************************************************
Chimp A1
LMITRTPEVTC
Chimp A2
LMITRTPEVTC
▼
CH3
Human
QDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
Chimp Contig ****************************************LPPSREKMTKNQVNLTCLVK

Human
GFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHE
Chimp Contig GFYPSDIAVEWESSGQPENNYNTTPTMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHE

Human
ALHNRFTQKSLSLSPGK
Chimp Contig ALHNHESQKSLSLSPGK
Tail of Membrane bound IgG3
M1
Human
ELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFK
Chimp Contig ELQLQESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFK

Figure A.4.
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and intra- chain disulfide bonds are conserved with human IgG3. The N-glycosylation
site CH3 N52 is also conserved in the chimpanzee protein.
Two partial sequences of chimpanzee IGHG3 have been deposited in GenBank by
Fortenfant et al. (accession numbers AF300434 and AF300435). These short cDNA
sequence fragments (CH1 codon 55 to CH2 codon 31) contain 764nt that overlap with the
contig sequence. These sequences are designated in GenBank as alleles A1 (AF300434)
and A2 (AF300435) and share 98.0% nucleic acid identity with each other and 97.4%
nucleic acid identity with the contig sequence for this overlapping region. Each of these
smaller sequences have hinge regions encoded by two hinge exons in contrast to the
contig sequence that contains three or more hinge exons (Figure A.4). Thus, chimpanzee
IGHG3 exists in multiple alleles, some of which differ because of the number of hinge
exons they possess, as found in humans. These data suggest the possibility that the human
IGHG3 alleles were established before the phylogenetic split of humans and
chimpanzees. Alternatively, duplication of the hinge exons may have occurred separately
in humans and chimpanzees, despite the short period of time since their divergence.
Overall, the chimpanzee IGH locus region surrounding IGHD is quite similar to
the human IGH locus. The intron sizes in all three genes are quite similar to those found
in humans (Figure 4.1, A.1, A.3). Where there are differences in intron sizes, the majority
of differences are due to longer chimpanzee introns. The locus region examined is much
larger in the chimpanzee primarily as a result of longer intergenic distances. All identified
chimpanzee introns for IGHG3, IGHD and IGHM have canonical GT…AG boundaries.
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Future analysis of other immunoglobulin genes in chimpanzees and other
hominoid species would likely help elucidate the extent to which inheritance from a
common primate ancestor contributed to human immunoglobulin polymorphisms. Here,
results from the analysis of chimpanzee IGHM and IGHG3 indicated that more than one
allele of many human genes are ancestral. Such finding would support the view that there
was a diverse genetic pool among the founders of our species.

Humans have two alleles of IGHD, is one more ancestral than the other?
The two described alleles of human IGHD (IGHD*01 and IGHD*02) differ by two
silent nucleotide substitutions, one at H1 codon 9 position 3 (C versus A) and one at CH3
codon 9 position 3 (T versus C). Both of these nucleotides are conserved in chimpanzees,
baboons, sooty mangabeys and macaques with the IGHD*02, indicating that IGHD*01 is
more ancestral.

What does our analysis tell us about the limitations of the bioinformatics program Gnomon
to predict open reading frames from the eukaryotic genome projects?
The bioinformatics program Gnomon is used to predict gene open reading frames and
create putative mRNA from DNA sequences. Through the release of different genomes from
the various genome projects, many of these putative mRNAs have been deposited into
GenBank. As mentioned above, a chimpanzee IGHM mRNA was constructed in this manner,
but the predicted transcript mistakenly incorporated sequence 5’ to the proper start of the
gene. This may represent a limitation of Gnomon. Immunoglobulin heavy region constant
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genes lack a canonical start codon and promoter, because their transcription begins at the
immunoglobulin genes encoding the variable domain, which is created through somatic
recombination. Therefore Gnomon may inappropriately identify start sequences for the
immunoglobulin constant heavy genes located upstream of their real start sequences.
By screening GenBank, we also found Gnomon predicted IgD-like mRNAs for
chimpanzee (GenBank XM_51026) and for dog (GenBank XP_548647). Both of these
sequences were assembled incorrectly and illustrate potential pitfalls of Gnomon analysis.
The chimpanzee mRNA and the deduced protein sequences are highly conserved with those
of human IGHD CH2 and CH3 exons and IgD respectively. However, other exons of the
IGHD gene are not present. 5’ of the CH2 exon the putative mRNA is conserved with CH1CH2 intron sequences and 3’ of the CH3 exon sequence is taken from IGHG3 found
downstream of IGHD. Additionally, the CH2 exon sequence has a single nucleotide insertion
that shifts the reading frame. The dog sequence has similar mistakes made in its assembly,
with the CH2 exon being preceded by sequences derived from the H2-CH2 intron. Mapping
out these genes may provide possible explanations for these errors.
Analysis of the chimpanzee contig for IGHD exons homologous to human IGHD
exon reveals seven of the eight anticipated exons (Figure 4.1). The putative second exon
encoding the tail of the transmembrane bound IgD is missing. This second exon has been
found in all the other characterized mammalian IGHD genes and encodes two amino acids
and the stop codon. Presumably, this second exon would be present in a region of the contig
where the sequence has not yet been resolved (consistent with the hypothesis that the intron
between the first and second transmembrane encoding exons is of similar size to that present
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in humans). Indeed, the intron sizes of the remaining IGHD gene are very close to those of
their corresponding human counterparts. Therefore, Gnomon may have inappropriately
incorporated a part of IGHG3 in its predicted chimpanzee IgD-like mRNA, because the
appropriate stop codon was not found as a result of the incomplete resolution of the contig it
used. The incorporation of an intron at the 5’ end of the predicted mRNA may be explained
because of the lack of any stop codons in this sequence. This is also true for the predicted
dog sequence, where the problem of predicting the correct reading frame may be
compounded by the H1-CH3 intron having a cryptic 5’end rather than the canonical GT
dinucleotide.
Gnomon is a useful tool for identifying genes. However, it appears prone to
errors. These errors may be due to incomplete sequence resolution, presence of unusual
introns, and presence of non-classical genes. The use of this program may lead to
underestimate numbers of genes as a result of predictions deriving from a combination of
two actual genes, as shown for chimpanzee IGHD and IGHG3. Therefore, Gnomon is a
practical tool for an initial genome screening. However, results related to predicted genes
should be carefully evaluated.

Do the IGHD of carnivora members use a cryptic splice site for the H2-CH2 intron?
As determined by comparing mRNA with the DNA sequence, dog IGHD has two
hinge region encoding exons. Examination of the DNA sequence alone does not readily
reveal the second exon (H2), since the contig sequence does not have the canonical GT at
the start of the intron between H2 and CH2 (Figure A.5). One simple explanation is that
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A.
Dog
catctccctttcctccctag/TGCCTCCCACCAGCCACACC
Panda cacgccctcttcccccgcag/TGCCCTCCACCAGCCACACC
Dog
CAGACGCAAGCCCAGGAGCCAGGATGCCCAGTGGACACCA
Panda CAGACACAAGCCGCGGAGCCAGGAAGCCCAGGGGATGCCA
Dog
TCCTCAGAG/gccagttcct-ggggtgcaga
Panda AGCACAGAG/gccagttccttggggcacaga
B.
Dog
VPPTSHTQTQAQEPGCPVDTILR
Panda VPSTSHTQTQAAEPGSPGDAKHR
Figure A.5. Dog and putative panda IgD second hinge region exons. Alignments of the
dog and panda IGHD H2 exon gene sequences with nucleotides of the flanking 5’ and 3’
introns (A) and the deduce amino acid sequences (B) are shown. The dog IGHD exon
boundaries have been confirmed from mRNA sequence. The 3’ exon does not start with
the typical GT dinucleotide. The sequence at this exon/intron junction is highly
conserved with putative panda H2 3’ exon. This suggests that the use of a cryptic splice
junction for the 3’ end of IGHD H2 may be a common feature of carnivora. Panda
nucleotides and amino acids different from those of dog are underlined.
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the contig sequence contains a miscalled nucleotide at the start of the intron.
Alternatively, the intron/exon boundary may be cryptic. An unpublished DNA sequence
of IGHD from panda, also a member of carnivora, is available in GenBank (AY818394).
The authors of the panda submission only identify the first hinge exon, but when we
screened the gene for a possible second exon we found a sequence with 66% nucleotide
identity and 69.6% deduced amino acid sequence identity with the second exon of dog
IGHD (Figure A5). The intron that would be present 5’ of the putative panda H2 exon
follows the canonical GT…AG rule, but the 3’ intron, similarly to what found in dogs,
does not start with GT. In panda IGHD, the putative H2 preceding the predicted
exon/intron junction and the first ten nucleotides of the intron are identical to the similar
dog sequence. Sequencing of panda IGHD mRNA could easily determine whether or not
this is a true H2. Assuming that the genomic sequences are correct and that the 5’ end of
the introns are correctly identified, then the intron would follow a GC…AG splice type.
Less than 1% of introns are spliced by the U2 spliceosome that contain a motif GC…AG
(Burset et al., 2001). However, these introns have 5’ sequences that are strongly
conserved with the complement sequence of the U1 snRNA (GAG/gcaagt) (Abril et al.,
2005). This sequence is only one nucleotide different from the sequences at the 5’ end of
the H2-CH2 introns of dog and panda IGHD genes. Taken together, the information
from dog and panda sequences suggests that an IGHD of canivora members may possess
H2 exons with cryptic 3’ exon/intron boundaries.
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How do the multiple immunoglobulin domains of fish IgD correspond to the mammalian IgD
domains?
Fish IgD is structurally quite different from mammalian IgD. Fish IgD heavy chains have
no hinge, require splicing of IgM CH1 to the N-terminus to provide the cysteines
necessary to form disulfide bonds with the immunoglobulin light chains, and consist of
up to seven immunoglobulin domains, which may be repeated depending on the species
(Wilson et al., 1997;Stenvik and Jørgensen, 2000; Hirono et al., 2003; Srisapoome et al.,
2004; Savan et al., 2005; Saha et al., 2004; Hordvik, 2002; Danilova et al., 2005;
Bengtén et al., 2002; Hansen et al., 2005; Hordvik et al., 1999). These structural
differences have made it difficult to immediately correlate the different immunoglobulin
domains of teleost fish to those in mammals. A general consensus present in the literature
is that the teleost CH1 and mammalian CH1, as well as teleost CH5 and mammalian CH2
domains, correspond most closely to each other. On the other hand, there is disagreement
about whether teleost CH6 or CH7, most closely correspond to mammal CH3 (Stenvik
and Jørgensen, 2000; Hordvik et al., 1999). To test the relationship of mammalian IgD
CH3 to fish IgD CH6 and CH7 we constructed phylograms using the different mammal
CH3 and teleost CH1, CH5 (or Atlantic cod CH2), CH6 and CH7 (Figure A.6). The
resulting phylogenetic tree matches the accepted taxonomy of mammals, with the
exception that the relationship between Old World monkeys is not resolved (probably
because of the shallow differences within the group). Fish CH6 appears to be the domain
most homologous domain to mammalian CH3. Accordingly, both of their clades share a
common node that follows the split of the teleost CH6 and CH7 clades.
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Figure A.6. Phylogenetic relationships of mammalian IgD CH3 domains and fish IgD CH
domains. Neighbor joining tree of IgD was constructed with deduced amino acid
sequences using the CLUSTAL method. The CH6 domains of fish cluster most closely
with mammalian CH3, indicating that these domains are more homologous than fish CH7
domains and mammalian CH3. CH3 differences in primates are small and resolved into
only two clades. GenBank accession numbers for mammals are included in the Materials
and Methods section of Chapter 4. GenBank accession numbers for fish are: channel
catfish U67437, fugu AB159482, Atlantic salmon AF141605, Japanese flounder
AB052658, Atlantic cod AF 155199 and halibut AY077849.
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What is the origin of the IgD secretory tail and is secretory IgD a common feature of
species with IgD?
Of the immunoglobulin heavy chain genes, only IGHD has a separate exon that encodes
the hydrophilic secretory tail (Lefranc and Lefrance, 2001). This tail has been identified
in some of the species possessing a IGHD gene and it is highly diverse among these
species (Figure A.7) (White et al., 1985; Mushinski et al., 1980; Zhao and Hammarström,
2003; Zhao et al., 2002; Wagner et al., 2004, Bengtén et al., 2002). In channel catfish the
IgD membrane bound and secreted forms are encoded by separate genes (Bengtén et al.,
2002). One secretory tail has been confirmed for mouse IgD. A second putative tail has
also been identified and its presence confirmed by Northern blot analysis (Cheng et al.,
1982). The chimpanzee CH-S is the least conserved of the IGHD exons when compared
to human IGHD. Although a polyadenylation site is found 5’ to the first dog IGHD
transmembrane domain exon, we could not identify a CH-S with homology to CH-S from
other species. Mouse CH-S is much longer than human CH-S and it only shares identity
at the nucleotide level with the carboxy-terminus of human CH-S (White et al., 1985). In
fish, CH-S has only been described for some species. In channel catfish, two separate
IGHD genes encode secretory and membrane bound IgD (Bengtén et al., 2002). It is
possible that similarly to the hinge exon, the secretory tail has evolved many times. For
several species it has not yet been established whether or not IgD is secreted. Therefore,
the importance of secreted IgD in the vertebrate immune responses cannot be fully
evaluated.
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Human
Chimpanzee
Rat
Mouse (Putative)
Mouse
Horse
Pig

-----------Y-VTDH---GPMK
-----------Y-VTDR---GPVK
GCY---HLLPESDGPPRRPDGPAFP
GCY---HLLPESDGPSRRPDGPALA
EDFLFKIYSKSYKISAR---TSHKA
GPSHGSSSGSRAGQPQE---TSSHA
PLLIQQRLGAEWKASKRAPASPE-A

Figure A.7. Alignments of characterized IgD secretory tails from mammals. The poor
conservation of the IgD secretory tails may be due to the exon evolving multiple times.
It has been hypothesized that mice may use more than one IgD secretory tail (Cheng et
al., 1982); the unconfirmed mouse IgD tail is shown here as putative (both tails are from
GenBank accession number J00450).
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Appendix B
IgG Subclass Evolution and Its Implications for IgG Fc Receptor Interactions

How do human and nonhuman primate IgG subclasses relate to each other? What do
these relationships tell us about their potential functional properties including
interactions with IgG Fc receptors?
IgG subclasses are often determined for immunological studies in mice and
humans, as they are a major indicator of different types of immune responses (Jefferis et
al., 1994). For example, human natural killer cell ADCC responses are associated with
IgG1 and IgG3, because CD16 binds these subclasses (Tamm and Schmidt, 1997). It is
desirable to similarly measure different IgG subclass responses in nonhuman primates
(Shearr et al., 1999). However, reagents that can be used for this purpose are not
currently available. In addition, it is unknown whether or not the four nonhuman primate
IgG subclasses correlate functionally with their human counterparts. In particular, it is not
known whether or not nonhuman primate IgG subclasses are able to engage immune
effector functions through CD16. If the IgG subclasses of human and nonhuman
primates were inherited from a common ancestor, then it would be reasonable to
hypothesize that they share cognate effector functions.
Phylogenetic analysis of immunoglobulin gamma heavy chains from different
species reveals that multiple IgG subclasses likely arose repeatedly from a single
ancestral gene in multiple species (Figure B.1; Scinicariello et al., in press; Wagner et al.,
2002; Flanagan and Rabbits, 1982). For primates, this analysis produces two separate IgG
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clades, one for hominoids and one for old world monkeys. Following branching of these
two clades, the IgG heavy chains cluster together by subclasses. Therefore, IgG heavy
chain gene duplication appears to have happened separately in Old World monkeys and
in hominoids, but prior to radiation of the representative species from each group. If this
analysis represents the true evolutionary history of these subclasses, then there is no a
priori reason for predicting that the IgG subclasses of Old World primates have functions
in common with the human IgG subclasses. By contrast, IgG subclasses from other
hominoids appear to be true orthologues of human subclasses. Phylogenetic analysis of
IgG genes should take into account that gene conversion is likely to have shaped these
genes, as shown for human IGHG genes (Lefranc et al,. 1986). Such genetic events
would lead to overestimating how closely related these genes are in Old World monkeys.
Old World monkey IgG subclasses are similar to those of humans. In humans,
baboons, sooty mangabeys and macaques (rhesus, cynomolgus, and pig-tailed), the lower
hinge of IgG2 molecules has a deletion of one amino acid. In addition in baboons and
humans, there is a common substitution of a glycine with an alanine in the IgG2 lower
hinge region. Phylogenetic analysis indicates these similarities represent convergent
evolution (Figure B.1). Human subclass differences in the IgG lower hinge regions
account for their varying capacities to bind to IgG Fc receptors, including CD16 (Tamm
and Schimdt, 1997). If nonhuman primate IgG subclass differences alter the ability to
form IgG/Fc receptor interactions, then convergent evolution would help to substantiate
the hypothesis of the selective advantage provided by IgG subclasses that vary in their
capacity to initiate effector functions. Homologues of CD16 have been identified in other
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Figure B.1. (Page 253) Phylogenetic relationships of IgG heavy chains from
different species. The neighbor joining (NJ) tree was constructed from the amino acid
sequences of the immunoglobulin gamma heavy chains of various mammalian species,
two birds and an amphibian. The NJ tree indicates that multiple IgG subclasses emerged
from one progenitor IgG in many groups after splits from other groups. The four
subclasses of old world monkeys appear to have evolved separately from those of
hominoids after the two groups split. Bootstrapping of the NJ tree was preformed with
10,000 replicates. The GenBank accession numbers for the reported species are:
Australian brushtail possum (Possum) (AF157619); baboon (Paca) IGHG1 (AY125048),
IGHG2 (AY125049), IGHG3 (AY125050), and IGHG4 (AY125051); camel IGHG1
(CDIGGC); cat IGHG1a (AB016710) and IGHG1b (AB016711); chicken (X07174);
chimpanzee IGHG1 (X65284-5, X61310-1); cow IGHG1 (X16701), IGHG2 (X16702),
IGHG3a (BTU63638) and IGHG3b (BTU63639); dog IGHG a (AF354264), IGHG b
(AF354265), IGHG c (AF354266), and IGHG d (AF354267); duck (X65219); echidna
(AF416949); gray short-tailed opossum (Opossum) IGHG (AF035195); hamster IgG2
(U17166); horse IGHG1 (AJ302055), IGHG2 (AJ302056), IGHG3 (AJ312379), IGHG4
(AJ302057), IGHG5 (AJ312380), IGHG6 (AJ312381), IgG7 (AY445517); human (Hm)
IGHG1 (J00228), IGHG2 (J00230), IGHG3 (D78345), and IGHG4 (K01316); mink
(L07788); mouse IGHG1 (D78344), IGHG2a (V00825), IGHG2b (J00461), and IGHG3
(D78343); platypus IgG1 (AY055781), IgG2 (AY055782); rabbit IGHG (K00752); rat
IGHG1 (M28670), IGHG2a (M28669), IGHG2b (M28671), IGHG2c (X07189); rhesus
macaque (Mamu) IGHG1 (AY292507), IGHG2 (AY292519), IGHG3 (AY292513), and
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IGHG4 (AY292521, AY292522, AY292524, AY292525); sheep IGHG1 (X69797) and
IGHG2 (X70983); sooty mangabey (Ceat) IGHG1 (AY544376), IGHG2 (AY544377),
IGHG3 (AY544378), and IGHG4 (AY544379), pig IGHG1 (U03778), IGHG2a
(U03779), IGHG2b (U03780) and IGHG3 (U03781); and Xenopus (X15114). IgG
sequences for cynomolgus macaque (Mafa) and pig-tailed macaque (Mane) have not yet
been published and have not been assigned GenBank accession numbers. The bar
indicates the number of substitutions per site.
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Figure B.1.
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other species including mice, cats and cows thus indicating that CD16 predates the
development of multiple IgG subclasses in primates (Nishimura et al., 2000; Yan 2000).
IgE and IgG are thought to have a common origin as a result of an ancient gene
duplication event, which is supported by the ability of mouse IgE to bind CD16 (Arase et
al., 2003). Therefore, IgG interactions with CD16 are likely ancient, predating the
evolution of the IgG subclasses. Taken together these observations indicate that some
subclasses selectively lost the ability to bind CD16, rather than evolving to bind CD16.
Under the phylogenetic scenario presented here, Old World monkey IgG subclasses
would not inherently be expected to bind or not to bind to CD16 based on relationships to
human IgG subclasses.

